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Abstract
Patients with systemic lupus erythematosus (SLE) have an increased propensity
for developing endothelial dysfunction. Declines in endothelial derived NO production
as evidenced by decreases in brachial artery flow mediated dilation, suggest that
inadequate NO levels may be one mechanism whereby vascular homeostasis is perturbed
in SLE patients. NO modifies progression to atherogenesis through inhibition of platelet
aggregation, smooth muscle cell proliferation, adhesion molecule expression, and
prevention of oxLDL. Recent studies suggest that Type I interferons and oxidative stress,
leading to endothelial nitric oxide synthase uncoupling, are critical for accelerated
vasculopathies observed in SLE. We postulate that two potential mechanisms are
responsible for abnormalities observed in SLE patients, as chronic inflammation has
pleiotropic affects. (1) Due to the chronic immune response, increases in oxidative stress
persist within the endothelial milieu in vivo. Inflammatory and injurious states enhance
vascular permeability, cytotoxicity, and inflammatory cell infiltration. While previous
reports in Framingham risk populations have implicated a role for eNOS uncoupling in
advanced atherogenesis, studies examining these mechanisms in SLE are limited.
Analysis of the effects of SLE sera on eNOS in vitro revealed an SLE-mediated induction
of eNOS that paralleled patient age and protein kinase R expression. Induction of eNOS
expression in non-autoimmune populations implicated a role for increased hydrogen
peroxide associated with eNOS uncoupling. To support this hypothesis, flow cytometry
analysis of NO production in SLE sera cultured HUVECs demonstrated a profound
reduction in NO that was partially restored with the addition of L-sepiapterin, an analog
iii

of the eNOS co-factor, tetrahydrobiopterin. We investigated correlations between NO
production and eNOS mRNA levels in vitro and found no relationship between basal NO,
however, there was a strong positive association between NO from cultures supplemented
with L-sepiapterin and eNOS.

Thus, enhanced NO production in response to L-

sepiapterin may explain a role for eNOS uncoupling and therapeutic possibilities for
recoupling in SLE endothelial dysfunction. Changes in NO also coincided with enhanced
neutrophil adhesion to the endothelial cell surface and neutrophil chemotaxis.
(2) Despite evidence that SLE sera modulates eNOS and NO production, specific
inflammatory factors responsible for this phenomenon remain unclear. Previous reports
showing that Type I interferons negatively associated with endothelial dysfunction in
concert with our preliminary studies showing a correlation between eNOS and PKR gene
expression incites the hypothesis that IFNα may negatively modulate eNOS and NO
production.
Inhibition of eNOS expression with the addition of IFNα was both time and dose
dependent that correlated with PKR and MX1 induction. As a downstream consequence,
we observed that protein, NO, and insulin induced NO levels were decreased in response
to IFNα treatment. Additional pro-atherogenic changes occurred in response to IFNα
stimulation in endothelial cells including decreased cGMP and ICAM-1, VCAM-1, and
MCP-1 induction. However, leukocyte adhesion did not change.
Finally, we examined used PKR and NFκB knockdown studies to demonstrate
that the removal of NFκB but not PKR, mediates IFNα effects on eNOS mRNA. In lieu
of IFNα mediated declines in eNOS stability, our investigation into microRNA 155, a
known eNOS gene de-stabilizer, revealed the novel finding that IFNα enhances miR155
iv

expression which may promote eNOS dysfunction and subsequent increases in
endothelial dysfunction.
Taken together, these results indicate that SLE sera and factors previously
identified to be associated with endothelial dysfunction negatively impact NO production
and eNOS expression in vitro. Due to differential expression of eNOS modulated by
rIFNα and SLE serum, we hypothesize that crosstalk between oxidative stress and IFNα
downstream signals may promote the accelerated phenotype observed in SLE patients.
Further, therapeutic targets that alleviate oxidative stress and prevent IFNα signaling may
be beneficial in improving cardiovascular disease outcomes.
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Chapter 1
Introduction and Significance
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Systemic Lupus Erythematosus
Course of Disease
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the
production of autoantibodies against nuclear antigens1.

Approximately 1.5 million

Americans and 5 million people globally are living with SLE. SLE has a striking
propensity to affect women of childbearing years (20 to 40 years) at a 9:1 female to male
ratio and is more common among women of African, Asian, and Hispanic descent2, 3, 4.
The cause of this racial and ethnic disparity remains unknown but it may be due to both
genetic and environmental factors5, 6. Over the past 40 years, prevalence of SLE has
nearly tripled possibly due to improvements in clinical diagnostic tools as well as a true
increase in incidence.
SLE is a disease of flares and remissions in which specific flare triggers vary.
Despite the heterogeneous nature and presentation of SLE, the American College of
Rheumatology outlined 11 specific criteria in 1997 to diagnose lupus for clinical research.
A SLE diagnosis encompasses a diverse range of symptoms including mild skin rashes,
discoid rash, photosensitivity, oral ulcers, and non-erosive arthritis. Severe and lifethreatening manifestations of lupus include neurological diseases such as stroke and
psychosis, premature atherosclerosis leading to coronary artery disease and myocardial
infarction, and glomerulonephritis7.

2

Overview of Immune Function in SLE
Advances in understanding interactions between the innate and adaptive immune
systems have unveiled potential pathways leading to the clinical syndrome of SLE.
Adaptive and Cellular Immunity
SLE patients display enhanced levels of apoptosis and subsequent necrosis in
macrophages, lymphocytes, neutrophils, and monocytes8.

Upon release nuclear matter

(i.e. self-DNA, cell nuclei, and ribonucleoprotein particles), antigen presenting cells (i.e.
dendritic cells

(DCs) and macrophages) phagocytose and present these cellular

components to autoreactive T and B-lymphocytes.
Autoreactive B cell overactivity is crucial in the pathogenesis of SLE. B cells
impede normal adaptive immune responses by aiding in the production of antibodies to
self-antigen antibodies (“auto” antibodies specifically targeted against “self” cellular
components), while T lymphocyte proliferation is enhanced. T cells including CD4+,
CD4+DR+,

CD8+DR+,

CD3+CD4-CD8-αβ+,

CD3+CD4-CD8-γδ-,

and

CD3+CD4+CR3+ cells, play a critical role in B cell function and pathogenic antibody
production9,

10, 11, 12

.

Immune complexes are ligands that activate Fcgamma RIIA

(FcγRIIA)13, the complement cascade, and initiate infiltration of immune cells such as T
lymphocytes, into tissues14; these mechanisms of action promote excessive autoantibody
production from B cells. Other factors that influence B cell function include estradiol15
and C5a16.

Although the actual cause of lupus has gone undefined, the wide

accumulation of evidence surrounding genetic, environmental, and hormonal influences
on B cell proliferation and subsequent pathogenic autoantibody synthesis raises the
3

hypothesis that B cell over activity may be essential for the progression from
autoimmunity to autoimmune disease.
As such, a number of therapies have been approved by the US Food and Drug
Administration to target B cells and B cell activation, including an inhibitor against the B
lymphocyte stimulator (BLs) known at belimumab or Benlysta®17. Another monoclonal
antibody that targets B cell CD20 (rituximab) has been studied in randomized controlled
trials in SLE and lupus nephritis but did not gain FDA approval for treatment of SLE18.
Moreover, abatacept was approved for rheumatoid arthritis for blocking CD28 to impair
T lymphocyte activation by B cells; nonetheless, it is not yet approved for use in SLE19.
Mycophenolate mofetil, also known as MMP or MPA

(Cellcept® or Myfortic®),

inhibits inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de
novo synthesis of lymphocytic purines expressing IMPDH II, which is more sensitive to
MPA20. FDA approved B cell targeted therapies may have contributed to the longevity
of SLE patients, yet, autoantibodies alone cannot sustain the auto-inflammatory response
identified in SLE patients.

4

Innate Immunity
Although the adaptive immune system largely impacts the development of SLE, it works
synergistically with the innate immune system. Pattern recognition receptors (PRRs)
serve as detectors of systemic pathogen antigens. PRR activation yields production of
various cytokines and chemokines that activates host innate immunity.

Toll-like

receptors are PRRs that serve as the “bridge” connecting both innate and adaptive
immune systems in SLE. TLRs 7 and 9 are endosomal receptors for DNA and RNA,
including bacterial, viral, and endogenous nucleic acids. Immune complexes consisting
of nucleic acid rich components of self DNA and RNA bind the Fc receptor,
FcgammaIIRa, are endocytosed, and promote TLR7/9 activation and subsequent
interferon alpha (IFN-α) production. Type I interferons such as IFN-α may serve as a
key mediator in the clinical manifestations of SLE21, 22.
Type I Interferons in SLE
Interferons are comprised of 3 different subgroups, including type I (α, β, ε, κ, τ,
δ, ζ, and ω ), type II (IFN γ), and type III (IFN-λ), also known as interleukin 28 and 29.
However, discussion of subtypes II and III are beyond the scope of this dissertation.
Amongst the plethora of immunological factors promoting dysregulation of the
immune system in SLE patients, type I interferons such as IFNα/β are well established as
key players in the pathogenesis of SLE. In 1969, New Zealand Black X New Zealand
White (NZW/NZB) mice induced with polyinosinic:polycytidylic acid (poly I:poly C)
developed accelerated lupus, suggesting that IFN-α is produced in immunological
response to nucleic acid immunization in SLE-prone mice23. This study was followed by
the discovery in 1982 that SLE patient serum induced elevated type I IFN responses in a
5

manner that correlated with disease activity and anti-dsDNA binding. Further, this study
challenged previous findings that by Hooks, et al. suggesting that type II IFNs were most
prevalent in SLE serum24, 25. These studies raised the possibility that type I IFNs were
important in the pathogenesis and secondary clinical manifestations of SLE.
In 1999, plasmacytoid dendritic cells were shown to produce 200 to 1000 times
more IFN than other isolated immune cells from human blood than any other immune
cells26. Further, pDCs are commonly identified in proximity to inflamed tissues while
IFN-α-related interferon inducible genes are readily identified in peripheral blood
mononuclear cells in patients with active and inactive disease27,

28

. Recent evidence

suggest that early depletion of pDCs in a BXSB lupus-prone mouse model attenuated
development of lupus, suggesting that pDC-derived IFN-α/β signaling is important in
initiation of disease.
Neutrophil-derived self-DNA released in the form of neutrophil extracellular
traps (NETs) have also proved to trigger pDC activation leading to subsequent IFN-α
production. Indeed chromatin-dependent neutrophil stimulation promoted bioactive IFNα production. pDCs were found to be 27 times more efficient at producing IFNα, while
neutrophils had a 100 fold-higher bioavailability in SLE blood than pDCs29. Thus, both
neutrophils and pDCs serve as major sources of Type I IFNs in SLE while minor sources
include epithelial cells and fibroblasts. Although Type I IFN concentrations may vary
depending on cell type, they have both autocrine and paracrine affects.
IFN-α binds the heterodimer (alpha/beta) IFN-A receptor (IFNAR), leading to
the induction of antiviral immune responses

Downstream molecular targets of IFN-α

signaling include induction of IFN signature genes, including myxovirus 1, ELK2AK
6

also known as protein kinase R (PKR), and interferon-induced protein 1 (IFIT1), that
impedes the replication abilities of viruses.

Accordingly, excessive production and

sustained downstream signaling of the IFN-α/β receptor (IFNAR), induced by IFNα
may support an autoimmune response and subsequent clinical manifestations of SLE. In
fact, Type I IFN signature gene expression has been shown to correlate with disease
activity and severity and with clinical manifestations of the lupus including abnormal
vascular repair, organ damage, atherosclerosis, and endothelial dysfunction
IFN-α in the Pathogenesis of SLE
The impacts of IFNα on the immune system are multifactorial, possibly
accelerating SLE disease severity and tissue organ damage. Studies in murine models as
well as clinical observations provide a glimpse into immune deregulation exerted by
IFNα downstream signaling pathways.
NZB/NZW lupus prone mice treated with IFNα adenovirus displayed somatically
mutated IgG2a and IgG3 antibodies, while B cells had elevated TLR7 expression and
systemically higher levels of IL-6, TNFα, and BAFF.

These animals had higher

induction of IL-21 in T cells and T cell dependent induction of anti-dsDNA antibodies,
leading the authors to conclude that IFN-α mediated effects are CD4-T cell dependent30.
Complications in severe glomerulonephritis have also been attributed to higher
plasmacytoid DCs counts correlative with interleukin-18 (IL-18), which may implicate a
role for IFNα in lupus nephritis31.

In vitro, IFNα priming of monocytes promotes

development of macrophage lipid uptake and subsequent foam cell formation32, while
others have identified the presence of IFNα producing neutrophils in atherosclerotic
plaques of SLE patients. High levels of IFNα are highly prevalent in the cerebrospinal
7

fluid

(CSF) of SLE patients, with expression increased in neurons and focal

accumulation in the microglia of brain tissues in central nervous system SLE patients33.
Collectively, these findings support a role for IFN-α in both the pathogenesis and
complications associated with SLE.
Synergy and crosstalk between innate and adaptive immune systems promote the
development of autoimmune diseases. However, the development of a unified proposal
explaining susceptibility to autoimmune disease is a difficult task. Genetic,
environmental, and hormonal factors may provide clues regarding etiology.

The Role of Genetic and Environmental Factors in the Loss of Self-Tolerance
Although an extensive review of the genetic susceptibility to systemic lupus
erythematosus is beyond the scope of this dissertation, we must make note of the role of
genetics in the pathogenesis of disease. Early studies in monozygotic twins provided
evidence the heritability of SLE34. C1q, tartrate resistant acid phosphatase (TRAP), and
3 primer repair exonuclease 1 (TREX1) are single gene deficiencies highly associated
with SLE patients35. Moreover, over 100 genetic variants associated with SLE risk have
been identified.

Many single gene deficiencies and genetic variants found in SLE

patients have been associated with abnormal production of Type I interferons in SLE.
In addition to genetic abnormalities, environmental factors are well known to
have adverse effects on the immune system, potentially triggering a lupus-like phenotype.
Environmental factors such as UV irradiation, certain drugs, hormones, stress, viral or
bacterial infections and, Vitamin D deficiency are well known SLE risk factors.

8

Current Therapeutics
Over the past 50 years, therapies have become more effective as evidenced by
improvements in survival among SLE patients. Unfortunately, these therapies tend to
cause side effects, are excessively costly, and negatively impact the quality of life for
lupus patients.
Conventional therapies for lupus patients include antimalarial drugs such as
hydroxychloriquine (Plaquenil), Chloroquine, and Quinacrine, and nonsteroidal antiinflammatory drugs

(NSAIDs).

Immunomodulatory therapies traditionally used for

organ transplantation are used in SLE and include corticosteroids, mycophenolate mofetil,
azathioprine, cyclosporine, and tacrolimous. Some medications traditionally used for
chemotherapy such as methotrexate and cyclophosphamide are also used to treat SLE. In
March 2011, Belimumab (Benlysta), which enhances B cell dysfunction, was approved
by the FDA for the treatment of autoantibody positive patients. Conversely, clinical trials
using IFN-α abs have proven ineffective with reducing the IFN signature in patients with
higher levels of Type I IFNs as well as disease activity.

Causes of Morbidity and Mortality in SLE
Heterogeneity in the pathogenesis of SLE yields varied clinical manifestations of
the disease across the adult population. Age at diagnosis, race, and sex appear to play
important roles in susceptibility and severity of disease as each of these components
impact individual immunity. Approximately one-half to two-thirds of lupus patients
develop some form of renal involvement with diffuse proliferative glomerulonephritis
9

and focal proliferative lesions yielding a worse prognosis36.

In addition cardiac

involvement is found in approximately 30-50% of SLE patients.
Cardiovascular diseases like atherosclerosis are now the leading cause of
premature mortality in SLE patients; still, the etiology is unclear. Chronic inflammation
coupled with conventional risk factors may promote atherogenesis and subsequent
fatalities.

Clinical and laboratory investigations are needed to clearly define the

mechanisms of interaction between Framingham risk, autoimmune disease mediators,
and chronic therapy that may initiate early atherosclerosis known as vascular endothelial
dysfunction.

10

Chapter II
Review of Literature

11

Systemic Lupus Erythematosus and Premature
Atherosclerosis
Over the past 50 years, cardiovascular diseases have emerged as the leading cause of
death in United States and Western Europe. This trend in disease is mainly due to
increased consumption of processed, high glycemic index foods paired with inactivity
resulting from industrialization. Cerebrovascular disease and ischemic heart disease are
the two major cardiovascular complications.
Cardiovascular complications have recently been identified as chronic inflammatory
diseases induced by both genetic polymorphisms and environmental changes (i.e. diet,
lifestyle) within the population. Thus, it is not surprising that patients with chronic
inflammatory autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis,
psoriatic arthritis, ankylosing spondylitis, and SLE, have more aggressive forms of
atherosclerosis and heart disease.

For the purposes of this investigation, the

cardiovascular disease risk in SLE patient populations is presented with an emphasis on
risk factors that impact preclinical disease outcomes.

Cardiovascular Disease Risk in the SLE Patient Population
Improvements in immunosuppressive therapies have led to improvements in SLE
patient survival rates37. As a result of increased longevity, cardiovascular disease (CVD)
has become a major cause of morbidity and mortality in this patient population. Patients
typically have CVD complications including accelerated atherosclerosis (AA) and major
cardiovascular events (MACE). Studies suggest that SLE patients are 17 times more
12

likely to die from coronary heart disease while SLE patients who are premenopausal
women, a conventionally low risk population, are 50 times more likely to have a
myocardial infarction38. Traditional risk factors such as hypertension, elevated
cholesterol, and insulin resistance play a major role in cardiovascular events found in
SLE patients; nevertheless, they do not fully account for the observed MACE and
advanced heart disease39. Although the pathogenesis of premature vascular disease in
SLE patients is not fully understood, multiple studies in patients have revealed an
increased prevalence of an initial breach in vascular wall integrity and endothelial
function, leading to altered vascular wall permeability, elasticity and thickness, and
finally the development of atherosclerosis. Moreover, due to the inflammatory nature of
SLE, chronic use of corticosteroids and higher levels of oxidized LDL tend to exacerbate
vascular damage in SLE patients.
Over the past 40 years, studies aimed at identifying subclinical disease have
examined SLE-specific risk factors, carotid plaque changes, and altered endothelial
function associated with myocardial infarction (MI). Collectively, SLE patients more
susceptible to MI include those with traditional cardiovascular disease risk factors, a
longer course of disease, long-term glucocorticoid treatment, chronic nephritis,
hypercholesterolemia, hyperlipidemia, anti-phospholipid antibodies, vasculitis, and antiphospholipid antigens, but, the mechanisms of this increased risk are unknown.
Common Risk Factors
Traditional

Framingham

risk

factors,

such

as

age,

hypertension,

hypercholesterolemia, diabetes, hyperlipidemia, obesity, smoking, and sedentary lifestyle,
contribute to the high prevalence of atherosclerosis and vascular endothelial dysfunction
13

observed in SLE patients. While the impact of these factors in the general population is
well established, whether these factors are primary or secondary hazards in SLE remains
to be elucidated. Among all risk factors, hypertension, abnormal lipid profiles, and
hypercholesterolemia tend to be most common in SLE patients40 41, 42, 43. Moreover, other
studies have shown that metabolic syndrome is an important Framingham risk factor for
predicting cardiovascular disease 44.
Patients with SLE tend to have a higher prevalence of conventional risk factors45. Still,
even after adjustment for Framingham risk factors, these patients still tend to have a
higher incidence of CVD.

Not surprisingly, a retrospective population-based study

showed that SLE patients with late onset of disease had double the mortality rates and
CVD events of age- and risk-matched controls46. Collectively, these studies suggest that
SLE-specific factors must be considered when determining cardiovascular disease risk in
this patient population.

Glomerulonephritis
Chronic kidney disease is common among SLE patients affecting between 40-60% of
patients with SLE.

However, studies are inconsistent regarding the role of kidney

involvement in accelerated atherosclerosis in SLE. Conventional risk factors, including
dyslipidemia, hypercholesterolemia, hypertension, and insulin resistance promote
endothelial abnormalities preceding kidney disease. Thus, renal disease associations with
cardiovascular disease may not be causative but associative. For example, a prospective
study examining the impact of conventional cardiovascular disease risk factors on renal
disease outcomes revealed that the presence of hypertension, hyperlipidemia, and anti14

phospholipid syndrome led to a higher incidence of death and end-stage renal disease

47

Moreover, Font, J et. al. showed that patients with hyperlipidemia and hypertension
developed renal failure and died from subsequent cardiovascular and cerebrovascular
complications48. Surprisingly, a retrospective study on SLE women with end-stage renal
disease (ESRD) revealed that cardiovascular and cerebrovascular mortality rates were
not greater when compared with women with ESRD due to diabetes49. Collectively,
these studies suggest that, although important, ESRD may be an associative but not a
causative factor in the increased prevalence of atherosclerosis observed in SLE
populations.

Corticosteroid Use
Acute administration of corticosteroids prevents disease flares in lupus while
long-term use is associated with adverse health effects.

Moreover, the association

between corticosteroids and atherosclerosis is complex. Steroid therapy is introduced as
part of a “therapeutic cocktail” to control acute disease flares. Unfortunately, patients
presenting with organ involvement may experience long-term use of these drugs. Lack of
steroids and cyclophosphamide for treatment was associated with higher rates of carotid
plaque, suggesting that immunosuppression may prevent vascular abnormalities

50

.

However, a long duration of steroid therapy greater than a 10mg daily dose also confers
increases in focal carotid plaque51, leading to a higher incidence of myocardial
infarction52 and other heart disease risks, suggesting that chronic use may exacerbate
metabolic factors.
Interestingly, the duration of glucocorticoid use is not a predictor of endothelial
15

function in humans53, and studies suggest that glucocorticoids like dexamethasone may
be beneficial in maintaining eNOS expression for the prevention of cyclosporine-induced
vasoconstriction in the rat renal vasculature54. However, little is known about its impact
on flow mediated dilation, vascular tone, and endothelial function.
Inflammatory Mediators and Inflammation
Pro-inflammatory pathways leading to the development of atherosclerosis have
gained substantial interest over the past 20 years. The development of atherosclerosis
begins with inflammatory-mediated activation of the endothelium, which serves as the
“gateway” for immune cells. Cytokines such as tumor necrosis factor alpha (TNF-α)
appear to play a role in endothelial dysfunction, the first step in the development of
atherosclerosis. TNF-α is especially pro-atherogenic in non-autoimmune populations
such as health subject, and those with diabetes or ischemia/reperfusion injury55. TNF-α
contributes to endothelial dysfunction by impairing endothelial nitric oxide synthase
expression, phosphorylation, and enzymatic activation56.
In addition, TNF-α enhances endothelin-1 production, ROS production, and
thromboxane A2 receptor signaling.

Thus, the finding that anti-TNF-α improved

endothelial function in diabetic patients is not surprising

57 58, 59

. In SLE, TNF-α levels

coincide with soluble ICAM-1 levels and are related to enhanced endothelial cell
activation, reflecting the presence of endothelial dysfunction60.

However, as yet

unexamined are correlations between brachial artery flow mediated dilation, a surrogate
marker of endothelial function, and TNF-α levels in SLE patients.
T lymphocytes and macrophages secrete interleukin 6, a cytokine thought to play
a role in B cell hyperactivity in SLE. IL-6 impairs insulin-mediated phosphorylation of
16

eNOS at the serine

1177

, desphosphorylation at threonine495

61

, eNOS-caveolin-1

dissociation,62 and correlates with endothelial dysfunction in non-autoimmune
populations63. IL-6 levels are elevated in SLE patients with higher SLEDAI scores and
anti-dsDNA levels

64

;however, its role in SLE-related endothelial dysfunction is

unknown.
IL-10 levels are 3-12 fold higher in SLE patients than healthy controls65and
coincide with higher SLEDAI scores and active disease

66

. Some evidence suggests,

however, that IL-10 protects against endothelial dysfunction by inducing endothelial
derived nitric oxide production, preventing production of monocyte chemoattractant
protein-1, and impairing superoxide anion production in vivo

67, 68

. However, studies

examining the role of IL-10 in SLE-related ED are missing.
Over the past decade, studies have shown that IL-17 is involved in the
development of vascular inflammation; but, its role in atherosclerotic plaque formation
remains controversial. IL-17 is abnormally elevated in lupus patients and is thought to
play a role in the pathogenesis of SLE.

The IL-17A receptor is expressed on the

endothelial cell surface and has pleiotropic effects on endothelial cell function. While
some studies show its induction of ICAM-1, VCAM-1, and a reduction in endothelial
derived NO production, others have shown that IL-17 induces eNOS in bone marrow
derived cells.

Moreover, IL-17A neutralization in ApoE-/- mice showed reduced

inflammation but did not result in plaque regression

69

. Further studies are needed to

determine the role of IL-17 in SLE-related vascular ED.
CD40 ligand has emerged as an important cell-signaling molecule essential for
the development of atherosclerotic plaque and more recently endothelial dysfunction70.
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In addition to atherosclerosis, activation of the CD40 receptor, by soluble CD40 ligand
(sCD40L) and preformed CD40L (pCD40L), plays an important role in the pathogenesis
of SLE. Recent studies suggest that pCD40L, stored in Th1, Th2, Th17, and T follicular
helper cells, is elevated in SLE patients with higher plaque levels71. Moreover, declines
in endothelial cell eNOS, mRNA, protein, and NO levels were observed while,
superoxide and NADPH oxidase activity levels were enhanced. Collectively, these data
suggest that sCD40L may play a role in SLE-related ED72
Human C-reactive protein (CRP) is a promiscuous molecule that correlates with
clinical cardiovascular disease and is predictive of cardiovascular events. Over the past
two decades, studies have shown its involvement as a negative regulator of eNOS,
resulting in endothelial dysfunction. Human CRP impairs eNOS transcription and
translation, preventing phosphorylation at the eNOS activation site Ser

1177

. Moreover,

CRP attenuates NO production and promotes eNOS uncoupling, leading to endothelial
dysfunction73, 74. Whether CRP is responsible for the endothelial dysfunction observed in
SLE patients is not known. Studies showing elevated levels of CRP in SLE patients are
limited and contradictory75, 76, 77, 78.
C-reactive protein is elevated in patients with increased risk for cardiovascular
disease and declines in endothelial progenitor cell circulation. In SLE, CRP associates
with clinical disease manifestations, including myocarditis, cardiac murmur, interstitial
pulmonary fibrosis, pulmonary hypertension, gastrointestinal lupus manifestations, and
anemia79.
Conversely, others have shown an insignificant increase in CRP levels with lupus
flares, suggesting that the CRP response is abnormal80. Forty percent of lupus patients
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have autoantibodies against CRP78, and these associate with renal disease81. Increased
CRP autoantibody production may lead to enhanced CRP immune complex formation
and subsequent immune system activation. C reactive protein was shown to reverse
proteinuria and decrease autoantibody production in murine lupus mouse models82.
Surprisingly, IFN-α halts CRP promoter activity, CRP secretion, and may be responsible
for the abnormal CRP response observed in SLE83.
Autoantibodies
Antibodies targeting self-antigens are known as autoantibodies. Predominantly
found in autoimmune populations, specific autoantibodies have emerged as key players
of accelerated atherosclerosis.

Although a plethora of autoantibodies have been

identified in SLE patients, only a small group associates with endothelial dysfunction and
abnormal plaque development. These include but are not limited to: antiphospholipid
(aPL), pro inflammatory high-density lipoprotein (piHDL), oxidized LDL (oxLDL),
anti-cardiolipin, and anti-apolipoprotein A-1 autoantibodies.
The literature is unclear about aPL-related cardiovascular complications, but to
some degree, supports a role for β2 glycoprotein, annexin V, and cardiolipin antibodies in
vascular endothelial dysfunction.

In general, APLs enhance superoxide and

peroxynitrite levels, which circumvent vascular homeostasis84.

Antiphospholipid

antibodies (aPLs) are well established as culprits of arterial and venous thrombosis in
patients with antiphospholipid syndrome and SLE. They include lupus anticoagulant,
anti-cardiolipin, and anti-beta2 GPI antibodies. Thrombosis ensues due to attacks on the
cellular phospholipid structures in the vasculature. Roughly 30-40% of SLE patients
have high levels of aPLs and may be more susceptible to MACE
19

85

. Howbeit, solid

evidence is missing regarding the impact of aPLs on cardiovascular disease in SLE
patients. Studies have shown conflicting results regarding correlations between vascular
health and the presence of aPLs. A prospective study examining the association between
aPLs and various vascular complications in roughly 200 SLE patients suggested that
aPLs were not associated with vascular abnormalities or the presence of carotid plaque 86.
Conversely, studies conducted in patients with retinal vascular disease showed that aPLs
was associated with retinal complications

87

. Similarly, aPLs were shown to associate

with cutaneous vascular lesions in SLE patients. Collectively, these studies represent
controversy surrounding the impact of aPLs on vascular disease.
Oxidized low density lipoprotein antibodies and immune complexes have become
increasingly important in the pathogenesis of SLE-related atherosclerosis. Studies show
that elevated titers of oxidized-low density lipoprotein (oxLDL) antibodies correlate with
IgG anti-cardiolipin antibody and IgG anti-beta2 GPI antibody 88. High circulating IgG
anti-oxLDL/β2GPI antibody complexes were found in both SLE and systemic sclerosis
patients, which may reflect the prevalence of oxidative stress in patient populations with
chronic inflammation89. More importantly, OxLDL antibodies are associated with the
prevalence of plaque in SLE patients, supporting their role in the pathogenesis of
atherosclerosis , while some studies suggest that oxLDL autoantibodies may serve as an
important biomarker of impaired endothelial-dependent flow-mediated dilation 90, 91.
Anti-endothelial cell antibodies (AECAs) are highly prevalent in the serum of SLE
patients and may also be important in SLE-related vascular disease. Early studies
examining the role of AECAs in vasculitis discovered that activation of endothelial cells
by IgG anti-endothelial antibodies promoted complement activation, deposition of the C3
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component into the endothelium, and disruption of the endothelial cell monolayer

92

.

Moreover, others showed that AECAs may be responsible for the in situ immune
complex formation observed in the glomerulus of the kidney and may be involved in the
pathogenesis of glomerulonephritis 93, 94. Conversely, more recent studies presented data
that suggests a milder role for AECAs. For instance, AECAs were shown to bind
apoptotic endothelial cells but not induce apoptosis, while prospective trials examining
the association between endothelial dysfunction and AECAs suggested that the two
factors were independent. Moreover, AECAs were associated with SLEDAI scores but
were not markers of endothelial cell damage

95 96

, . Collectively, these data suggest that

AECAs may not be responsible for endothelial cell damage but may be indicative of
vascular anomalies and perhaps disease activity. More studies are needed to provide
definitive answers about the role of AECAs in lupus-related vascular pathologies.
Complement Cascade
The complement system plays a major role in the development of autoimmune
diseases, such as SLE, as well as vascular complications like atherosclerosis.
Complement activation can occur via three different pathways, including the classical and
alternative, both of which lead to formation of the membrane attack complex (MAC) and
the mannose-binding lectin or MBL pathway. The classical pathway encompasses
complement components C1, C2, and C4 and is activated by the presence of immune
complexes often identified in the blood of SLE patients.
The role of complement in the development of SLE is complex since roughly
75% of patients with SLE are complement deficient, lacking the C3 and more commonly
C4 components97, 98. Thus, the complement cascade is protective under pathophysiologic
21

conditions, acting as an opsonin for ridding the body of cellular debris and immune
complexes. As a result of absent early components, immune complexes can no longer
activate the complement cascade. Immune complexes then deposit more readily in the
vasculature, and inflammation persists99.
On the other hand, complement activation plays a major role in the recruitment of
monocytes to the endothelial cell surface, leading to endothelial and smooth muscle cell
activation. Still a wealth of knowledge, including in vivo and in vitro data in both murine
models and human disease, supports a role for complement in the development of
vascular abnormalities and atherosclerosis.
C3 deposition in the intimal and inner medial compartments increases upon
hypercholesterolemia and the formation of atherosclerotic intimal plaque induced by a
high fat diet in rabbits. Further, CR2-Crry treatment, which inhibits C3 activation,
reduced atherosclerotic plaque development in Apoe-/- mice on a high fat diet. This
change was probably due to impaired macrophage and T cell infiltration typically
promoted by C3 cleavage. A retrospective study examining coronary arteries from
deceased patients with ischemic heart disease showed enhanced C3 deposition, which
correlated with the presence of atherosclerotic lesions100.
In genetically engineered mice possessing the Sle16 locus backcrossed to a Ldlr
(-/-) mouse model, accelerated atherosclerosis and reduced C3 levels were observed

101

.

In SLE patients, a prospective study showed that carotid intimal media thickness (cIMT)
correlated with C3, C4, and CH50 levels while the cIMT was best predicted by age.
Moreover, the authors showed that small dense HDL particles were partially responsible
for activating complement in these patients
22

102

.

While actual mechanisms whereby

complement induces atherosclerotic plaque development are unclear, studies support the
notion that complement activation causes vascular damage and subsequent endothelial
dysfunction in the general population.
Lennon, P.F et al. showed that rabbit aortic rings stimulated with various
concentrations of complement rich human serum lost the ability to respond to
acetylcholine- and calcium-mediated relaxation. This study suggested that complement,
namely C5-9 and 3, may negate endothelial nitric oxide synthase activity and/or nitric
oxide bioavailability103. Moreover, a cross-sectional study examining the links between
sC5-9 and C5a products showed strong associations among these complement
components and endothelial dysfunction 104. Complement has also been shown to induce
inducible nitric oxide and reactive oxygen species, two mediators, when produced in
close proximity, that can form peroxynitrite and lead to eNOS uncoupling105 106.
Collectively, these studies support a role for complement deregulation in vascular
damage and atherosclerosis, especially in patients with autoimmunity. Nonetheless, exact
mechanisms of this pathophysiological impact are unknown.

Longer Course of Disease
Improvements in SLE patient longevity have not come without consequence.
Notably, Urowitz et al. first observed that cardiovascular-related deaths were more
prevalent among premenopausal SLE women five years after diagnosis38. Likewise,
others have shown that older patients with a longer duration of disease have a higher
prevalence of renal and ocular vascular complications. Unsurprisingly, patients with a
longer duration of disease have higher levels of coronary artery calcification, thus
23

suggesting that duration of disease serves as a lupus-specific risk factor for
cardiovascular complications

107, 108

. However, studies are missing regarding the impact

of disease duration on endothelial function.
In summary, this group of risk factors for ED and atherosclerosis in SLE patients
are important to note.

Nevertheless, inconsistent findings throughout the literature

suggest these risk factors only partially account for the advanced atherosclerotic
phenotype observed in SLE patients. In fact, recent studies provide a strong rationale for
studying mechanisms whereby type I interferons may induce ED in SLE patients.
Collectively, these risk are thought to contribute to the development of
accelerated atherosclerosis in SLE. Further, there may be crosstalk between pathways
that influence the synergistic impact of risk (Figure 2-1).
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Figure 2-1. Accelerated atherosclerosis in SLE patients arises from a complex
interplay between common risk, shared factors, and SLE-specific risk including
immune dysregulation.
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Endothelial Dysfunction
Endothelial Cell Homeostasis
The endothelium lining the blood vessels has a dynamic role in maintaining vascular
homeostasis. Homeostasis is maintained under quiescent conditions by the release of
paracrine and autocrine signaling between the blood and tissue. Vasodilation, trafficking
of hematopoietic cells, and unperturbed flow allow for optimal vascular function109.
Endothelial cell perturbations arise in the presence of pathogenic factors including
cytokines, chemokines, shear stress, and conventional cardiovascular disease risk factors
leading to endothelial cell activation. Endothelial cells are part of the innate host defense
system, releasing chemokines and expressing proteins that may promote injury resolution.
Howbeit, constant insult leads to deleterious effects on genes and endothelial cell
responses that promote “endothelial dysfunction.”

Endothelial responses in chronic inflammation
Vascular architecture is quite heterogeneous where large diameter vessels including
arteries and veins, are responsible for regulating blood flow. In contrast, small vessels
like capillaries and arterioles modulate blood pressure. Moreover, microvascular
functions within the body are quite organ specific. There are three main types of blood
capillaries, which include continuous, fenestrated, and sinusoidal. Continuous capillaries
form the blood-brain barrier and contain endothelial cells that form a confluent
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monolayer, allowing only ions and small gas molecules to diffuse across the layer110.
Porous endothelial cells lining the walls of fenestrated capillaries found in the glomerulus
contains a diaphragm made up of glycocalyx that allows passing of small protein and
molecules to pass through these cells111. On the other hand, sinusoidal capillaries have
an incomplete basement membrane, which makes this type of vessel quite leaky allowing
for clearance of larger proteins and cells. Sinusoidal capillaries are found mainly in
lymph, bone marrow, adrenal tissues, and the liver112.
Although heterogeneity persists throughout the vasculature, inflammatory insults
elicit similar endothelial cell responses. Upon injury or infection, antigen presenting cells
such as macrophages and dendritic cells, process the foreign antigen and release
chemokines and cytokines that recruit more immune cells to the site of inflammation113.
Activation of the endothelium by cytokines such as tumor necrosis factor –α (TNF-α)
yields exocytosis of stored coagulation factors such as von Willebrand Factor (vWF)114,
115

. TNF-α also promotes endothelial selectin and immunoglobulin superfamily receptor

expression on the endothelial cell surface116. Macrophages and endothelial cells feed the
inflammatory response by releasing the chemokine CXCL8, also known as interleukin-8
(IL-8)117. IL-8 serves as a guide for neutrophils and monocytes expressing the IL-8
receptor (CXCR1) , promoting their migration into the sub endothelial space118.
Immune cells have specific carbohydrate chains, cytokine and/or chemokine receptors,
as well as integrin which consist of alpha and beta domains that aid in the process of
diapedesis which consists of four stages including rolling, adhesion, binding, and
diapedesis. Rolling neutrophils are recruited to the site of inflammation by chemokines
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such as monocyte chemoattractant protein 1 and IL-1β, and TNF-α119. Upon reaching the
site of inflammation, neutrophils slow down and adhere to the inflamed endothelium
through interactions between CD18, a carbohydrate ligand, and P-and E-selectin120.
Moreover, macrophage derived cytokines enhance neutrophil β2 integrin affinity to their
respective receptors. β2 integrin involved in neutrophil cellular adhesion include LFA-1,
VLA4, and α4β7 which bind ICAM-1, VCAM-1, and MADCAM-1, respectively. IL-8
transforms the inflammatory microenvironment to promote massive leukocyte infiltration
to the site of infection. Finally, diapedesis is facilitated via endothelial cell permeability
and interactions with G-protein coupled receptors on the endothelial cell surface121.
A similar process is observed in monocyte extravasation as well.

Briefly,

tetrasaccharide sialyl-LewisX carbohydrate molecules are expressed on the cell surface of
monocytes recruited to the site of inflammation by chemokines such as monocyte
chemoattractant protein-1. Further up regulation of ICAM-1 and VCAM-1 allows for
secured endothelium-leukocyte interactions. Both monocytes and neutrophils play an
integral role in the development of atherosclerosis and endothelial dysfunction through
promoting unresolved insult to the endothelium.
In vitro and in vivo studies provide insight on endothelial cell responses to
inflammatory mediators that may perturb normal blood flow and endothelial cell health.
Vascular NO serves multiple functions as a vasodilator, immune system modulator, and
anti-atherogenic molecule. NO dilates blood vessels by stimulating the heme group of
soluble guanylyl cyclase (sGC), leading to cyclic guanosine monophosphate (cGMP)
production122. NO binds to the vascular adhesion molecule-1 (VCAM-1) specific nuclear
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factor kappa B (NF-κB) activation site and prevents expression of VCAM-1 on the
endothelial cell surface123.

Similarly, NO reduces specificity protein-1

(Sp1) and

activator protein 1 (AP-1) binding to the ICAM-1 promoter region124. NO can also
inhibit leukocyte adhesion molecule CD11/CD18 expression and interfere with the
leukocyte CD11/CD18 binding to the endothelial cell surface125.
In preventing atherogenesis, most of its effects are mediated through cyclic guanosine
monophosphate (cGMP) derived from activation of the “NO receptor” soluble guanylate
cyclase (sGC)

126

. sGC contains an NO heme binding site that changes confirmation

upon NO interactions.
protein kinase G

cGMP serves as a second messenger molecule which activates

(PKG)127.

PKG isozymes are serine/threonine kinases.

PKG is

expressed highly in smooth muscle cells and platelets where its activation leads to
inhibition of intracellular calcium (Ca2+ ) flux and subsequent loss of myosin light chain
kinase (MLCK) activation resulting in blood vessel relaxation128.
Early studies showed that in platelets, prevention of Ca2+ impairs integrin mediated
conformational changes in GPIIb/IIIa fibrinogen receptors responsible for platelet
aggregation129, 130. While recent findings suggest that NO inhibits platelet aggregation
under pathophysiologic conditions by blocking adenosine diphosphate

(ADP) and

collagen conformational changes in platelet gpIIb/IIIa receptors131.
Furthermore, NO prevents smooth muscle proliferation, which is important for
fibrous cap formation in atheroma. NO reacts with alkoxyl radicals to prevent oxidation
of lipids and LDL typically engulfed by macrophages that morph into foam cells, forming
atherosclerotic plaques.132
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It is clear that release of endothelium-derived NO under normal and pathophysiologic
conditions is protective against atherogenesis and vascular endothelial dysfunction .
However, NO produced in excess can be detrimental to the endothelial milieu and may
perpetuate the atherogenic process.133 Thus, tight regulation of eNOS is necessary for the
maintenance of vascular homeostasis.
`
Endothelial

Nitric

Oxide

Synthase

Regulation

Under

Normal

and

Pathophysiologic Conditions
Endothelial nitric oxide synthase (eNOS) is a member of the nitric oxide synthase
family and is encoded by the NOS3 gene present on chromosome 7 of the human
genome134. The three members of the NOS family include neuronal (NOS1/nNOS),
inducible (NOS2/iNOS), and endothelial (NOS3/eNOS). Neuronal NOS is one of two
constitutively expressed NOS isozymes and is located on chromosome 12. nNOS is
found in neuronal cells, skeletal muscle, and cardiac muscle and has been implicated as a
critical player in neurotransmission. Inducible NOS, found on chromosome 17, is not
active in resting cells but can be induced upon stimulation by proinflammatory cytokines,
LPS, and infectious pathogens. As such, iNOS is essential for host innate immune
mechanisms that prevent infection. eNOS is expressed in the endothelium and cardiac
myocytes where its primary role is the maintenance of vascular health.
All NOS isoforms consists of homodimers with uniquely structured oxidase and
reductase domains. The reductase domain of one monomer consists of binding sites for
NADPH, FMN, and FAD while the second monomer containing the oxygenase domain
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supplies the prosthetic heme group and binding sites for (6R) 5,6,7,8-tetrahydrobiopterin
(BH4), molecular oxygen, and the substrate L-arginine135, 136. Upon enzyme activation,
electrons derived from NADPH are passed to flavins and then transferred to the heme
group in the oxygenase domain. The heme iron then binds dimeric oxygen, leading to the
stepwise production of NO. In all cases, NO synthesis occurs with two enzyme cycles.
During the first cycle, L-arginine hydroxylation to Nω-hydroxy-L-arginine occurs. In the
final step, oxidation from Nω-hydroxy-L-arginine to L-citrulline occurs, and NO is
synthesized

137, 138

.

Although catalysis of L-arginine leads to NO production, the NOS enzymes have
divergent activation mechanisms. Activation of nNOS and eNOS can be dependent or
independent of increases in intracellular Ca2+ concentrations that support the binding of
calmodulin139, 140. On the other hand, iNOS immunoactivation (i.e. LPS, IFNγ) does not
require elevated Ca2+ due to iNOS’s high affinity for calmodulin in resting cells141, 142, 143.
Moreover, the duration and concentration of NO produced varies depending upon the
enzyme isoform, stimulus, and microenvironment 144.
The kinetic determinants for molecular targets are the contingent rate of production
and consumption of NO, diffusion distance, and interactions with reactive nitrogen
species

145

.

NO production rates depend on substrate and cofactor availability in

addition to the rate of electron transfer from the reductase to the oxygenase domains.
Low doses of NO (<1-30nM), generally produced by eNOS, target the conversion of
soluble guanylyl cyclase

(sGC) to cyclic guanosine monophosphate

(cGMP) and

subsequent phosphorylation of PKG ERK. At this level, NO has both proliferative and
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anti-inflammatory effects.

Moreover, the accumulation of NO between 30-60nM

promotes phosphorylation of Akt. At levels between 100-200nM, the direct effect of NO
on HIF-1α stabilization promotes cell proliferation and angiogenesis while preventing
tissue damage. Inducible NOS found in macrophages generally produces NO at the
400nM range, leading to phosphorylation of p53. Due to the scope of this dissertation,
the remainder of the discussion on NOS enzymes will be solely focused on eNOS and
endothelial-derived NO signaling pathways.

Pathobiology in eNOS Deficient Mice

Pharmacologic inhibition of NOS isoforms limits the ability to decipher between
the impacts of specific NOS isoform deficiencies as many antagonists are non-specific.
Thus, genetic manipulation of NOS isoforms is used to further understand the role of
each isoform independently.

eNOS knockout mice display hypertension, deficient

vasorelaxing activity146, and heart failure147. They also have abnormal aortic valve
function and altered wound healing capacity148, resulting from deficient response to
vascular endothelial growth factor (VEGF)-stimulated angiogenesis149 Moreover, they
are more prone to insulin resistance and moderate albuminuria, as well as developing a
phenotype mimicking human metabolic syndrome 150. However, eNOS deficient animals
do not spontaneously develop atherosclerosis due to NO synthesis by nNOS and iNOS151.
Thus, genetic manipulation of atherogenic pathways or changes in the environment (i.e.,
diet) is used in animal models to examine the role of eNOS in atherosclerosis.
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For instance, ApoE/eNOS double knockout animals on a high fat diet show
enhanced atherosclerotic lesion development and more pronounced coronary artery
disease, left ventricular dysfunction, and ineffective pharmacological blood pressure
control

152

.

Moreover, LDLr-/- animals have reduced eNOS expression and

phosphorylation, likely due to hyperactivation of the oxidized low density lipoprotein
(oxLDL)-LOX-1 pathway, which silences eNOS expression and NO production153.
Diabetic vascular complications are partially attributed to chronic suppression of
eNOS pathways.

Genetic disruption of the eNOS gene predisposes streptozotocin

(STZ) diabetic mice to accelerated retinopathy and nephropathy154. Moreover, diabetic
mice with genetically ablated eNOS present with hypertension, enhanced endothelial cell
proliferation, vascular endothelial growth factor production within the glomerular and
peritubular capillaries, and overall renal incompetency155.
Recent studies from our lab showed that in

156

MRL/lpr mice developing

spontaneous lupus, lack of NOS 3 resulted in increased aortic lipid deposition157 and
increases in clinically significant crescentic and necrotic glomerulonephritis156 . These
studies demonstrated that eNOS is a significant regulator of oxidative stress, which can in
turn signal inflammation.

Physiological stress exacerbates renal injury in these animals158. In addition, diabetic
NOS 3 (eNOS) -/- mice develop accelerated retinopathy159, more pronounced glomerular
capillary complications160, and increases in insulin resistance and hyperlipidemia150.
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Furthermore, atherosclerotic NOS 3-deficient mice exhibit larger atherosclerotic plaque
lesions161.

eNOS Polymorphisms
eNOS gene polymorphisms identified within the human genome associate with an
increased propensity toward endothelial dysfunction and cardiovascular disease
162

Furthermore, eNOS polymorphisms in exon 7 (894 GT) and in the promoter region

(T-786C) predispose patients to enhanced carotid intima-media thickness and
functional changes in the endothelium163. A study examining the GluAsp or AspAsp
genotype of the Glu298Asp eNOS polymorphism in 337 diabetic patients showed a
significant association with ischemic heart disease164. Subsequently, a study of 8 variants
of the eNOS gene in Caucasian diabetic patients revealed that -786T>C, Glu298Asp and
an intron 8 polymorphism are possibly involved in the atherosclerotic pathway 165.
Several studies have assessed the relationship between common eNOS variants and
risk or severity of SLE. The eNOS gene intron 4a/b VNTR polymorphism, consisting of
27 base-pair tandem repeats, is a risk factor for glomerulonephritis in SLE patients and
implies rheumatoid arthritis (RA) susceptibility166 167. In an evaluation of 225 northern
Chinese lupus nephritis patients, logistic regression analysis revealed a strong association
between the 894T allele and lupus nephropathy but not genotype frequency of the -786C
allele 168. In a meta-analysis examining 8 independent studies to that investigate the role
of eNOS polymorphisms in SLE disease risk, the frequency of the -786T>C genotype
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showed a moderate association with SLE disease risk167.

Nevertheless, studies

examining the link between endothelial dysfunction and eNOS polymorphisms in SLE
patients have not been reported, suggesting that changes in eNOS function in SLE are not
solely due to germ line mutations. This raises the possibility that pro-inflammatory
mediators leading to altered gene expression or enzyme function are responsible for loss
of endothelial function in lupus.
Thus, understanding mechanisms of eNOS gene regulation, expression, and
enzymatic activation may provide insight on therapeutic targets important for the
prevention of vascular abnormalities such as endothelial dysfunction.

Regulation of Endothelial Nitric Oxide Synthase Expression
Transcription, translation, and post-translational modifications regulate eNOS
expression within cells. Although there is some controversy as to whether impaired
transcription negatively impacts NO output, it is important to note that various factors
play a role in the bioavailability of NO.
Modulation of the eNOS Promoter
The eNOS promoter region contains several binding motifs for AP1 complex, Sp1/2,
NF-κB, KLF2, IL-6, p53, PEA3, YY1, shear stress, heavy metal, acute phase response-,
cAMP response-, retinoblastoma control, interferon γ response, sterol-regulatory ciselements, and GATA. Cloning experiments coupled with site specific mutations revealed
that Sp1 is an essential cis-element transcription factor responsible for eNOS basal
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transcription. Specific mutation of GATA sites within the eNOS promoter further
revealed that GATA mediated eNOS promoter activation largely influences gene
transcription169. Phorbol-12-myristate-13-acetate (PMA) induces PKC-α/Δ mediated
eNOS promoter activity in bovine aortic endothelial cells170.

Laminar shear stress

modulates eNOS mRNA expression and promoter activity by inducing transient nuclear
translocation of the p50 NF-κB subunit to the NF-1/SSRE eNOS promoter region. Yet,
NO negatively regulates NF-κB mediated transcription by nitrosylating the p50171, 172.
Unsurprisingly, controversies exist surrounding NF-κB involvement in endothelial
dysfunction173.
Growth factors also regulate eNOS promoter activity. Fibroblast growth factor 2
promotes AP-1 binding to the eNOS promoter through an ERK1/2Jun B mediated
pathway174. Vascular endothelial growth factor (VEGF) induces eNOS gene expression
possibly through an ERK1/2 dependent pathway175. Other growth factors involved in
eNOS gene expression include transforming growth factor β (TGFβ) and epidermal
growth factor (EGF)176.
Cytokines and pro-atherogenic inflammatory mediators such as TNF-α, C-reactive
protein, and oxidized LDL can impair eNOS gene expression. It is well established that
TNF-α has pleiotropic effects on eNOS gene expression. Studies have shown that TNF-α
suppresses eNOS promoter activity by promoting GATA-4 binding to the (-231) site and
Sp3 binding to the (-370) CACCCC site in pulmonary micro vessel endothelial cells177.
Of conventional cardiovascular disease risk factors, hyperglycemia was shown to impair
eNOS expression through up regulation of reactive oxygen species production and
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subsequent activation of AP-1 in human aortic endothelial cells178. Moreover, C-reactive
protein reduces eNOS gene expression, leading to diminished activity and loss of eNOS
derived NO production 179, (Figure 2-2).
Gaseous molecules also regulate eNOS transcription in physiologic and
pathophysiological conditions. Hydrogen peroxide (H2O2) enhances eNOS transcription
and mRNA half-life in response to laminar shear stress180 Yet, under pathophysiologic
conditions, up regulation of eNOS by H2O2 derived from NADPH oxidase 4 (NOX4)
activity may result from eNOS uncoupling, yielding enhanced non-nitrous reactive
oxygen species production and diminished endothelial function181

182

. Thus, controversy

exists as to whether up regulation or diminished expression of eNOS alone is sufficient to
influence NO production.
Following transcription from DNA to RNA, RNA is further processed into messenger
RNA (mRNA), which includes splicing and protein synthesis. Studies have shown that
TNFα induces post-transcriptional modifications in multiple ways. TNFα causes mRNA
instability through up regulation microRNA 155 (miR155)183. This microRNA binds to
the 3’UTR region of eNOS mRNA and causes destabilization.

This is an NF-kB-

mediated mechanism whereby TNFα causes nuclear translocation of the p65 subunit and
subsequent up regulation of microRNA 155. On the other hand, miR155 transfection in
endothelial cells lead to diminished NFkB mediated adhesion molecule expression
possibly through diminished p65 activation. These studies suggest that miR155 may play
a dual role in regulating inflammatory and anti-inflammatory responses on the proatherogenic gene axis184 Although little is known about the direct impacts of mediators
38

on translation of eNOS, eNOS activity is regulated by the availability of enzymatic cofactors, including tetrahydrobiopterin (BH4) and L-arginine.
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Figure 2-2. Cis-acting elements in the human NOS3 promoter. External
factors such as shear stress, hyperglycemia, and fibroblast growth factor-2 are able
to impact NOS3 by activating specific transcription factors.
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This figure was adapted from 185.
Searles CD. Transcriptional and
posttranscriptional regulation of endothelial nitric oxide synthase expression. Am J
Physiol Cell Physiol 2006, 291(5): C803-816.
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Post-transcriptional regulation of eNOS Activity
The Importance eNOS localization on eNOS activity
eNOS activity is highly contingent upon its cellular location. Previous studies
demonstrated that N-co-myristoylation at Gly2 in addition to post-translational Cys15/26
palmitoylation target eNOS to specific cellular membranes186, 187. In endothelial cells
following palmitoylation, eNOS is trafficked to the plasmalemmal caveolae, where it
binds to the major coat protein of the caveolae, caveolin-1188. The caveolae are a
specialized subset of lipid rafts enriched in cholesterol, glycosphingolipids,
sphingomyelin, and lipid-anchored membrane proteins189.
Caveolin-1 is comprised of approximately 82-101 amino acids and directly interacts
with the oxygenase domain of eNOS in its inactive state

190

. In vivo and in vitro

experiments support a role for caveolin-1 in the direct steric inhibition of calmodulin
(CaM) binding to the CaM binding site located within the oxygenase domain of eNOS191,
192, 193, 194

. However, upon increases in intracellular Ca2+, the Ca2+/CaM interaction leads

to CaM binding, dissociation from Cav-1, and activation of the enzyme. Other studies
have shown that enhanced Ca2+ promotes cycling of eNOS off the plasma membrane to
the Golgi apparatus, further promoting NO production195.

Still, controversy exists

regarding the relationship between eNOS location and optimal NO production.
Interestingly, evidence suggests that location-specific activation of eNOS depends on the
stimulus (i.e., vascular endothelial growth factor, insulin, etc. ).
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Influence of Regulatory Proteins on eNOS activity
In addition to Cav-1, other proteins associated with eNOS impact the enzyme’s
activity. NOSIP and NOSTRIN are novel proteins that interact with eNOS to inhibit its
activity. NOSIP is a C-terminal domain binding protein that has a direct impact on eNOS
trafficking from the plasma membrane to intracellular compartments196. On the other
hand, NOSTRIN-eNOS interactions result in trafficking from the plasma membrane and
Golgi apparatus to cytosolic compartments within the cell197. Although little is known
about the effects of inflammation on these proteins, NOSTRIN and NOSIP are
upregulated in pathophysiological conditions198 Thus, enhanced expression of these
proteins may partially contribute to the loss of NO production under pathogenic
conditions.
Heat shock protein 90

(HSP-90) is a molecular chaperone protein required for

proper folding, conformational maturity, and subsequent activation of eNOS. HSP-90
also plays a crucial role in eNOS dimerization199. HSP90 plays a protective role in
ischemia/reperfusion kidney injury through modulation of eNOS function200.

The Importance of Co-Factors in eNOS Activation
The literature suggests a causal role for BH4

deficiency in endothelial

dysfunction. BH4 is an eNOS cofactor responsible for maintaining enzyme coupling.
The rate-limiting step in de novo BH4 synthesis is GTP cyclohydrolase (GTPCH)
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.

Although the exact role of BH4 in eNOS enzymatic activity is not fully known, BH4 is
essential for proper electron transport as well as enzyme stability. Rodent and human
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studies suggest that, in the absence of BH4, endothelial dysfunction and cardiovascular
complications are exacerbated.
availability,

including

Several pathophysiological mediators impact BH4

peroxynitrite

and

other

reactive

oxygen

intermediates.

Peroxynitrite, produced from the reaction of NO and O2-, creating ONOO−, causes
reduction of BH4 to BH2. With loss of BH4, eNOS uncouples and instead of producing
NO, it produces superoxide. In addition, vasoconstrictors, such as angiotensin II reduce
BH4 levels in the endothelium by impairing activation of BH4 salvage enzyme
dihydrofolate reductase (DHFR) )202. Finally, depletion of eNOS substrate L-arginine
occurs under pathophysiological conditions.
L-arginine is an essential amino acid and serves as a substrate for eNOS-mediated
NO production by maintaining eNOS dimerization and coupling.

L-arginine is

synthesized by argininosuccinate synthetase (ASS) and argininosuccunate lyase (ASL)
from citrulline
arginine.

203

. Endothelial cells express arginases that compete with eNOS for L-

Arginase II appears to be the most dominant isozyme expressed in the

endothelium. Isolated carvernosal tissue from non-diabetic and diabetic patients with
erectile dysfunction revealed an increase in arginase II levels and reductions in nitric
oxide production204. Moreover, genetic ablation of arginase II in a streptozotocin induced
diabetic mouse model restored corpora cavernosal relaxation205. The expression and
activity of arginase II were shown to be elevated in placental vessels from women with
intrauterine growth restriction complications, while eNOS protein expression was
reduced206 . Similarly, arginase up regulation in aged aortic mice coincided with
decreased NO production and increased ROS bioavailability due to the resulting eNOS
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uncoupling207. Further supporting these studies was the finding that arginase inhibition
restored endothelial dependent vasorelaxation in response to acetylcholine, eNOS
recoupling, and subsequently reduced ROS levels in aged rats208. Thus, depletion of Larginine resulting from excessive arginase activity could explain loss of NO
bioavailability and eNOS uncoupling that perpetuate endothelial dysfunction. Studies
showing enhanced arginase II expression in SLE are missing.
The therapeutic effects of L-arginine supplementation have been well documented in
both animal and humans studies of endothelial dysfunction. L-arginine supplementation
in Type I diabetic patients significantly improved basal lower limb blood flow209.
Moreover, in patients with coronary artery disease, L-arginine was shown to improve
insulin sensitivity and cyclic guanosine monophosphate (cGMP) levels
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. Thus, both

L-arginine deficiency and loss of BH4 may contribute to deregulated eNOS coupling and
activity, leading to enhanced production of superoxide and loss of NO.

Regulation of eNOS Activity via Ca2+ Flux and Phosphorylation
Constitutively expressed eNOS cycles between active and inactive states depending
upon intracellular calcium levels within the cell. eNOS is activated via Ca2+ dependent
and independent pathways. Intracellular calcium flux leads to calmodulin binding and a
conformational change, enhancing electron transfer between domains. On the other hand,
phosphorylation of the eNOS at Ser1177 can lead to enhanced CaM binding as well as
electron flux from the reductase to oxygenase domains. Therefore, Ca2+ independent
activation of eNOS relies heavily upon endothelial cell kinase signaling pathways
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triggered by specific growth factors, cytokines, and biochemical mediators. As such,
localization of eNOS within the cell limits the rate of enzymatic activity and NO
production.
Indeed, eNOS phosphorylation plays a critical role in the activation of the enzyme.
Phosphorylation sites persist throughout the reductase and oxygenase domains. Serine
residues include Ser1177, Ser116, Ser614, and Ser633. However, phosphorylation at the
Ser1177 site controls the bulk of the phospho-eNOS activation (Figure 2-3).
Extensive research suggests that shear stress211, VEGF212, bradykinin213, and
insulin214 induce phosphorylation at the Ser1177 site in humans and Ser1179 in bovine and
mice. Ser1177 phosphorylation induces a conformational change in the auto inhibitory
loop located in the C-terminus, which promotes the flow of electrons from the reductase
to oxygenase domain. Conversely, trafficking of eNOS to the plasma membrane is
required for adequate phosphorylation, as loss of palmitoylation and myristoylation
impedes these processes 215, 216.
A number of kinases phosphorylate eNOS at the Ser1177 site, including Akt, AMPK,
CAMKII, PKA, and PKG. However, which kinase is active depends heavily upon the
stimulus as well as the microenvironment of the cell. For instance, upon extracellular
insulin binding to the insulin receptor tyrosine kinase
phosphorylation of insulin receptor substrate 1

(IR), recruitment and

(IRS-1) persists
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. This substrate

encompasses multiple binding sites whereby co-signaling partners bind to induce
downstream signaling to the phosphatidylinositol (PI) 3-kinase (PI-3K) / protein kinase
B (PKB/Akt) pathway. Akt is a serine/threonine specific kinase that phosphorylates
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eNOS at the phosphor-Ser1177 site. Akt is also activated by VEGF, Bradykinin, estrogen,
and shear stress in a similar manner. Shear stress, histamine, atorvastatin, adiponectin,
and thrombin induce AMP-activated protein kinase (AMPK)-mediated phosphorylation
of eNOS at the Ser1177 sites; while calmodulin kinase II (CaMKII)-mediated
phosphorylation can be induced by bradykinin 218.
Other studies examining the impact of Ser633 increase eNOS activity to levels
comparable to Ser1177 219, 220. In addition, Ser614 appears to have a more functional role of
stabilizing eNOS in earlier stages of activation. Yet, it appears to be a minor factor in NO
production.
Conversely, the threonine495 amino acid residue

(Thr495) is constitutively

phosphorylated by protein kinase C, an enzyme regulated by diacylglycerol, Ca2+, and
phospholipids such as phosphatidylserine
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.

Phosphorylation at this site impairs

electron flux from the reductase to the oxygenase domain by reducing Ca2+/CaM binding.
Conversely, additional studies have shown that total loss of Thr495 results in eNOS
uncoupling, suggesting that steric conformation warranted by modifications here are
essential for proper enzymatic function. Moreover, phosphorylation at Ser116 impairs
eNOS activity and NO production. Further studies are needed to determine the impact of
Ser116 phosphorylation on eNOS-derived NO.
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eNOS Agonists
Various factors promote or impair eNOS activation.

Importantly, some eNOS

agonists have the dual-role of enhancing pSer1177/1179 while inducing reciprocal
dephosphorylation of pThr495/497, shifting the enzyme to an active state.

Transient

increases in intracellular Ca2+ are also regulated by specific eNOS agonists. However, the
predominant action of biochemical factors regulating eNOS is through kinase activation
or protein-protein interactions.
Bradykinin (BK) is a well-known regulator of blood pressure control that transiently
induces PI3K/Akt mediated phosphorylation at the eNOS-serine1179 site, while reducing
Thr497 in bovine aortic endothelial cells222.

Further, BK-mediated increases in Ca2+ lead

to activation of CaM-dependent kinase II (CaMKII), which phosphorylates at the ser1177
site in porcine aortic endothelial cells213. It should be noted that BK was shown to impair
eNOS activation in bovine aortic endothelial cells, likely through activation of the ERK
pathway. Nevertheless, the phosphorylation site is unclear. Other mechanisms of BK
mediated inhibition include B2 receptor allosteric inhibition in a time and concentration
dependent manner
Insulin was initially identified as a stimulus for endothelial-derived NO production in
1994. Steinberg, et al. examined intrafemoral artery dilation in response to metacholine
chloride or sodium nitroprusside in patients who received a saline infusion or
hyperinsulinemic clamp created to double the rate of blood flow99. This pioneer study
led others to investigate mechanisms whereby insulin induces eNOS activation and NO
production. Among other Akt/PKB activators, insulin activates eNOS through Akt48

mediated phosphorylation of Ser1177/1179 in a Ca2+ independent manner223. While the
insulin receptor negatively regulates eNOS activity by promoting caveolin-1 Tyr14
phosphorylation224. Moreover, insulin induces translocation of the eNOS/Cav-1 complex
to the perinuclear region to the plasma membrane in cultured bovine aortic endothelial
cells in a PI-3K dependent manner and contingent upon increases in palmitoylation225.
Recent studies highlight the role IL-6 in insulin-resistance suggesting that inflammatory
mediators are important in modulating the insulin-eNOS axis61 Consequently, insulinmediated signaling pathways are impaired by protein kinase C-β in obesity-associated
insulin resistance.

eNOS Negative Feedback Inhibition
Caveolin-1 phosphorylation enhances Cav-1/eNOS interaction to prevent further
production of NO Moreover, NO activates NF-kB, a transcription factor which directly
binds the promoter region of the NOS3 gene to prevent transcription of the enzyme226.
While cGMP impairs calcium mediated activation of eNOS via prevention of
intracellular Ca2+ flux

227

.

Moreover, studies in cardiomyocytes revealed that NO

modulates L-arginine transport through impairing cationic amino acid transporter
activity228 .
In conclusion, Endothelial nitric oxide synthase

(eNOS) is a key regulator of

homeostatic mechanisms within the cardiovascular system.

eNOS is regulated by

multiple mechanisms including transcription, post-transcriptional, and post-translational
modifications.

Accumulating evidence suggests that interference with phosphorylation
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or protein-protein interactions may impede processes leading to NO synthesis.
Furthermore, recent evidence suggests a role for transcriptional and post-transcriptional
modifications that may be essential for NO bioavailability as well. Understanding
regulation of eNOS in physiologic and pathophysiologic conditions is essential for the
development of therapies that improve endothelial dysfunction and cardiovascular
disease highly susceptible patient populations. Recent studies suggest that Type I
interferons, specifically interferon alpha, may be a reasonable therapeutic target for
preventing endothelial dysfunction in SLE. Still, its effects on eNOS and NO production
have not been well described (Figure 2-4).
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Figure 2-3. Endothelial nitric oxide synthase is activated by calcium dependent and
calcium independent mechanisms.
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Figure 2-4. Pathophysiologic conditions negatively modulate nitric oxide
production through various pathways. Oxidative stress, for example, is known
to induce eNOS uncoupling and subsequent loss in NO. While, inflammatory
cytokines often impair eNOS activation and expression leading to deficient eNOS
derived NO.
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Endothelial Dysfunction and Type I Interferons in SLE
Type I interferons accelerate atherosclerosis in both mice and humans.
Atherosclerotic plaque area, triglyceride levels, and serum cholesterol levels were
increased following low dose IFN-α treatment in LDLr-/- mice, a phenomenon possibly
due to enhanced lipolysis229. Moreover, NZM (lupus prone) Apoe-/- Ifnar-/- mice have
improved aortic ring relaxation, less platelet aggregation, decreased T lymphocyte and
macrophage plaque infiltration, and declines in thrombosis compared to animals with the
receptor intact230.

Surprisingly, rat aortic rings treated with high dose IFN-α show

reductions in relaxation, which may be an indication of impairments in endothelial cell
function231. These combined studies show effects of IFN-α on multiple stages of
atherosclerosis and vascular complications in mouse models, thereby providing further
evidence for type I IFN-specific mechanisms involved in the increased incidence of CVD.
As is true of Framingham risk factors and vasodilation, IFN-α also alters levels of
circulating endothelial progenitor cell (cEPCs), an additional marker of ED. Moreover,
like patients with Framingham risk factors, SLE patients have reduced levels of cEPCs,
leading to loss of vascular repair and potentiated vessel damage232.
Previous studies indicate that eNOS-derived NO regulates cEPC mobilization and
functions in response to VEGF233, shear stress, estrogen234, and exercise235. In support of
these findings, studies in mice show that VEGF-mediated NO production leads to the
release of EPCs from bone marrow following enhanced matrix metalloproteinase-9
(MMP-9) secretion from stromal cells236. Similar to conventional CVD risk factors, type I
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IFNs associate with attenuated mobilization and function of EPCs in SLE patients.
Moreover, SLE EPCs mature abnormally and display reductions in VEGF and human
growth factor gene expression in vitro. In addition, these abnormalities are restored with
the addition of anti-IFN-α neutralizing monoclonal antibodies237. Lupus patients with
significant reductions in peripheral blood EPCs display increases in peripheral blood
mononuclear cell (PBMC) expression of MX1, a reporter gene for Type I IFN. Patients
with elevated MX1 levels also exhibit declines in vascular reactivity and endothelial
dysfunction as measured by peripheral arterial plethysmography238. Studies associating a
type I IFN signature with endothelial dysfunction are limited in SLE patients; however,
examples of this phenomenon are demonstrated in other non-autoimmune populations,
such as those with hepatitis C.
Early studies in chronic hepatitis C patients demonstrate a role for IFN-α in
exacerbating cardiovascular complications and endothelial dysfunction. Compared to
those not treated with IFN, patients receiving IFN-α 2b therapy had increased incidence
of atrioventricular block239, myocardial disease240, ischemic heart disease241 and severe
sinus bradycardia242 in the absence of traditional cardiovascular risk factors. Accordingly,
upon discontinuation of IFN treatment, patients improved, suggesting that IFN-α
treatment effects were transient rather than permanent 243.
During treatment, Hepatitis C patients demonstrated impaired flow mediated
vasodilation244 in addition to increases in VCAM-1, monocyte chemotactic protein-1
(MCP-1) production, and fibrinogen release245. These findings demonstrate that high
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serum levels of Type I IFN directly mitigate proper endothelial function and counteract
pathways normally regulated by NO. Still, controversy remains about whether or not
these effects of IFN-α in therapeutic settings are causes for concern, as some studies
suggest only modest effects of IFN-α on cardiac toxicity243, 246.
Furthermore, this elevation in Type I interferons may play a role in the suppression of
eNOS activity expression within the vasculature in SLE patients, making them more
susceptible to vascular pathologies. To understand the effects that Type I interferons may
have on eNOS function, the role of eNOS in physiologic and pathophysiologic conditions
must be elucidated.

Endothelial Nitric Oxide Synthase and Type I Interferons
It is now understood that inflammatory production of Type I IFNs and their
therapeutic use may cause changes in vascular endothelial function. Thus, a focus on the
mechanisms whereby IFN-α may alter eNOS and NO production is justified.

The

question therefore arises as to how and if Type I interferons can affect eNOS function
and NO production. To date, no studies have published the impact of IFN-α on eNOS
enzymatic function and NO production. However, type I IFNs have been reported to
have direct and indirect effects on eNOS specific transcription factors, co-factors
important for eNOS regulation, kinases and phosphatases important for enzyme
regulation, and oxidative stress pathways.
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Modulation of transcription factor binding to the eNOS promoter is affected by
humoral and physical factors in (patho) physiologic states. Regulatory transcription
factors were shown to include the followings: Sp1/3 and AP-1 and 2-transcription factors.
Reductions in the binding of Sp1/3-containing complexes with the eNOS promoter leads
to declines in eNOS expression in TNF-a–treated bovine aortic endothelial cells.20
Like TNF-α, IFN-α reduces Sp1/3 activation, leading to decreases in VEGF
transcript levels in pancreatic carcinomas247. IFN-α also alters Sp1 binding in primary
human hepatocytes, leading to decreased c-Met mediated cell proliferation248. eNOS
promoter activity is also dependent upon AP-1 binding. Previous studies showed that
porcine aortic endothelial cell (PAEC) exposure to hydrogen peroxide (H2O2) lead to
declines in eNOS expression as a result of impaired AP-1 eNOS promoter binding249.
Likewise, transfection of IFN-α adenovirus into 253J BV cells blocks AP-1 activation in
addition to other nuclear pro-angiogenic signals250. Thus, IFN-α may reduce eNOS
transcription by affecting the expression of transcription factors essential for eNOS
promoter activation.
eNOS is activated by phosphorylation at serine sites located within the reductase
domain, including serine1177, serine 633, and serine
threonine

495

615

and dephosphorylation at serine114,

and tyrosine657 251. Phosphatase 2A (PP2A) blunts phosphorylation of the

enzyme at the activation sites in CRP-primed human aortic endothelial cells (HAECs)73.
PP2A activation occurs upon stimulation by intracellular enzymes, including the IFN
response gene protein kinase R (PKR)252. Further, PKR stimulates other kinases known
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for preventing eNOS-S1177 activation, including Jun N-terminal kinase (JNK) and
extracellular signal regulated kinase1/2 (ERK1/2) activation253. Alternatively, it has been
demonstrated that PKR promotes p38 activation, a kinase previously shown to
phosphorylate eNOS-S1177 in human vascular endothelial cells in response to insulin254.
eNOS-specific kinases are activated by extracellular stimuli like VEGF. IFN-α, given as
a treatment for liver cancer, suppress VEGF mRNA transcription, VEGF plasma levels,
and micro vessel densities255.

Moreover, human umbilical vein endothelial cells

(HUVECs) treated with IFN-α and 5-fluorouracil

(5-FU) had reduced VEGF

transcription and secretion256. Collectively, these studies suggest a possible role for IFNα induced changes in eNOS phosphorylation through down-regulation of VEGF and loss
of kinase activation (Figure 2-5).
Type I Interferon and Tetrahydrobiopterin (BH4)
BH4 is essential for proper eNOS coupling and the flow of electrons from the
reductase domain to L-arginine and subsequent NO production. Proper BH4 levels are
important for endothelial cell maintenance, where 60% of all BH4 has been identified in
the vascular wall257,
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Inadequate supply of BH4 during oxidative stress can lead to

eNOS uncoupling, either through inadequate synthesis by guanosine 5’-triphosphate
cyclohydrolase 1 (GTPCH) or oxidation of BH4 259. Although the exact effects of IFN-α
on BH4 synthesis and oxidation remain unclear, both animal and human studies support a
role for IFN-α in BH4 depletion.
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IFN-α (105 units/kg) injections in rat amygdala and raphe areas leads to abatement of
BH4 260. Moreover, IFN-α-treated hepatitis C subjects have low levels of BH4 and higher
levels of its inactive oxidized form dihydrobiopterin (BH2)
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. Thus, IFN-α may serve

as a potential mediator of eNOS uncoupling and oxidative stress in vascular ED by
promoting depletion of eNOS co-factors.

Collectively, these studies suggest that

exposure to IFN-α may lead to BH4 depletion via oxidation
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(Figure 2-6).

When BH4 levels are low and eNOS remains uncoupled, the enzyme can act as an
NADPH oxidase, producing reactive oxygen species (ROS) in excess. Superoxide (SO)
scavenges NO via a direct chemical reaction that yields peroxynitrite

(ONOO-)

production within the vascular wall. It is important to note that peroxynitrite has multiple
pro-atherogenic effects. First, it oxidizes the eNOS cofactor BH4 to BH3. radical. This
oxidation, in turn, uncouples NOS and reduces NO production, while simultaneously
increasing SO production. Second, it causes inhibition of cellular L-arginine transport
important for NO production 262. Third, ONOO- stimulates release of thromboxane A2 , a
known contributor of eNOS dysfunction
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. Fourth, ONOO- activates the production of

PP2A, leading to dephosphorylation of eNOS and endothelial dysfunction. Thus, ONOOcauses eNOS uncoupling and inactivity in addition to perpetual SO production.
SO has multiple indirect effects on eNOS function. For example, it oxidizes LDL to
oxLDL. OxLDL, in turn, binds to LOX-1 and CD36 expressed on the endothelial cell
surface, which, upon activation, can inhibit eNOS activation. OxLDL also stimulates
xanthine oxidase and NADPH oxidase (NOX) to produce SO anions, which likely
promotes eNOS deactivation. Collectively, these studies suggest that SO negatively
impacts the endothelium by reducing availability of physiologic NO and promoting a
continuous cycle of oxidative stress.
Type I Interferons, Arginase, and L-arginine
Studies examining the role of interferon on L-arginine availability are also limited.
However, a study conducted in high-risk melanoma patients showed that pegylated IFNα caused reductions in arginine availability and overall declines in NO production 264. In
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addition, IFN-α induces NO synthase 2

(iNOS) in various cell types, resulting in

depletion of extra- and intracellular L-arginine stores 265. Thus, IFN-α mediated depletion
of L-arginine may result in loss of NO ultimately leading to ED observed in patient
populations including SLE.
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Figure 2-6. IFNα may impact NOS3 transcriptional regulation. Factors
regulated by IFN-α potentially involved in the loss of endothelial derived NO are:
negative regulation of vascular endothelial growth factor (VEGF) production
important for eNOS activation; impaired activator protein-1 (AP-1) activation and
specificity protein 1 and 3 (SP1/3) function, both responsible for nitric oxide
synthase 3 (NOS3) transcription.
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Type I Interferons, Reactive Oxygen Species, and Endothelial Dysfunction
Imbalances in L-arginine and other co-factors essential for proper eNOS regulation
can lead to the phenomenon known as oxidative stress. Oxidative stress is characterized
as an imbalance in the production of reactive oxygen species and antioxidants, leading to
dysfunctional endothelial cells. ROS impacting endothelial cell signaling mechanisms
include free radicals such as SO, ONOO.- (peroxynitrite), and OH. (hydroxyl radical),
and non-radicals including H2O2.

Conventional risk factors including hypertension,

diabetes mellitus, and hypercholesterolemia dramatically potentiate ROS levels in the
vascular wall, promoting oxidative stress.
The magnitude of oxidative stress depends on levels of oxygen free radicals

(SO)

within the cell and the availability of antioxidants to reduce these molecules. In addition
to uncoupled NO synthases (NOSs), a number of enzyme systems produce ROS in
endothelial cells including NADPH oxidases (NOX)266, xanthine oxidases, arachidonicacid metabolizing systems, the mitochondrial electron transport chain, and the
cytochrome P450 enzyme. Conversely, three superoxide dismutase enzymes are
important for counteracting superoxide production including copper zinc SOD,
manganese SOD, and endothelial cell SOD. On the other hand, H2O2 degrades in the
presence of glutathione peroxidase and catalase.
SO production in the endothelium is mainly derived from NOX, xanthine oxidase,
and NOS enzymes. NOX 2 and 4 are the major producers of SO in the endothelium;
however, other isoforms of these enzymes can be expressed by vascular smooth muscle
cells and infiltrating inflammatory cells that could ultimately impact NO production and
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availability along with endothelial function. Evidence for NOX activation in the vascular
wall has been provided in human studies. In a clinical setting, NOX2 was shown to be
most important in producing cytotoxic levels of ROS in insulin-resistant endothelial
cells267. Moreover, studies in patients undergoing coronary artery bypass graft surgery
showed NOX as the major source of ROS production resulting in ED268. In addition to
NOX, others have shown exogenous xanthine oxidase prevents VEGF-induced NO
production and endothelial cell survival whereas endogenous levels of NO are important
for normal cell signaling mechanisms269. Uncoupled NOS is also a significant generator
of SO and is reportedly involved in the pathogenesis of atherosclerosis270, 271, 272.
Free radical reactions between SO and NO result in ONOO.- synthesis and,
inactivation of NO. NO is not only important for blood vessel dilation and homeostasis,
but also binds and inhibits complex IV in the electron transport chain, impairing release
of ROS. NO also impairs activation of NOX enzymes within the cell, thus further
regulating ROS production. NO also serves as a paracrine agent by modulating NOX 1
expression in mesangial cells and regulating the activity of NOX2 via phosphorylation of
the NOX 2 p47 subunit273.

However, an imbalance in NOX activation yields NO

depletion and subsequent endothelial dysfunction.

IFN-α induces NADPH oxidase

activation and SO production in endothelial cells, promoting leukocyte adhesion to rat
vessel walls, a phenomenon abrogated by SOD and other immune modulators274.
Moreover, IFN-α induces NADPH oxidase activation in rat liver pre-neoplasia leading to
apoptosis. However, studies are missing showing the downstream impacts of IFN-α
triggered

NOX

stimulation

and

loss
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of

NO

signaling

(Figure

2-7).

Figure 2-7. IFNα may promote oxidative stress leading to eNOS uncoupling
and NF-kB induction. Nicotinamide adenine dinucleotide phosphate oxidase
(NADPH oxidase) transcription via NF-kB and its activation were also previously
shown to be mediated by IFN-α and, are important for superoxide (O2.-)
production contributing to peroxynitrite (ONOO-) synthesis in the presence of NO.
ONOO- has detrimental impacts on the endothelium including reduction of
tetrahydrobiopterin (BH4) to dihydropteridine (BH2) resulting in eNOS
uncoupling. The uncoupling of eNOS disturbs oxidative balance by increasing the
production of O2.- within the cell and, may cause cellular dysfunction owing to an
overwhelming amount of oxidative stress. Incidentally, loss of NO yields platelet
aggregation, monocyte chemoattractant protein-1 (MCP-1) production, vascular
adhesion molecule-1
(VCAM-1) transcription and, intracellular adhesion
molecule-1 (ICAM-1) expression that may be partially due to unhalted activation
of NF-kB.
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Conclusion
Endothelial dysfunction is highly prevalent among lupus patients and associates
with multiple circulating factors including Type I interferons. Studies in other tissues and
disease states support a role for IFN-α in reducing transcription of eNOS, reducing posttranslational activation of eNOS, reducing eNOS cofactor availability leading to
uncoupling, and increasing reactive oxygen production that can lead to scavenging of NO.
However, studies regarding the role of Type I interferons in eNOS dysfunction and loss
of NO bioavailability both directly and indirectly in lupus patients are missing. As
detailed here, Type I interferons may serve as novel, rational targets for study in
preventing ED in SLE patients.
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Chapter III
Materials and Methods
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Common Methods for Chapters IV and V
Patient population
This research was conducted in accordance with the Helsinki Declaration with approval
from the Institution Review Board at the Medical University of South Carolina.
Specimens for this study were stored and collected from study visits that were part of a
longitudinal observational cohort study known as the SLE Gullah Health or SLEIGH
study initiated in 2002 by Dr. Diane Kamen. A thorough description of the study has
previously been described275.

All patients classified as SLE meet 4 of the 11

classification criteria as specified by the American College of Rheumatology (ACR)7.

Clinical Characteristics of the Study Population
Clinical characteristics of the study populations are outlined in Table 3-1. There
was no significant difference between the two groups in patient age, race, or sex.
Systolic and diastolic BP were similar as well. Lupus disease activity was assessed
by SLE Disease activity index (SLEDAI) scores and systemic lupus international
collaborating clinics

(SLICC) scores which is an assessment of irreversible

damage.

70

71

Table . 3-1.

Data Collection
Blood from healthy and SLE participants were collected in a sterile vacutainer blood
collection tube and whole blood was allowed to clot at 25°C for 10 minutes. Samples
were centrifuged to remove the clot and remaining serum was stored at 80°C for future
use.

Neutrophil Isolation
The Institutional Review Board at the Medical University of South Carolina approved use
of human neutrophils and all donors provided informed consent. Neutrophils were
isolated as previously described
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. Briefly, 20 mls of human blood was acquired from

healthy volunteers and cells were isolated using Lymphocyte Separation Medium
(Cellgro, Manassas, VA, USA). The assay was validated based on forward scatter and
side scatter using flow cytometry as shown in Figure 3-1.

Endothelial Cell Culture and Serum Treatment

Primary HUVECs from pooled donors were purchased from Lonza (Walkersville, MD)
and cultured according to the manufacturer’s instructions in 5% CO2 at 37°C. HUVECs
were subcultured using TryPLE Express dissociation reagent when cells were 70-80%
confluent. Cell growth was limited to 12 population doublings and all experiments were
carried out using cells between passages 3-5.
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Figure 3-1. A. Depiction of neutrophil-like subset isolated from whole blood
using lymphocyte separation medium. Cells are characterized using the flow
cytometer forward and side scatter measures. B. A transwell assay is used to
determine the impact of serum on neutrophil cell migration.
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Real Time Reverse Transcription-PCR (RT2PCR)
To detect changes in mRNA levels, HUVECs were treated for 0,1,6,12, and 24hr with
various concentrations of IFN-α 2a (PBL Interferon Source, Piscataway, NJ) or 20%
SLE or control sera.

Cells were harvested following treatment and total RNA was

extracted using a Trizol (Life Technologies)-RNeasy® kit (Qiagen, Frederick, MD,
USA) hybrid protocol as previously described277. RNA integrity was assessed using a
NanoDrop 2000c UV-Vis spectrophotometer (ThermoScientific, Wilmington, DE, USA)
and samples with A260/280 ratios of 1.8-2.1 were used.

Single strand cDNA was

synthesized from 1ug of RNA using an iScript™ cDNA synthesis kit (BioRad, Hercules,
CA, USA ). For each reaction, 1uL of cDNA product was used for signal amplification
with SsoAdvanced™ universal SYBR® (BioRad) in a CFX96 Real Time PCR Detection
System (Bio-Rad Hercules, CA), was used to assess changes in NOS2, NOS3, CCL2,
VCAM-1, ICAM-1, NOX2, NOX4, GAPDH, and RPL13A using commercially available
primers

(SABiosciences, Frederick, MD, USA).

The following additional

oligonucleotide primers were used: PKR: Forward 5’CTT CCA TCT GAC TCA GGT
TT—3’ and Reverse 5’ TGC TTC TGA CGG TAT GTA TTA—3’, IFIT1: Forward 5’
CTC CTT GGG TTC GTC TAT AAA TTG 3’and Reverse 5’- AGT CAG CAG CCA
GTC TCA G -3’ , MX1: Forward 5’- TAC CAG GAC TAC GAG ATT G3’ and Reverse
5’-TGC CAG GAA GGT CTA TTA G-3’. Each cycle was initiated for 3 minutes at 95ᵒC
required for enzyme activation, followed by 39 cycles of denaturation at 95ᵒC for 15s
75

and annealing 55-60ᵒC for 30s depending on the primer sequence. Melt-curve analysis
was set for 80 cycles with stepwise increments of 0.5ᵒC for 5s/step starting at 65°C. The
relative expression was calculated using the equation 2-ΔΔCt. The fold change gene
expression of interest was calculated based on normalization to GAPDH or RPL13A
housekeeping genes. PCR was performed ≥ 3 independent experiments with at least
three replicates.

Measurement of Nitric Oxide Production
For real time detection of NO production in HUVECs, 1.2x105 cells were seeded in a 12
well tissue culture plate.

Following adherence, cells were serum starved for 6h in

endothelial basal media (EBM) containing 0.2% FBS. Cells were stimulated with either
50% healthy or SLE sera ± L-sepiapterin (5uM; 6h), 1000IU IFN-α 2a (30 min, 6h, or
24h pre-incubation), the eNOS specific inhibitor L-NNA (10uM; 30 min pre-incubate),
or the NO donor DD1. Following stimulation, cells were washed twice with PBS and
loaded

with

1uM

DAF-FM

diacetate

(4-Amino-5-Methylamino-2’,7’-

Difluorofluorescein Diacetate (Invitrogen, OR, USA) in phenol red free Endothelial
basal media

(EBM) for 30-45 minutes. Cells were washed twice with PBS and

stimulated with Insulin (100nM, Sigma Aldrich) for an additional 20 minutes. The
stimulated cells were dissociated from plates using phenol-red free TryPLE™ Express
(Invitrogen) and fixed with 2% paraformaldehyde (PFA) for 3 minutes. A population of
7,000-10,000 cells were gated and analyzed based on their fluorescence intensities using
FACS Calibur (Becton Dickenson; San Diego, USA). The median fluorescence intensity
and was normalized to respective populations in unstimulated cells. In order to
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discriminate between NO other gaseous molecules previously shown to augment DAFFM fluorescence, we performed an urate assay to optimize our assay.

Neutrophil Adhesion Assay

HUVECs were plated at 5.0x 104 cells/ml in a 24 well plate (Costar) and allowed to
adhere overnight. HUVECs were serum starved for 3h in phenol-red free 0.2% FBS EBM
media (Lonza) prior to activation with 10% sera or IFNα for 4 hours. TNFα (100ng/ml)
was used as the positive control. Neutrophils isolated from healthy human blood as
outlined previously were labeled with Calcein AM (Life Technologies) at 5x105 cells/ml.
Neutrophils were washed gently four times in warm serum free EBM culture media prior
to co-culturing with HUVECs for 60 minutes after which, non-adherent cells were
removed by repeated gentle washing (four times) with EBM culture media. Fluorescence
intensity was measured at 520nM with a FLUOStar Omega microplate reader (Cary,
NC), and images were captured using confocal microscopy. See Figure 3-2 for a visual
depiction of the assay.
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Figure 3-2. A. Nitric oxide prevents neutrophil adhesion to the endothelial cell
surface. B. Neutrophil adhesion assay requires four different steps. These include
stimulation of endothelial cells with serum or interferon alpha, the cells are then
washed and calcein AM stained neutrophils are added to the well. The neutrophils
are co-cultured with endothelial cells for one hour and all non-adherent cells are
removed using gentle washing. Cells are then analyzed using a fluorescent
microreader and fluorescent microscopy.
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Western Blot
HUVECs in culture were serum starved overnight in EBM phenol red free media
containing 0.1% FBS. Cells were treated with IFN-α (1000IU/ml) at various time points
and/or insulin 100nM for 15 minutes following IFN-α pretreatment. Cells were washed
once with cold PBS and lysed using a 1X RIPA lysis buffer (50mM Tris-HCl, ph 7.5,
150mM NaCL, 1% Triton X-100, 0.5% deoxycholate, 0.1 mM EGTA, and 1mM EDTA,
0.1% SDS, 100nM okadaic acid, 1:100 protease/phosphatase inhibitor cocktail (Cell
Signaling, Danver MA, USA). Protein concentrations were determined using the Bio-Rad
Protein Assay (Hercules, CA). Protein lysates (30ug) were separated on precast 4-12%
Tris-HCL Invitrogen gels and transferred for 12-18 hours at 40mAmps in transfer buffer
(192mM glycine, 25mM Tris-HCl, and 20% (v/v)methanol) onto a PVDF membrane.
Following transfer, blots were rinsed for 10 minutes in 1X PBS and then blocked for 1h
in Odyssey® Blocking Buffer, TBS (Li-CR Biosciences, Lincoln/Nebraska, USA) at
room temperature. Membranes were incubated overnight with mouse monoclonal
antibody specific for eNOS, eNOS Ser1177, eNOS Thr495 (BD Biosciences) and β-actin
(Cell Signaling, Danver, MA) were detected using their respective antibodies. Infrared
dye goat anti-mouse secondary antibodies

(Li-COR Biosciences, Lincoln/Nebraska,

USA) were used for signal enhancement, and all blots were visualized with the Odyssey
scanner (Li-COR Biosciences). Quantitative analyses of band intensity was performed
using Image Studio Software v3.1 (Li-COR Biosciences).
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Measurement of MCP-1
MCP-1 concentrations in HUVEC supernatants were determined by enzyme-linked
immunosorbent assay (ELISA, eBioscience) according to the manufacturer’s instructions.

Statistical Analysis and Data Handling
Statistical analysis was conducted using IBM SPSS Software

(Armonk, NY) or

GraphPad Prism Version 6.0f (San Diego, CA). Gaussian distribution was determined
using the D’Agostino-Pearson omnibus normality test and the Shapiro-Wilk normality
test. Paired and unpaired (where appropriate) Student’s t and nonparametric MannWhitney test were used depending on the distribution of the data when data were
normalized to control.

Analysis of variance (ANOVA) and Tukey’s post-tests where

data were normally distributed and Wilcoxin Rank’s Sum with Dunn’s post test was used
to analyze neutrophil adhesion data. Data are presented as mean ± standard deviation.
Differences were considered significant if the p value was less than 0.05.
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Chapter IV Specific Methods

Neutrophil Migration Assay
Transwell migration assays were performed as described elsewhere. Briefly, transwell
inserts (3um pore) were pre-coated with fibrinogen and allowed to incubate overnight for
24 hours. HUVECs were seeded in 24 well plates at 1.0 x 104 cells per well and allowed
to adhere overnight. Cells were activated with 50% sera from healthy and SLE controls
for 6hrs and washed once in PBS. Neutrophils were added to chambers and inserted into
media ± IL-8. After 60 minutes, the number of neutrophils in the lower chambers using
confocal microscopy. See figure 3-1 for a visual depiction of the assay.

Low Temperature Electrophoresis (Uncoupling Assay)
To determine the impact of sera on changes in eNOS dimer/monomer ratios, low
temperature electrophoresis was conducted. Growth arrested HUVECs were treated with
50% healthy or control sera in the presence or absence of L-sepiapterin (5uM) for 6h.
Cells were washed in ice-cold PBS and lysed in Tritox-X 100 buffer supplemented with
protease/phosphatase inhibitors (1:100) and okadaic acid (1000nM). Nupage sample
buffer (4x) was added to samples and lysates were incubated for 5 minutes in a 37C
water bath prior to electrophoresis.

NuPAGE Novex 3-8% Tris-Acetate gels

(Invitrogen) and buffers were cooled to 4C prior to the addition of protein samples to the
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gel. Electrophoresis and transfer were performed on ice at 4C and membranes were
subsequently probed for eNOS and β-actin.

Chapter V Specific Methods

cGMP Assay
HUVECs were cultured at 5x105 cells per ml and allowed to adhere overnight. Cells
were treated with various compounds and assayed following the protocol provided with
the cGMP commercially available assay kit (cGMP EIA Biotrak,GE Healthcare, HK
Limited, Buckinghamshire, UK).

Heteronuclear RNA Assay
cDNA was synthesized as outlined above.

The following primer sequence for

heteronuclear eNOS RNA was used: Forward-5’-ACC CTC ACC GCT ACA TC-3’ and
Reverse 5’-C GGG GAC AGG AAA TAG TTG A-3’. PCR Master Mix (Promega,
Fitchburg, WI, USA) was used for PCR. Each cycle was initiated for 3 minutes at 95°C
followed by 40 cycles of 45s at 95°C, 45s at 49°C, and 45s at 72°C. The final cycle was
ran at 72°C for 7 minutes. Samples were separated on a 1.5% agarose gel, and bands
were quantified using Image J Software

(NIH, Bethesda Maryland). Commercially

available S26 was used as the internal control, and values are reported as the mean and
standard deviation of the fold change of unstimulated cells.
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Actinomycin D Stability Assay
To determine changes in NOS3

(eNOS) mRNA stability, cultured HUVECs were

pretreated with Actinomycin D (5ug/ml, Sigma Aldrich) for 2hrs followed by treatment
with IFNα (1000IU/ml) and TNFα (100ng/ml, control) for 6 and 24hrs. Samples were
processed for RNA extraction as described above and assayed accordingly using RT2PCR.
β-actin was used as the internal housekeeping control.

Transfection of PKR and NF-kB-specific siRNA into endothelial cells
PKR, NF-κB, and negative control siRNA were purchased from Invitrogen (Grand
Island, NY, USA). HUVECs were plated at 1.0*10^5 cells per well in a six well plate
and allowed to adhere overnight. Cells were then transfected using Lipofectamine®
RNAiMAX reagent according to the manufacturer’s instructions. After 24-36h, cells
were stimulated with IFN-α (1000IU/ml) for 6h and RNA was isolated to examine
changes in eNOS gene expression using RT2PCR.

Analysis of microRNA 155 Expression
Real Time RT-PCR analysis was conducted using a relative quantification (ΔΔCT)
method to calculate changes, and all values were normalized to untreated samples.
Analysis was performed using a TaqMan MicroRNA Reverse Transcriptase Kit and the
individual TaqMan MicroRNA 155 assays (Applied Biosystems, Grand Island, NY,
USA) and TaqMan Universal PCR Master Mix. Isolated RNA was reverse transcribed,
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and expression of mature hsa-miR-155 (assay ID: TM 002623) was determined using
CFX96 Real Time Detection System as outlined previously. RNU6B (assay ID:001093)
was used as an internal control.
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Chapter IV
SLE Serum Induces eNOS
Uncoupling in Human Umbilical
Vein Endothelial Cells
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Introduction
Myocardial infarction, preceded by accelerated atherosclerosis, constitutes a
major cause of morbidity and mortality in patients with SLE. Immune dysregulation
contributes to poorer prognosis in cardiovascular disease outcomes in SLE; however, the
exact mechanisms are unknown. SLE serves as an independent risk factor for endothelial
dysfunction, which precedes atherosclerotic plaque development. Endothelial integrity
preservation occurs when endothelial nitric oxide synthase (eNOS) activity and nitric
oxide (NO) bioavailability are intact.
Biopsies isolated from patients with severe lupus nephritis show diminished
eNOS expression; while we previously reported that MRL/Faslpr/J mice deficient in
eNOS developed increases in proteinuria had lower rates of survival. These findings
indicate that advanced vascular disease occurs in a lupus-like microenvironment in the
absence of eNOS. Patients with CV risk factors

(i.e. diabetes, hypertension, and

smoking) have diminished flow mediated brachial artery dilation, a surrogate marker of
endothelial dysfunction. Further, in vitro studies using serum from these patient
populations confirmed alterations in eNOS (NOS3) mRNA levels and diminished NO
bioavailability from endothelial cells; a phenomenon mainly due oxidative stress-induced
eNOS uncoupling.
Oxidative stress is an imbalance in the production and neutralization of reactive
intermediates

(i.e. reactive oxygen species, reactive nitrogen species).

Sources of

superoxide in the endothelium include gp91 phox (Nox2), Nox4, and mitochondrial
biogenesis as well. Conventional cardiovascular risk factors (i.e. hypertension, diabetes
87

mellitus, and hypercholesterolemia) promote generation of reactive oxygen species
(ROS) including hydrogen peroxide (H2O2) and superoxide (O2.-) leading to endothelial
dysfunction.
Controversy regarding the role of eNOS gene expression in NO bioavailability
persists.

Several studies have implicated an increase rather than a decrease in eNOS

expression in response to cardiovascular risk factors including hypertension278,
diabetes279,

280

, and smoking. Accordingly, a positive correlation between H2O2 and

eNOS levels in vitro

180

peroxynitrite (ONOO-).

. Paradoxically, NO produced in the presence of O2.- yields
Peroxynitrite oxidizes the essential eNOS co-factor BH4 to

dihydrobiopterin (BH2) and biopterin which results in ROS rather than NO production
281, 282

.
In the present study, we used human umbilical vein endothelial cells to study the

impact of SLE serum on eNOS expression and NO production in vitro. We report for the
first time that SLE serum induces NOS3 expression and suppresses NO production in
HUVECs.

Importantly, we show that L-sepiapterin, a precursor of BH4 synthesis,

restores abnormal NO production in lupus sera cultured endothelial cells leading to
restoration of eNOS dimer/monomer ratios. Further, we report that SLE serum induces
neutrophil chemotaxis and adhesion to the endothelial cell surface; but, L-sepiapterin
fails to impair SLE-serum mediation neutrophil adherence. These results point to a role
for eNOS uncoupling in lupus-mediated endothelial dysfunction.
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Results

SLE sera enhances NOS3 mRNA Abundance

Compared with healthy controls, SLE serum induced NOS3 mRNA < 2-fold
(Figure 4-1A), which may suggests that mediators present in SLE serum are inducing
oxidative stress.
It is well established that aging is a risk factor for endothelial dysfunction and
cardiovascular disease; thus, we examined correlations between NOS3 mRNA and age in
controls versus SLE patients

(Figure 4-1B) and observed a significant negative

correlation with age in the SLE group (rho= -0.5884, p=.0025) but, not in controls.
Similar significant correlations were found

NOS3 mRNA levels did not correlate with

SLE disease activity index (SLEDAI) scores (r=0.2482 and p=0.2419; Figure 4-2A, B),
however; a positive correlation was identified with SLICC scores
p=0.0887).

(r=0.3550 and

Similarly, no correlation was found between NOS3 mRNA levels and

prednisone use status (Figure 4-2C).
Due to NOS3/eNOS modulation of blood pressure regulation 283, 284, we examined
associations between systolic and diastolic blood pressure with NOS3 mRNA (Figure 42D, E). We observed an association between NOS3 mRNA induction and systolic but not
diastolic BP (r=-0.5176 and p=0.0590 and r=0.2399 and p=0.3709, respectively).
Studies supporting a role for type I interferons in the pathogenesis of endothelial
dysfunction in SLE led us to hypothesize that type I interferon induction may impact
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NOS3 mRNA levels. Type I interferon signature gene analysis indicated that protein
kinase R gene induction negatively correlated with NOS3 mRNA levels (r=-0.442,
p=0.031; Figure 4-3A). While MX1 and IFIT1 did not (Figure 4-3B, C).
Given that our cohort had relatively low Framingham risk factors (4% smokers
and 4% diabetic), and the fact that age, PKR, SLICC scores and blood pressure all
modulate the inflammatory response in vivo and in vitro, lupus specific-inflammatory
mechanisms may promote abnormal levels of NOS3 induction observed in our studies.
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Figure 4-1. SLE Sera induces NOS3 mRNA expression in human
umbilical vein endothelial cells.
A. Induction of NOS3 mRNA is
significantly increased by 20% SLE serum versus healthy serum. The
scatter plot represents the mean fold change and error bars are the 95%
confidence intervals whiskers of 14 healthy and 25 SLE patient samples.
Analyses were performed using a student’s T-test (**p<0.01). B. Lupus
induced NOS3 mRNA levels correlate with patient age but, not in
healthy serum samples. NOS3 is plotted as a function of individual
patient age. Lines are drawn based on linear regression and
correlative analysis was conducted using a Spearman’s rho test.
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Figure 4-‐2. Correlative associations between SLE sera mediated NOS3
mRNA induction and clinical parameters. A. Changes in NOS3 mRNA
levels do not correlate with disease activity. NOS3 mRNA levels are
plotted as a function of SLEDAI scores in individual patients. B.
Altered NOS3 mRNA levels associate but do not significantly correlate with SLE
damage index (SLICC) scores. NOS3 mRNA levels are plotted as a function of
SLICC scores for individual patients. C. Lack of association between NOS3
mRNA and prednisone use status. The graph represents the average fold change
in NOS3 mRNA levels in patients with or without prednisone in their daily
therapeutic cocktail. Error bars are 95% confidence intervals. D. Changes in
NOS3 mRNA levels correlate with systolic blood pressure in
individual patients. NOS3 mRNA levels are plotted as a function of
systolic blood pressure. (E) NOS3 mRNA does not associate with diastolic
BP. Analysis were performed using a Spearman’s rho test and values were
significant if p<0.05. A student’s T-test was used for prednisone status analysis.
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Figure 4-3. NOS3 mRNA correlates with PKR induction by SLE serum. A-C.
Correlation between NOS3 mRNA and PKR, MX1, and IFIT1 induction by SLE
serum. Statistical analysis was performed using the Spearman’s rho (r)
correlation and p is significant if <0.05.
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HUVECs stimulated with SLE Serum Display Abnormal NO production

To determine the impact of serum on NO production using protocols outlined in
the materials and methods section, we stimulated HUVECs with 50% healthy or SLE sera.
Control serum clearly suppressed NO production but these changes were not significant
(Figure 4-4A), indicating that factors present in serum in vitro (absent of shear stress)
may alter basal NO levels, as measured by DAF-FM intensity. Strikingly, SLE serum
stimulation lead to an 80% decrease in NO production compared to EGM-2 medium
cultured cells (Figure 4-4B). The paradox of increases in NOS3 mRNA and diminished
NO is a hallmark of eNOS uncoupling.
L-sepiapterin is a precursor for tetrahydrobiopterin (BH4) synthesis and previous
studies have shown its efficacy in restoring eNOS function, possibly through a recoupling mechanism.

To test the hypothesis that L-sepiapterin could restore eNOS

dimerization, we conducted a proof of principle experiment examining differences
between eNOS monomer/dimer levels in response to L-sepiapterin. Indeed, increases in
dimer levels, as measured by western blot, were observed in all treatment groups (i.e.
EGM-2 buffer, controls, and SLE) with L-sepiapterin (Figure 4-5A).
Next, to further understand the therapeutic efficacy of L-sepiapterin in reversing
NO loss, we co-cultured cells with serum and L-sepiapterin and observed significant
restoration of NO production in healthy and SLE serum induced cells
0.6604±0.6812 vs L-sepiapterin buffer control: .0.7603±0.7793)

(SLE:

(Figure 4-6A-C).

Collectively, this body of data suggests that factors present in lupus serum may augment
endothelial-derived NO production through mechanisms that promote eNOS uncoupling.
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Figure 4-4. SLE serum impairs NO production in HUVECs. A. A histogram
of one representative control and one representative SLE sera treated HUVEC
culture sample displaying changes in DAF-FM fluorescence intensity. The gray
represents the buffer control, the green line represents control serum, and the red
line represents SLE serum. Total events for acquisition were 7,000. B. Results
represent the fold change median fluorescence intensity normalized to buffer
controls ± SD. Analyses were conducted using a 2-Way Anova and Bonferonni’s
post test. n=12 for buffer, n= 5 for healthy, and n=12 for SLE.
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Figure 4-5. L-sepiapterin promotes eNOS dimerization. A. A western blot
of eNOS monomers (140kDa) and dimers (200kDa) from one representative
control, healthy sera, and SLE sera treated HUVECs with and without Lsepiapterin treatment.
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Figure 4-6. L-sepiapterin restores NO production in SLE sera treated
HUVECs. A - B . One representative sample of DAF-FM intensity in
HUVECs stimulated with healthy serum with and without L-sepiapterin. Buffer control
(gray), L-sepiapterin (blue), healthy serum (light green), and healthy + Lsepiapterin (dark green) samples are represented in panel A while SLE serum
(red) and SLE serum + L-sepiapterin (orange) are represented in the panel B.
Total events for acquisition were 7,000. C. Results represent the fold change
median fluorescence intensity normalized to buffer controls ± SD. Analysis was
conducted using a 2-Way Anova and Bonferonni’s post test of 12 buffer, 5
healthy, and 12 SLE samples.
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SLE Serum Induces Neutrophil Chemotaxis and Neutrophil Adhesion

Neutrophil extracellular traps play a prominent role in the development of
endothelial dysfunction leading to atherosclerosis. Neutrophil chemotaxis in the context
of IL-8 production yields neutrophil netosis, a phenomenon recently associated with
activation of matrix metalloproteinaise-2 (MMP-2), a known modulator of endothelial
function, by MMP-9 within neutrophils. Thus, the ability of SLE serum to induce
neutrophil chemotaxis may serve as a functional consequence of eNOS impairment, as
correlations between MMP-2/MMP-9 and NO bioavailability have previously been
observed.
As with earlier studies, we treated endothelial cells with 50% SLE serum for 6hrs
prior to addition of neutrophils to transwell chamber and changes in migration were
assessed. Contrary to our initial hypothesis, our studies suggest that SLE patients have
higher neutrophil/endothelial cell ratios compared to healthy controls (SLE: 0.99±0.54
vs healthy: 0.50±0.15; Figure 4-7A,B).
To further assess SLE mediated functional consequences of changes in NO, we measured
changes in neutrophil adhesion to the endothelial cell surface in response to SLE sera.
Unlike control sera, SLE sera treated cells had significantly higher levels of neutrophil
adhesion to the endothelial cell surface compared to buffer control (SLE: 0.1808±0.0709
vs control: 0.1202±0.0841, p<0.001). Surprisingly, the addition of L-sepiapterin did not
reverse the proatherogenic phenotype induced by SLE sera as there were significant
differences detected between lupus cultures supplemented with L-sepiapterin and Lsepiapterin controls (Figure 4-8A,B). These findings suggest that eNOS uncoupling may
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be partially responsible for deficient NO levels in response to SLE serum but does not
fully account for SLE serum induced changes in endothelial function.
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Figure 4-7. Lupus serum induces neutrophil chemotaxis
A. HUVECs were stimulated for 6h with 50% control or lupus serum and
transwell inserts containing 50,000 neutrophils /well were placed as outlined in the
materials and methods section. Images are representative of 2 of 2 buffer controls,
1 of 1 IL-8 controls, 4 of 5 healthy serum, and 4 of 5 SLE serum samples. Images
represent calcein AM (top) and bright field + calcein AM (bottom) of neutrophils
that migrated to endothelial cell layers stimulated with serum (10X objective
magnification). B. The graph represents the ratio of neutrophils/endothelial cells
±SD of 2 buffer controls, 1 IL-8 control, 5 healthy controls and 5 SLE serum
samples. All data were analyzed using Kruskal-Wallis Anova and Dunn’s post-test.
**p<0.01 compared to healthy control.
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Figure 4-8. Lupus serum induces neutrophil adhesion to the endothelial cell
surface. A. HUVECs were stimulated for 6h with 10% serum and exposed to
neutrophils isolated from fresh human blood as outlined in materials and methods.
Images are representative of 5/5 buffer control, 6/8 SLE serum, and 3/3 healthy
serum samples. Images represent calcein AM (left), and bright field merged with
calcein AM (2nd column), calcein AM + L-sepiapterin (3rd column), and merged
+ L-sepiapterin (right) of HUVEC cells exposed to buffer (top), control serum
(middle), or SLE serum (bottom; all images were taken at 10X magnification).
The green represents neutrophils adhered to the endothelial cell surface. B. Graphs
represent the mean ratio of adhered neutrophils/endothelial cells ±SD.
Quantification of neutrophils is reported as means ±SD of 5 buffer controls, 9 SLE,
and 3 controls. **p<0.01 as compared to buffer control. All data were analyzed
using an ANOVA.
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Discussion
We’ve shown that SLE serum induces endothelial dysfunction by augmenting
eNOS mRNA levels, reducing NO production, and enhancing neutrophil adhesion to the
endothelial cell surface. Our results also show a role for eNOS uncoupling in response to
SLE serum which is reversed with L-sepiapterin supplementation.
Endothelial dysfunction is the initial step in the development of premature
cardiovascular disease complications identified in SLE patients yet, the mechanisms
leading to accelerated CVD risk are missing. Our group has proposed a prominent role
for eNOS deficiency leading to more pronounced vascular diseases in SLE. Indeed,
abnormalities in endothelial dysfunction have been attributed to eNOS uncoupling in
multiple vasculopathies.
Controversy persists as to whether or not eNOS mRNA abundance is a crucial
parameter for predicting endothelial derived NO production as a number of studies in
vascular disease models including smoking, ageing, and diabetes have not provided
definitive results. Interestingly, in our SLE serum induced HUVECs, we observed an
increase in eNOS mRNA levels that negatively correlated with patient age and protein
kinase mRNA induction. Ageing is known to greatly impact endothelial dysfunction as
multiple studies have reported a direct correlation between patient age and FMD. Still,
specific-SLE serum factors associated with ageing in SLE have yet to be revealed.
Importantly, these associations were not observed in control sera treated cells. Protein
kinase R is an interferon inducible gene previously shown to associate with declines in
FMD when elevated in peripheral blood mononuclear cells isolated from SLE patients.
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While the exact role of PKR in endothelial cell regulation is obscure, potential
mechanisms include impairment of genes that support eNOS regulation and
phosphorylation of the p65-NF-kB subunit which may indirectly impact eNOS
transcription. Further, studies show that PKR impairs insulin growth factor mediated
signaling where one of its most well studied targets is eNOS.
Our study reports the following findings: (1) NO production in SLE induced
endothelial cells is diminished compared to buffer controls and healthy sera cultures
which coincide with previous findings that sera from populations at risk for endothelial
dysfunction deplete basal eNOS derived NO levels in vitro285. Since NO production is
important for anti-atherogenic pathways and protection of the endothelium, loss of NO
may accelerate the development of endothelial dysfunction observed in SLE patients.
Further, changes in NO production coincided with MX1 and IFIT1 interferon signature
gene expression.

Nonetheless, our studies were not powered to truly assess the

association between NO production and IFN signature genes which may implicate a role
for IFNα in the deregulation of eNOS in vitro. Thus, future studies are needed that may
explain the effects of Type I interferons on these pathways.

(2) Lupus sera induced

changes in NO production are reversed with addition of L-sepiapterin.

Since L-

sepiapterin serves as a precursor for BH4 synthesis by GTP cyclohydrolase I and BH4 is
an essential co-factor for NO generation by NOS enzymes, it’s possible that SLE sera
may induce pathways that promote BH4 oxidation and depletion in vitro.

(3) SLE

cultured endothelial cells have an increased capacity to bind neutrophils compared to
buffer treated cells. These findings suggest that factors present in serum may induce
adhesion molecule expression. Further, they provide evidence for functional
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consequences due to diminished NO. (5) Surprisingly, we did not observe diminished
neutrophil adhesion with the addition of L-sepiapterin. Additional studies examining
optimal concentrations for therapeutic efficacy are needed. Supporting this claim, others
have shown that sepiapterin supplementation reduced post-ischemic myocardial
infarction

injury

by

ameliorating

NO-mediated

cGMP

levels

myeloperoxidase activity associated with neutrophil activation

286

and

reducing

. Impaired eNOS

function along with additional mechanisms may contribute to diminish NO
bioavailability as well.
Our results implicate a role for factors in SLE sera that may contribute to
endothelial dysfunction via eNOS uncoupling. We have previously reported that eNOS
is protective against vascular disease manifestations in SLE287 . Since NO production is
crucial for adequate vessel relaxation and atherosclerotic plaque prevention, we
hypothesize that therapeutic interventions restoring eNOS coupling may strongly
promote vascular endothelial function and subsequent prevention of premature
atherosclerosis observed in SLE. This proposal is supported by multiple observations.
Prospective studies provide evidence that BH4 supplementation restores endothelial
function in high risk cardiovascular disease patient populations including coronary artery
disease, hypercholesterolemia, hypertension, and diabetic vasculopathy

288, 289, 290

.

Further, BH4 supplementation was shown to prevent neutrophil adhesion and
transmigration in a myocardial ischemia/reperfusion injury rat model which suggest that
BH4 overcomes inflammatory signaling mechanisms associated with tissue injury.
Overall, our results strongly support a role for SLE serum mediated changes in
eNOS mRNA, NO production, and neutrophil adhesion to the endothelial cell surface.
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Although mechanisms leading to these changes are unclear, we show strong correlations
between interferon inducible gene expression and alterations in eNOS and NO mediated
by SLE sera. Future studies will need to assess changes in eNOS and NO production in
vitro following Type I interferon neutralization. Nevertheless, our results extend the
clinical understanding of SLE in attenuating endothelial function. Future interventions
targeted at eNOS preservation may reverse premature atherosclerosis observed in SLE.
The relevance of our findings may be applied to other populations developing endothelial
dysfunction in response to chronic inflammation.
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Chapter V
Interferon alpha contributes to
endothelial dysfunction possibly by
upregulating miR155 and impairing
insulin mediated nitric oxide
production
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Introduction
Unexplained by conventional risk factors (i.e. smoking, diabetes), systemic lupus
erythematosus (SLE) patients have as much as a 50-fold increase in cardiovascular
disease 38, 291, 292. Inflammatory mediators are associated with accelerated atherosclerotic
plaque development in SLE 293; still, mechanisms explaining these complications are not
well characterized.
SLE patients display lower levels of circulating endothelial progenitor cells
(EPC), a hallmark sign of endothelial dysfunction,
type I interferon (IFN) signature induction

295

294

, which strongly associates with

. In fact, approximately 50% of SLE

patients have an interferon signature gene expression in their PBMCs

296

. The type I

interferon signature is associated with SLEDAI Score, impaired vascular repair, and
increased vascular inflammation 297, 298. Depletion of IFNα in SLE sera lead to improved
EPC monolayer formation in vitro 237. Further, genetic ablation of the IFNAR in NZB/W
lupus prone animals improved acetylcholine-mediated aortic constriction and EPC
circulation 230. These studies indicate that type I interferons are important in promotion of
premature endothelial dysfunction and may promote atherosclerosis in SLE.
The pathogenesis of endothelial dysfunction is multifactorial; however, many
signaling pathways converge on the diminished activity of endothelial nitric oxide
synthase

(eNOS) and loss of nitric oxide

(NO) bioavailability.

NO is an anti-

atherogenic gaseous molecule that regulates blood vessel relaxation, platelet aggregation
299, 300, 301, 302

, leukocyte chemotaxis and, leukocyte adhesion.

Hypercholesterolemia

302, 303

, smoking

304

, and elevated CRP levels

305, 306

are

associated with diminished eNOS activity and loss of adequate endothelial-derived NO.
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In hypercholesterolemia, oxidative stress induced by elevated LDL levels is thought to
induce eNOS uncoupling307. Moreover, cigarette smoke causes eNOS uncoupling and
shifts the eNOS phosphorylation pattern to an inhibitory state in vitro

308

. Nevertheless,

loss of NO-dependent flow mediated dilation (FMD) has been reported in numerous
diseases, including coronary artery disease 309 and type I diabetes 310.
Given the high levels of type I IFN signatures observed in SLE patients and
previously identified correlations between type I IFNs and impaired vascular function, we
hypothesized that one way that IFN-α may contribute to endothelial dysfunction is by
impairing eNOS activation and NO production in human endothelial cells. This study
supports a role for IFN-α in reducing endothelial derived NO production in endothelial
cells.
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Results
HUVEC myxovirus resistance protein 1 (MX1) and protein kinase r (PKR)
are induced by SLE Serum

Prior to the investigation of IFN-α mediated endothelial dysfunction in HUVECs, IFN
signature gene induction by SLE sera was investigated to determine physiologically
relevant levels of type I IFN for future experiments. We selected PKR and MX1 due to
their previously identified strong association with IFNα and disease activity in lupus
patients

296, 311

. Moreover, IFNα neutralizing antibodies can inhibit IFIG expression in

healthy donor PBMCs cultured in SLE serum, strongly supporting a dominant role for
IFNα in IFIG expression. Treatment of HUVECs with 20% SLE serum for 24 hr.
induced a 4.9 fold increase in PKR mRNA (Figure 5-1A) and a 493.2 fold increase in
MX1 mRNA (Figure 5-1B) over buffer treated HUVECs. Following recombinant IFN-α
a concentration curve experiments, we observed that treatment of cells at a 1000IU
concentration induced PKR

(Figure 5-1C) and MX1

(Figure 5-1D) to levels

commensurate with SLE serum at 20%. Therefore, this concentration of IFN- α was used
for the remainder of the experiments.
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Figure 5-1. SLE Serum induces type I interferon signature gene expression in
HUVECs. A-B. HUVECs were incubated with 20% SLE serum or IFN-α for 24
hours and cellular RNA was subjected to cDNA synthesis. RT2PCR was used to
assess changes in gene expression. PKR and MX1 were induced by 24 SLE serum
samples in HUVECs. Graphs display dot plots of the fold change induction
normalized to GAPDH and error bars are 95% CI whiskers. C-D. PKR and MX1
induction by IFN-α at various concentrations. Each bar graph represents the mean
± SD for 3-6 IFNα treatment groups; *p<0.05, **p<0.01, ***p<0.001. Statistical
analysis for patient samples was performed using a Student’s T-test. A One-Way
Anova was used for rIFNα statistical analysis.
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IFN-α impairs eNOS expression in HUVECs

Type I interferon signature gene induction correlates with decreases in endothelial
function in SLE patients thus, we hypothesized that type I interferons may negatively
impact NOS3 mRNA levels. Supplementation of culture media with IFNα suppressed
eNOS gene expression in a dose and time dependent manner after 6 and 24 hours (50%
and 77%, respectively; Figure 5-2A,B). In titration experiments, declines in eNOS gene
expression negatively correlated with PKR (R2 =0.9855) and MX1 (R2 =0.8555) (Figure
5-2C-D). Supporting the functional significance of reduced gene expression, HUVECs
treated with recombinant IFNα for 6 and 24 hours (Figure 5-3A-B) had lower levels of
total eNOS protein when compared to buffer treated controls (6 hours:1.00 vs. 0.41,
p=0.001, and 24 hours: 1.00 vs. 0.6281, p=0.144).
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Figure 5-2. IFN-α impairs eNOS gene expression. A. HUVECs were incubated
with IFN-α and cellular RNA was subjected to cDNA synthesis and qRTPCR as
implicated in the materials and methods section. NOS3 mRNA expression in
HUVECs treated at various IFN-α concentrations B. or time points C. MX1 D.
PKR correlative expression with NOS3 mRNA. Each bar graph represents the
mean ± SD. **p<0.01, ***p<0.001, n=3-6. Statistical analysis were performed
using non-parametric Kruskal-Wallis Test. Correlations were conducted using
Spearman’s test.
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Figure 5-3. IFN-alpha reduces eNOS protein abundance. A. Cell lysates from
HUVECs stimulated with IFN-α (1000IU/ml) for 6h and 24h were immunoblotted
for eNOS and b-actin., B. The graph represent the mean of the fold change
normalized values ± SD, n=3. *p<0.05, **p<0.01. Western blot data was
analyzed using an unpaired One-Way Anova.
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24h

IFN-α reduces NO Production In Vitro

Due to the observed changes in eNOS gene and protein expression, we hypothesized that
NO levels would also reduce with IFN-α treatment. HUVECs exposed to IFN-α for 6h
displayed lower levels of DAF-FM fluorescence as a surrogate for NO production versus
media alone

(1±0.08 vs 0.4696±0.1192, p=0.001, Figure 5-4A,B). There were no

differences after 24h of treatment.
Next, we assessed the impacts of IFN-α on insulin-mediated activation and found
that insulin-stimulated NO production in vitro at both 6 and 24 h was significantly
impaired (1.047 vs 0.667, p=0.0148 and 1.047 vs 0.6847, p=0.0022, respectively; Figure
5-4A, B). These data suggest that reduced protein levels may contribute to IFN-αmediated NO loss and may potentiate IFN-α mediated “insulin resistance.” Further
assessment of functional consequences of reduced NO production revealed a 37%
reduction in cGMP bioavailability after culture of HUVEC with IFN-α in vitro (p<.01,
Figure 5-5A).

125

Figure 5-4. IFN-alpha reduces nitric oxide production in HUVECs.
A. Histograms representing changes in DAF-FM intensity following stimulation
with buffer (gray), insulin 100nM (blue), IFNα (red), or IFNα + insulin (green)
at various time points. Total events acquisition was 10,000. B. MFI quantification
of HUVECs loaded with 1uM DAF-FM diacetate. Samples were analyzed using
flow cytometry following IFNα treatment at the specified times. Means of the
median fluorescence intensity are reported ± SD, n=3-9. *p<0.05, **p<0.01 as
compared to buffer control and Φp<0.05 and ΦΦp<0.01 compared to insulin
control. Flow cytometry data was analyzed using a Two-way Anova and
Bonferonni’s post test.

126

A

24hr

# of Events

6hr

10

0

10

1

10

2

10

3

10

4

10

0

10

1

DAF-FM Intensity

B

127

10

2

10

3

10

4

Figure 5-5. IFN-alpha reduces cGMP production in HUVECs.
A. HUVECs were stimulated for 6h with IFN-α. Cell lysates and supernatants
were assayed using a cGMP EIA kit as outlined in materials and methods.
Differences are reported as percentage of control±SD; n=3 **p<0.01. cGMP data
was analyzed using an unpaired One-Way Anova.
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IFN-α enhances adhesion molecule expression and monocyte chemoattraant 1
production but not leukocyte adhesion
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Nitric oxide prevents intracellular adhesion molecule 1 (ICAM-1) expression and
monocyte chemoattractant protein 1 (MCP-1) production in endothelial cells. This leads
to down regulation of neutrophil adhesion to the endothelial cell surface that is necessary
for ultimate transmigration of inflammatory cells 312.
Leukocyte adherence anchors expressed on the endothelial cell surface include,
among others, intracellular adhesion molecule-1

(ICAM-1) and vascular adhesion

molecule-1 (VCAM-1). Moreover, recent studies have proposed that MCP-1 is important
for neutrophil recruitment to the endothelial cell surface 313. Hence, we examined changes
in IFN-α mediated ICAM-1 and MCP-1 induction.
HUVECs cultured in IFN-α displayed higher levels of ICAM1; although,
differences were not significant

(p=0.068). MCP-1

(CCL2) as well as VCAM-1

expression were significantly increased compared to buffer controls

(p<.0001 and

p=0.0124, respectively). Moreover, we observed that supernatant MCP-1 protein levels
also increased in response to IFN-α, which further confirms a functional role for IFN-α
in immune cell chemotaxis and adhesion to the endothelial cell surface (Figure 5-6A, C
and Figure 5-7A,B). When S-nitrosoglutathione (GSNO) was added to cells in the
presence of IFN-α, MCP-1 levels were significantly reduced, suggesting that IFNα
mediated increases in MCP1 may be dependent upon loss of NO production (Figure 56B).
As a functional assay, we wanted to assess the impact of IFN-α on this NO-modulated
process in vitro. HUVECs treated with IFN-α for 6h did not display enhanced neutrophil
adhesion to the endothelial cell surface. (119300 ± 705.1 vs. 94908± 5869 relative
fluorescent units or RFUs, p<.001; Figure 5-8A,B.
130

Figure 5-6. IFN-alpha induces monocyte chemoattractant-1 expression
and production in HUVECs. HUVECs were stimulated for 6h with IFN-α
and RNA isolates or cell supernatant was assayed using RT2PCR or an
ELISA as outlined in the materials and methods section. A-B. CCL2 mRNA
expression after a 6 hour stimulation with IFNα, normalized to GAPDH.
CCL2 induction was enhanced with IFNα treatment as previously shown.
GSNO was able to reverse IFNα induction of CCL2. Results are mean
fold change ± SD. C. Interferon alpha cultured cells assayed for MCP-1
protein. Means are reported ±SD of 6 buffer controls and 6 IFNα treated
groups. *p<0.05, **p<0.01. All data were analyzed using a non- parametric
Mann-Whitney test.
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Figure 5-7. IFN-alpha induces adhesion molecule expression. HUVECs were
stimulated for 6h with IFN-alpha and RNA isolates were assayed using RT2PCR
as outlined in the materials and methods chapter. A. mRNA expression of
VCAM-1 and B. ICAM-1, normalized to GAPDH. VCAM-1, but not ICAM-1,
was significantly induced by IFNα treatment. Results represent the fold change of
the mean expression ±SD of n=3 for each treatment group. *p<0.05 as determined
by Mann-Whitney analysis.
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Figure 5-8. IFN-alpha does not enhance neutrophil adhesion to the
endothelial cell surface. A. HUVECs were stimulated for 6h with IFNα and
calcein AM stained neutrophils were added to cultures for 1hr. Wells were gently
washed and differences in fluorescence were assessed. Images are representative
of 4 of 4 buffer controls and 3 of 4 IFNα treatment groups. Images represent
calcein AM (top) and bright field merged with calcein AM (bottom); (40X
magnification). B. Graph represents the fold change of the mean of relative
fluorescent units (RFUs) ± SD. All data were analyzed using a non-parametric
Mann-Whitney test.
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Protein Kinase R induction associates with SLE serum mediated declines in
eNOS gene expression

To establish the potential in vivo relevance of these findings in SLE, we analyzed levels
of PKR and MX1 induction by SLE serum in relationship to eNOS. The eNOS gene
expression was down regulated in a PKR-dependent manner (r=-0.63, p=0.0009), as
shown in chapter IV. However, eNOS did not associate with MX1 induction (Figure 59A, B). To determine if PKR directly regulated IFN-α-mediated changes in eNOS gene
expression; we used siRNA to knockdown PKR expression in HUVECs and determined
changes using RT2PCR. IFN-α treated HUVECs deficient in PKR had 30% lower levels
of eNOS (Figure 5-10A, B). PKR is known to enhance NF-κB activity
ameliorates it via S-nitrosylation of the p50 subunit

226, 315, 316

314

, while NO

. NF-κB is a pleiotropic

mediator of immune responses and inflammatory gene control. Thus, we sought to
determine if NF-kB activation was partially responsible for diminished eNOS expression
in response to IFNα. After a 6h IFNα treatment, eNOS increased 50% in NFκB deficient
cells over cells transfected with negative siRNA oligonucleotides (Figure 5-10 C,D).
This suggests that the effect of IFNα on eNOS may be partially due to activation NFkB
and subsequent increases in downstream inflammatory targets.
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Figure 5-9. NOS3 mRNA correlates with PKR induction by SLE serum. A.
SLE serum induces expression of PKR in HUVECs and this induction negatively
correlates with altered NOS3 gene expression. The dot plot is representative of 24
SLE patients and NOS3 is graphed as a function of PKR. B. SLE serum induces
MX1 gene expression in HUVEC cells but this induction lack association with
NOS3 gene expression. Statistical analysis was performed using the Spearman’s
rho (r) correlation and p is significant if p<0.05.
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Figure 5-10. NF-kB silencing restores NOS3 expression. A-D. mRNA
expression of PKR, NOS3, and NF-kB genes following siRNA transfection for
30h and IFN-α (1000IU/ml) treatment for 6 hours. Samples are normalized to
GAPDH. No differences were detected in NOS3 mRNA in HUVECs deficient in
PKR although, there were declines in NOS3 mRNA levels. However, NOS3
mRNA levels were restored with NF-kB silencing. Results are fold change of the
mean expression ± SD of n=3 for each experimental group. *p<0.05, **p<0.01.
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Declines in eNOS gene expression are due to enhanced mRNA instability,
possibly through miR155 induction

Previous studies have demonstrated that declines in eNOS mRNA abundance may
occur through changes in transcription and post-transcriptional modifications.
Surprisingly, IFNα enhanced heteronuclear RNA levels, a surrogate measure of
transcriptional rates (Figure 5-11A). However, IFN-α co-culture resulted in a significant
9% decline in eNOS mRNA half-life at 22h compared to control (Figure 5-10B).
MicroRNA binding to the 3’ UTR region of human eNOS destabilizes the enzyme. We
investigated whether IFNα induced miR155, which was previously shown to destabilize
eNOS 317. Treatment with IFN-α substantially increased miR155 expression compared to
controls (Control:1.000 ± 0.3381 vs IFN-α 1.5223± 0.2133, p<0.05; Figure 5-11C).
However, our studies were not adequate to determine if IFN-α mediates decreases in
eNOS mRNA through NF-kB responsive miR-155.
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Figure 5-11. IFNα promotes NOS3 mRNA instability. A. NOS3 heteronuclear
RNA expression following treatment of HUVECs with IFN-α (1000IU/ml).
Values are normalized to S26. B. Cells were incubated with 5ug/ml Actinomycin
D for 2 hours to stop transcription. IFNα (1000IU/ml) or negative control (TNFα
100ng/ml) was added at for various time points and RNA samples were analyzed
using qRT-PCR as outlined in the materials and methods. Values are normalized
to RPL13A. C. miR155 expression following IFN-α (1000IU/ml) for 6h. Values
are normalized to U6. Fold change of the mean is reported ±SD, n=3-9. *p<0.05,
**p<0.01.
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IFN-α suppresses insulin mediated NO production in response to acute
treatment

To further understand the impact of IFNα mediated changes in eNOS phosphorylation
following acute treatment, we examined NO production as well as changes in cGMP.
Insulin stimulated cultured HUVEC NO production almost 3-old. IFN-α treatment did
not significantly impair unstimulated NO production at early time points. However, IFNα greatly impaired insulin-mediated NO production by 53%, 60%, and 44% at 15, 30, and
60 minutes, respectively (Figure 5-12A,B). Further supporting the notion that IFNα does
not significantly basal NO levels, results from our cGMP assay indicated that IFNα had
minimal influence over cGMP levels in vitro.
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Figure 5-12. IFN-alpha impairs insulin mediated NO production. A.
Cells were incubated with IFN-α at 15, 30, and 60 minutes and loaded with
1uM DAF-FM diacetate, a nitric oxide sensitive dye. Cells were incubated
with or without insulin for 30 minutes and samples were analyzed using the
flow cytometer. Histograms displaying DAF-FM intensity of 1 representative
buffer control, 1 representative insulin (100nM), 1 representative IFNα
treatment, and 1 representative IFNα and insulin (100nM) treatment group.
Total events for acquisition were 10,000 for all treatment groups and cells
were gate on live cells based on propidium iodide stain and DAF-FM
diacetate stain. B. The graph represents mean fold change ± SD of the
median fluorescence intensity (MFI) of 4 independent experiments. Data was
analyzed using a Two-way Anova and Bonferonni’s posttest. *p<0.05,
**p<0.01 as compared to control and Φp,<0.05, ΦΦp<0.01 as compared to
insulin control.
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IFN-α induces eNOS phosphorylation in vitro
Post-translational modifications in response to G-protein receptor agonists such as
insulin regulate eNOS activity and NO synthesis.

Insulin activates eNOS via

phosphorylation at the serine 1177 (Ser1177)223 site, and by inducing desphosphorylation
at the negative regulatory site, threonine 495 (Thr495 )318.

Due to changes in eNOS

mRNA and protein levels at 6 and 24 hours, examining phosphorylation after late time
points would present another level of complexity, as changes in protein expression
upstream make it difficult to distinguish the mechanism whereby NO is diminished.
Furthermore, evidence suggests that eNOS phosphorylation is typically expedient and
transient. Early timed studies indicated that changes in NO were greatest at the 30-minute
time point. Therefore, the 30 minute treatment model was used in the remaining studies.
Insulin potentiated phosphorylation at the Ser1177 site

(Insulin: 1.5±0.56 vs.

Control 1.0±0.033) as well as the Thr495 site (Insulin: 1.5±0.34 vs. Control 1.00±0.03,
p<0.05; Figure 5-13A-C. This is contrary to previously published findings suggesting
that insulin impairs pThr495 phosphorylation

61

. IFN-α

surprisingly induced phosphorylation at the Ser1177
1.00±0.003, p<0.05).

(1000IU/ml) treatment

(IFNα: 1.3±0.33 vs Control:

Further, phosphorylation at the Thr495 site was significantly

increased (IFNα: 1.99± 1.06 vs Control: 1.00±0.03, p<0.05). Further, insulin suppressed
IFNα mediated inductions in Thr495 phosphorylation (IFNα + Insulin: 1.27± 0.43) while
enhancing phosphorylation at the Ser1177 site (IFNα + Insulin: 1.51 ± 0.65). However,
these changes were not significant (Figure 5-13A-C). Taken together, these data suggest
that IFNα may cause eNOS phosphorylation to shift from its active to inactive state but,
insulin does not have the capacity to restore the normal phosphorylation paradigm as
149

evidenced by loss of NO production. This would suggest that IFN-α induces insulin
resistance to endothelial cells.
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Figure 5-13. IFN-alpha promotes Thr495 phosphorylation. A. Cell
lysates were immunoblotted for eNOS, p-Ser1177 or p-Thr495 following
a 30 minute IFNα stimulation. Blots are representative of 3-6
independent experiments. B. Fold expression of quantified
phosphoeNOS/eNOS bands normalized to control. Means ± SD of the
fold change, normalized to eNOS are reported. n=3-9. *p<0.05.
Western blot data was analyzed using a Two-way ANOVA and
Bonferonni’s post test.
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Discussion

Summary of Findings
The main finding of our study is that IFNα decreases NOS3 mRNA expression,
protein expression, and insulin-mediated NO production by decreasing NOS3 mRNA
stability, possibly through NF-kB mediated miR155 expression. Many studies support the
critical role of Type I IFNs in the pathogenesis of lupus as well as secondary clinical
manifestations of the disease. Moreover, a number of studies have shown links between
Type I IFN signature gene expression in peripheral blood mononuclear cells and
endothelial dysfunction. For the first time, we’ve shown that IFNα modulates eNOS
which is important for endothelial cell homeostasis and function (Schematic 5-1).

Interferon Signature Gene Induction
Physiologically relevant concentrations of IFNα are difficult to discern given the
lack of sensitivity and specificity of ELISAs296. Thus, we rely on interferon signature
gene induction to understand translatable concentrations for in vitro studies. For the first
time, we’ve shown that 1000IU/ml IFNα and 20% SLE serum induces MX1 and PKR
interferon signature genes in a similar manner thus, we used 1000IU IFNα for our studies.
Previous studies in WISH cells have shown MX1 and IFIT1 induction levels are quite
different than what we found depending on the concentration of serum and/or IFN296.
This may be due to the physiology of endothelial vs epithelial cells including other
proteins and genes expressed in cells, IFNAR expression on the cell surface, etc.
However, it is unlikely that IFN-α in SLE serum is the only inducer of our
selected IFIGs in endothelial cells. Nevertheless, previous studies suggest that it may be
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the dominant mediator upstream of PRKR and MX1 specific transcription. A number of
cytokines and chemokines present in SLE serum may also impact expression of IFIGs,
including IFNβ, IFNλ, or IFNγ, which all partially contribute to PRKR expression

319

.

Moreover, Cates et. al., 2014 showed that IL-10 synergizes with IFN-α to amplify its
effects on impaired endothelial progenitor cell function

320

. The presence of dsDNA

(CpG) immune complexes or viral agents containing dsRNA present in patient blood may
also lead to activation of toll-like receptor (TLR) signaling pathways that further induce
IFN-α signature gene induction321.

Interferon alpha impairs eNOS expression
Multiple studies have shown that IFN-α is a potent pro-atherogenic factor;
however, its impacts on early stage atherogenesis or endothelial dysfunction are only
recently being investigated. In this study, we demonstrated that IFN-α exerts its
deleterious effects on endothelial function in part through suppression of eNOS/NOS3
gene expression. Furthermore, these changes negatively correlated with both IFNα and
SLE serum induction of PRKR and but only IFNα induced MX1.
These findings are supported by a previous study that reported an association
between SLE serum mediated PRKR induction in WISH cells and reduced brachial artery
flow mediated dilation, a surrogate marker of endothelial dysfunction
lupus endothelial progenitor cell

322

. Moreover,

(EPC) circulation and function are impaired in

association with high type I IFIG ex vivo. Mobilization of EPCs is regulated by eNOS.
Thus, one potential mechanism whereby EPC circulation is impaired in SLE patients is
through type I interferon downregulation of eNOS expression. Yet, controversy exists as
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to whether or not eNOS gene expression impacts endothelial function and nitric oxide
production. In hyperglycemia and diabetes, eNOS levels are increased, decreased, or
unchanged. Moreover, when levels increase, they are typically associated with a rise in
superoxide production and are likely increased to compensate for loss of NO
bioavailability 323.
Our studies also showed a significant decline in eNOS protein expression in
response to IFNα . Moreover, these cells had enhanced phosphorylation at the Ser1177 site
and the Thr495 site and subsequent declines in NO followed. Nitric oxide bioavailability
is modified based on a number of factors including enzyme expression and activity. Thus,
changes in eNOS expression may have lead to altered NO production. Our studies are
limited due to lack of eNOS activity measurements. Furthermore, given that NOS3
mRNA abundance was significantly suppressed at both 6 and 24h, but NO production
was only impacted at 6h might suggest a role for iNOS induction. However, we did not
detect iNOS (NOS2) induction in our cell cultures.
Our findings contradict a previous study showing that IFN-α2b had no impact on
eNOS expression or NO production 324. Our studies differ from this one in that they were
conducted in HUVECs. However, preliminary findings in HAECs showed an even more
drastic impact of IFN-α on eNOS expression after 24hr treatment at 1000IU/ml.
Moreover, the authors measured nitrate/nitrite levels reported in the micromolar range.
Given that NO produced by eNOS is measured in the nanomolar range, it is difficult to
detect eNOS NO using this type of assay when background levels are in the micromolar
range 324, 325.
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One possible mechanism whereby IFN-α may impair insulin-mediated up
regulation of NO production is through PKR induction. Prior studies showed that PKR
phosphorylates the insulin receptor substrate 1 (IRS1) at Ser312, an inhibitory site, and
suppresses phosphorylation at that activation site, Tyr941 leading to loss of downstream
signaling

326

. Thus, upregulation of PKR may be responsible for impaired insulin

mediated NO production. However, we did not assess IFNα mediated changes in NO in
PKR deficient cells.
NO is an anti-atherogenic molecule, with multiple downstream targets including
adhesion molecules, chemokines, and cyclic guanosine monophosphate. NO exerts it
anti-atherogenic effects by inhibiting NF-κB activation in two different ways. NO
promotes IκB expression preventing NF-κB activation while S-nitrosylating the cysteine
group located on p50. Collectively, these mechanisms prevent nuclear localization of NFκB and subsequent upregulation of ICAM-1, VCAM-1, and MCP-1 associated with
atherogenic plaque formation. We showed that IFNα stimulation enhances adhesion
molecule expression and MCP-1 production; but, enhanced neutrophil adhesion to the
endothelial cell surface was not significant. MCP-1 and VCAM-1 are important for
leukocyte adhesion to the endothelial cell surface including monocytes which our studies
failed to examine.
. Collectively, these studies suggest that IFN-α perpetuates endothelial
dysfunction as evidenced by loss of NO production and upregulation of targets generally
suppressed by physiologic levels of endothelial derived NO.
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To further understand the in vivo relevance of our findings, we compared changes
in SLE mediated induction of PKR expression to changes in NOS3 mRNA showed a
strong negative association between the two genes suggesting a possible intrinsic coregulation by IFNα. However, our experiments in which PKR induction was blocked by
siRNA indicated that eNOS expression was not regulated by PKR. This suggests that the
effect is not at the level of expression.
PKR phosphorylates IKK independent of dsRNA-mediated activation, leading to
phosphorylation of IκB-α and subsequent activation of NF-κB. Conversely, the NF-kB
p50 subunit promotes eNOS transcription by binding to the shear stress response element
(SSRE) in the eNOS promoter region. Surprisingly, we found that siRNA-mediated
knockdown of PRKR led to further reductions in eNOS mRNA levels and NFκB (Figure
5-8A-C), suggesting a possible protective role for PKR.
Further, we observed that NFκB knockdown resulted in a 1.5 fold increase in
eNOS mRNA compared to IFN-α stimulated controls. NF-κB was previously shown to
upregulate eNOS transcription during shear stress by binding to the SSRE promoter
region.

Conversely, NF-κB activation enhances IL-1b, IL-6, and TNFα production.

These cytokines antagonize eNOS protein or gene expression via destabilization or
changes in eNOS transcription rates (Figure 5-8C). Thus, NF-KB may be regulating
eNOS expression indirectly. However, these studies do not address these mechanisms.
NF-kB has pleiotropic effects on eNOS expression at both the transcription and
post-transcriptional modifications levels.

Our studies showed that transcription was

unchanged in response to IFNα. This led us to examine changes in NOS3 mRNA stability
where we observed decreases eNOS half-life with IFNα stimulation. As an anti-viral
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cytokine, IFNα is known to activate pathways that limit intracellular viral replication
possibly through alterations in gene stability. Previous studies have reported that IFNα
and NF-kB induce miRs known to destabilize eNOS including miR155317, 327
Previous studies have shown that miR155 is upregulated in atherosclerotic
plaques isolated from patients with coronary artery disease. Moreover, as previously
stated, miR155 overexpressed in HUVECs drastically reduced eNOS expression and NO
production by decreasing eNOS mRNA stability by binding to the 3’UTR region.
Cytokines such as TNF-α have previously been shown to induce miR155 expression in a
NF-κB dependent manner. Here, our studies demonstrated that treatment with IFN-α
induced miR155 expression which may explain the amelioration observed in eNOS gene
expression over time. To date, studies examining upregulation of miR155 in SLE patient
plaques and EPCs are missing. Our preliminary studies engender the hypothesis that
miR155 upregulation in endothelial cells by IFN-α serves as one possible mechanism
whereby endothelial dysfunction ensues in vivo. Further studies need to be conducted to
determine factors at play downstream of PKR and NFκB, which lead to, increases
miR155 expression.
Systemic lupus erythematosus patients have interferon inducible gene expression
in PBMCs that correlated in disease activity and endothelial dysfunction. This is the first
study to demonstrate that that IFNα impairs insulin mediated NO production in
endothelial cells. Moreover, we show that mechanisms leading to reduce NO include
loss of eNOS mRNA, protein, and possibly alterations in eNOS phosphorylation. Novel
mechanisms leading to increased eNOS instability by IFN alpha may be NF-kB/miR155
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mediated. Future studies examining changes in eNOS genetically in IFNAR deficient
NZM/NZW animal models may provide insight on the impact of IFNs on eNOS in vivo.
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Schematic 5—1. Recombinant IFNα negatively regulates eNOS and suppresses NO
production in human umbilical vein endothelial cells. IFNα suppresses NOS3 mRNA
stability resulting in loss of eNOS protein and NO production. One possible mechanism
leading to impaired NOS3 mRNA stability is up regulation of NF-kB. NF-kB may lead to
impaired NOS3 expression via increases in miR155. IFNα impairs insulin mediated NO
production possibly by increasing phosphorylation at the Thr495 site. Losses in NO
production yield diminished cGMP production. IFN-α treatment up regulates MCP-1 as
previously shown in the literature and up regulates VCAM-1 and ICAM-1 gene
expression. However, increases in adhesion molecule expression does not yield elevated
neutrophil adhesion to the endothelial cell surface.
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Chapter IV
Discussion and Conclusions
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Introduction
Over the past 60 years, with large-scale socioeconomic improvements, morbidity
and mortality rates in SLE patients have slowly declined.

On the other hand,

cardiovascular disease rates have increased drastically and are now the leading cause of
morbidity and mortality in non-autoimmune and in SLE populations. Synergy between
chronic inflammation and the development of atherosclerosis results in a more
accelerated and aggressive form of disease, leading to greater morbidity in SLE patients.
Although the cause of advanced disease is unknown, it is well established that damage to
the vasculature precedes atherosclerotic plaque development.
Vascular biology encompasses the study of vascular cells, including smooth
muscle cells and endothelial cells. In the past 35 years, since the discovery of NO by
Furchgott, Ignarro, and Murad, studies examining the endothelium show its obligatory
role in maintaining cardiovascular homeostasis

328, 329, 330

{Ignarro, 1980 #8146. The

prominent L-arginine/NO pathway requiring BH4 appears to be a key mediator of
vascular health.
The roles of endothelial-derived NO range from cGMP-mediated vasorelaxation
to aiding in endothelial progenitor cell and bone marrow cell homing injured sites within
the vasculature

331, 332

. Studies in SLE patients have shown a disproportionate increase in

vascular endothelial dysfunction; however the etiology is unclear.
The emerging question following these observations was which SLE specific
factors contribute to impaired endothelial function and worse disease prognosis. A pattern
of increased injury and impaired repair mechanisms has been proposed and associated
with increases in type I interferon signature gene expression in peripheral blood
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mononuclear cells. While others reported increases in conventional cardiovascular risk
factors such as hypercholesterolemia and dyslipidemia that may promote accelerated
disease, several more SLE-specific factors exist that could potentially account for a
reduction in endothelial-dependent vascular function. Therefore, identification of triggers
leading to accelerated atherosclerotic plaque development in this complex and
heterogeneous disease is difficult.

Coupling and Uncoupling: A possible mechanism of endothelial dysfunction
in SLE
Increasing evidence points to a role for eNOS uncoupling, yielding increased
degradation and reduced production, in the pathogenesis of endothelial dysfunction.
Properly functioning eNOS converts L-arginine to L- citrulline and NO through a series
of oxidative steps. A key co-factor in this enzymatic process is BH4, which is diminished
under pathophysiologic conditions marked by oxidative stress

333, 334

. Seemingly

paradoxical, oxidative stress promotes increases in NOS3 gene expression due to
enhanced H2O2-mediated transcriptional regulation in the vascular microenvironment.
Our findings support the hypothesis that eNOS uncoupling may serve as one
mechanism of endothelial dysfunction. Briefly, SLE serum increased NOS3 mRNA
expression over control serum in cultured HUVECs. Initially, these findings seemed
contradictory to previous studies from our lab showing that eNOS deficiency was
pathogenic in the lupus microenvironment

287, 335

. Moreover, SLE serum suppressed

HUVEC NO production even with increased NOS3 gene expression. Our experiments
failed to measure oxidative stress and NADPH oxidase activity in vitro; however, the
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literature suggests that the observed paradigm in our studies may result from oxidative
stress induced eNOS uncoupling. Oxidative stress, in the form of superoxide, rapidly
reacts with NO to form peroxynitrite.

This molecule deactivates BH4 through its

oxidation to BH2. BH4 is essential for stabilizing the eNOS dimer and facilitating transfer
of electrons from the reductase to the oxygenase domain. Our experiments also failed to
measure BH4; however, we conducted BH4 repletion experiments, using L-sepiapterin, to
examine changes in eNOS coupling in the presence of serum. Indeed, L-sepiapterin, a
BH4 precursor, restored SLE serum-mediated reductions in NO production from
HUVECs. These findings demonstrate that SLE serum may promote oxidative stress in
vitro, leading to eNOS uncoupling. Also, eNOS uncoupling leads to loss of NO
bioactivity, which is restored, with L-sepiapterin.
Quite remarkably, administration of BH4 in LDL-cultured endothelial cells
prevented uncoupling of eNOS336. In contrast, sepiapterin supplementation in vivo led to
enhanced eNOS uncoupling due to competitive binding with BH4337. Thus,
upplementation with L-sepiapterin may be most effective in more severe cases of
oxidative stress where BH4 is deficient. Whether or not L-sepiapterin is actually working
to restore eNOS coupling in our in vitro model was not addressed.

However, our

preliminary findings suggest that L- sepiapterin is effective in restoring NO production,
regardless of culture conditions. Thus, L-sepiapterin may serve as a logical therapeutic
option for SLE-related endothelial dysfunction.
Molecular pathways involved in endothelial dysfunction are diverse and
pleiotropic. For example, NF-kB activation yields enhanced adhesion molecule
expression and subsequent leukocyte adhesion to the endothelial cell surface. Moreover,
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increases in H2O2 have been shown to enhance ICAM-1 and IL-8 expression in various
endothelial cell types. The observation that SLE serum induced neutrophil adhesion to
the endothelial cell surface may suggest that NO concentrations are too low to impact
downstream targets. Surprisingly, L-sepiapterin supplementation was not able to
significantly reverse these changes. A titration study designed to assess therapeutic
dosing of L-sepiapterin in vitro would provide insight on whether our initial results were
due to inadequate L-sepiapterin concentrations. In addition, these studies will allow
assessment of the oxidative stress load and provide insight on other possible sources of
superoxide genesis.
In addition to our initial group of studies, we conducted a stratified analysis of
healthy and lupus serum effects on neutrophil chemotaxis, a functional consequence of
increases in IL-8 production. Our results show that serum from patients with SLE
significantly induces neutrophil chemotaxis over healthy controls. Endothelial cells are
the major producer of IL-8; however, the relationship between IL-8 and endothelial
derived-NO has only been investigated recently. Thus far, IL-8 has been shown to
enhance IL-8 but, no effect of IL-8 on nitric oxide production has been shown. Further,
IL-8 elicits plasminogen activator inhibitor-1 (PAI-1) expression in HUVECs, giving the
cells increased coagulative capacity
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. Controversy exists as to the role of NO in

modulating IL-8 production. While early studies showed that impaired NO production
resulted in increased leukocyte adhesion to the endothelial cell surface, other studies have
suggested that NO promotes cGMP production, leading to upregulation of IL-8 mRNA
levels and subsequent neutrophil adhesion.
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S-nitrosation of cysteine 62 and 179 of the NFkB p50 subunit and IKKβ of the
p65 NFκB subunit renders the protein inactive.
nitrosylation can occur at the p65 subunit as well

Moreover, studies show that S-

226, 315, 316, 339, 340

. Thus, with enhanced

low nanomolar NO production, NF-κB activity is compromised, further reducing
inflammation. Studies designed to determine NO concentrations for impairing NFκBmediated neutrophil adhesion in our model were lacking.
Collectively, these data point to role for SLE serum-mediated eNOS uncoupling.
However, results from these studies must be interpreted in context. Lack of shear stress
serves as one limitation associated with in vitro endothelial cell culture since it induces
endothelial abnormalities in and of itself. SLE- mediated endothelial dysfunction is a real
phenomenon in vivo. eNOS uncoupling may be a pathogenic mechanism in this process,
and therapies that restore eNOS coupling and reduce other endothelial sources of
oxidative signaling may be beneficial in preventing endothelial dysfunction observed in
SLE patients.

Future Directions
Studies similar to ours have investigated the relationship between brachial artery
flow mediated dilation and NO production in vitro, suggesting that serum factors
contribute to modulation of eNOS in vitro. Further, in vitro changes induced by serum
may parallel clinical measurements of FMD. Preliminary data from our studies show
trends towards an association between eNOS, NO and FMD; however our studies remain
inconclusive (Figure 6-1A,B).
We also showed L-sepiapterin mediated reversal in serum-induced reductions in
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NO. These findings warrant further research examining changes in BH4 in response to
SLE serum treatment. The extent to which MRL/lpr and NZM/NZW mice develop eNOS
uncoupling is not clearly understood. Thus studies examining eNOS uncoupling and Lsepiapterin efficacy in reversing vascular complications may provide useful information
for treating SLE patients with endothelial dysfunction.
Preliminary data implicates a possible role for oxidative stress in eNOS
uncoupling. Thus, investigations regarding superoxide production along with NADPH
oxidase activity warrant assessment.

Tools that we could potentially employ for these

experiments include: NADPH oxidase inhibitors such as apocynin, VAS2870, or
diphenylene iodonium (DPI) and fluorescent superoxide probes. Parallel experiments
should assess changes in serum induced peroxynitrite (ONOO- )and iNOS derived NO
production.
Functional consequences of subpar NO levels include leukocyte migration and
adhesion, both of which were evident in response to SLE serum. Future studies are
needed to tease out the role of SLE serum in mediating these pathways of IL- 8
production, neutrophil adhesion, and NO bioavailability. Studies should also measure
cytokine and chemokine changes induced by SLE serum that may prompt leukocyte
migration and adherence.
L-sepiapterin supplementation failed to reverse leukocyte adhesion. This finding
warrants future L-sepiapterin titration experiments that assess correlations between NO
concentration (as measured by a Griess assay) and leukocyte adhesion in the presence of
SLE serum.
Lastly, SLE serum fractionation by size, protein A/G depletion, or removal of
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abundant proteins will help identify serum factors responsible for diminished NO
production. Preliminary studies in our lab point to a role for IgG in mediating changes in
NO production, while interferon alpha neutralization studies appear to reverse SLE serum
mediated impacts on NOS3 gene expression (Figure 6-2A-C).
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Figure 6-1. Correlative assessment of brachial artery flow mediated dilation
with in vitro changes. A. HUVECs were cultured as previously described and
treated with 50% serum from SLE patients for 6hr. NO production was assessed
using DAF-FM diacetate. A total of 7,000 events were collected and changes in
fluorescence are expression as median fluorescence intensity. All values were
normalized to buffer control and plotted as a function of brachial artery FMD
assessed on the same day as the serum sample collection of 8 SLE patients. B.
NOS3 mRNA expression plotted as a function of FMD of 8 SLE patients. These
studies were under powered for accurate analysis but provide insight on possible
trends between in vivo and in vitro clinical parameters.
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Figure 6-2. Nitric oxide production in IgG-fractionated serum treated
HUVECs. A-B. Cells were treated with 50% healthy or SLE serum ± IgG
fractionation and ± insulin treatment (100nM). Removal of IgG promoted basal
NO production and insulin mediated NO production in SLE serum treated cells but
not healthy serum treated cells.
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A novel role for IFNα in eNOS dysfunction and insulin –resistance

The secondary goal of our study was to determine the impact of lupus-specific
factors that might explain premature cardiovascular diseases in our patient population.
We discovered that IFNα negatively regulated eNOS gene expression and that these
changes correlated with PKR and MX1. These observations raised the hypothesis that
IFN-α might be responsible suppression of eNOS in vitro. Excitingly, associations
between eNOS expression and PKR induction by rIFNα paralleled human serum
mediated changes.
Basal NO and insulin-mediated production declined in response to rIFNα,
possibly due suppressed protein expression. Insulin resistance is increased in patients
with SLE. Thus, for the first time, our studies may explain a novel mechanism whereby
insulin resistance occurs in SLE, despite the absence of conventional risk factors. These
findings are supported by previous observations that Type I interferon signature gene
induction correlate with reduced FMD and declines in EPC circulation , both of which
dependent on adequate endothelial derived NO.
IFNα impaired cGMP production, a functional consequence of diminished NO
levels. Accordingly, IFNα induced ICAM-1, VCAM-1, and MCP-1 production; yet, only
a slight increase in neutrophil adhesion occurred. Thus, IFNα is not sufficient to
significantly increase endothelial cell stickiness. These data support the hypothesis that
interplay and crosstalk amongst several SLE factors promote a pro-atherogenic
phenotype in vitro, with IFNα serving as a key player.
PKR deficient cells decreased in eNOS expression in response to IFNα, while
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eNOS levels in NFκB deficient cells treated with rIFNα were restored. NF-κB has
pleiotropic effects on eNOS including: modulation of shear stress induced eNOS,
induction of eNOS antagonists (TNFα, IL-1β) and upregulation of the eNOS destabilizer
microRNA 155. MiR155 upregulation by rIFNα in our cultures coincided with previous
findings that rIFNα modulated miR155 expression in dendritic cells
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. A regulator of

NOS3 mRNA stability, MiR155 is a key player in cardiovascular disease 342 and may be a
novel factor in SLE related vasculopathies. Further confirming the role of miR155 in
these pathways, we examined changes in eNOS mRNA stability in response to IFNα and
observed a significant reduction. Collectively, these data provide the rationale for further
studies investigating miR155 expression in patients with SLE.
Post-translational modifications (i.e. pThr495 and pSer1177) largely influence NO
production. In response to rIFNα, we observed enhanced pThr495, which may account for
declines in basal and insulin mediated NO production. Previous studies support these
findings as PKR induced by IFNα prevents insulin receptor activation via inhibitory
phosphorylation at Ser312, leading to subsequent inhibition of phosphorylation at the
activation site, Tyr941326. Future studies examining IFNα/insulin mediated signaling in
PKR deficient endothelial cells are needed.
Insulin

signaling

occurs

through

the

PI3K/Akt

pathway

leading

to

phosphorylation at the Ser1177 site. We did not observe significant alterations in Ser1177
phosphorylation in response to IFNα treatment. Moreover, insulin was recently reported
to prevent phosphorylation of eNOS at the Thr495 site through activation of PP1. Our
studies did not define mechanisms through which IFNα induces insulin sensitivity, but
this would be a logical goal for future research.
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Upon examination of functional outcomes of diminished NO, we did not observe
decreases in cGMP at early but did during late time points, suggesting that effects of
deficient NO on cGMP production are a late rather than early event. Further, these
studies might suggest that IFNα does not activate the cGMP phosphodiesterase type 5,
which could result in diminished cGMP bioavailability with acute treatment. However,
further studies are needed to confirm this finding.

Future Directions
A key limitation in our studies was the absence of shear stress in vitro which
mimics blood flow across the endothelial cell layer. Shear stress activates eNOS and
serves as a major factor in vascular homeostasis. Thus, incorporating flow chambers into
our studies may provide stronger evidence for IFNα mediated eNOS suppression.
Another limitation of our studies was the absence of other IFNα subtypes including α2b,
α4, etc. Thus, future studies might examine the impact of all factors on eNOS expression,
activation, and NO production. Finally, our studies utilized HUVECs, which are limited
in their ability to provide information on the effect of cytokines and chemokines on
vascular endothelial cell complications. Preliminary data in human aortic endothelial
cells showed that IFNα negatively affects eNOS expression (Figure 6-3A); however,
these studies are not powered to draw conclusions.
Animal models examining the role of miR155 in lupus associated CVD are
missing. Our preliminary data show that miR155 may be essential in IFNα-mediated
eNOS expression, driving the hypothesis that miR155 suppression may improve vascular
complications in IFNα dependent NZM/NZW lupus mouse models. Further, in vitro
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using NF-kB inhibitors and a miR155 antagonist may clarify the relationship between
these two modulators that promote IFNα dependent eNOS alterations.
Activation of eNOS is key for NO production, however our studies did not
examine eNOS activation. Thus, using activity assays, future studies should delve into
the impact of IFNα on eNOS activity by possibly examining the conversion of Lcitrulline to L-arginine. Further PI3K/Akt, PP1, PP2A, and PKC expression and
phosphorylation/activation are possibly affected by IFNα. Thus, future studies could
examine these pathways to further understand how IFNα might exploit these proteins to
impair eNOS- NO capacity.
Finally, our studies failed to assess IFNα induced oxidative stress in our HUVEC
cultures; although, we did measure NOX4 levels and did not observe any differences
between the treated and non-treated groups

(Figure 6-3B). Thus, future studies

investigating IFNα mediated changes in oxidative stress may provide insight on losses in
NO production with acute and long-term treatment.
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Figure 6-3. NOS3 and NOX4 gene expression in human aortic endothelial
cells or HUVECs treated with IFNα. A. The graph represents the mean fold
change ± SD in NOS3 expression in HAECs stimulated for 24 hours. All samples
are normalized to GAPDH. B. mRNA expression of NOX4 in HUVECs
stimulated for 6 hours. All samples were normalized to GAPDH and bars
represent fold change of the mean expression ± SD.
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Conclusions
Given the initial findings in the first portion of our research, it is evident that
eNOS uncoupling may be important in SLE-mediated endothelial dysfunction. However,
we did not examine the effect of IFNα in these pathways. The IFNα-oxidative stress axis
is complex, as multiple studies propose a regulatory loop whereby oxidation and
nitrosylation of inflammatory protein mediators interact to oppose each other. Thus,
future studies examining the cross-talk between interferon alpha and oxidative stress are
necessary to fully understand the complexities presented in SLE- related endothelial
dysfunction.
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Impact on Field
Atherosclerosis is a public health concern that impacts non-autoimmune and autoimmune disease populations alike. In addition to Mariana Kaplan’s extensive work on
IFNα in EPCs, we now know that IFNα modulates NO, the key regulator of endothelial
function. The effect of IFNα on insulin sensitivity is a critical finding. Further, we
understand that one potential mechanism whereby endothelial dysfunction in SLE
patients occurs is through eNOS uncoupling. Pre-clinical studies examining the efficacy
of IFNAR antibodies, BH4 supplementation, as well as other targets impacting eNOS
coupling is justified by this work.

181

References
1.

Tan EM, Kunkel HG. Characteristics of a soluble nuclear antigen precipitating
with sera of patients with systemic lupus erythematosus. J Immunol 1966, 96(3):
464-471.

2.

Siegel M. Lupus' racial prevalence questioned. Jama 1966, 196(13): Suppl:28.

3.

Fessel WJ. Systemic lupus erythematosus in the community. Incidence,
prevalence, outcome, and first symptoms; the high prevalence in black women.
Archives of internal medicine 1974, 134(6): 1027-1035.

4.

Feng PH, Boey ML. Systemic lupus erythematosus in Chinese: the Singapore
experience. Rheumatol Int 1982, 2(4): 151-154.

5.

Arnett FC, Shulman LE. Studies in familial systemic lupus erythematosus.
Medicine (Baltimore) 1976, 55(4): 313-322.

6.

Winchester RJ, Nunez-Roldan A. Some genetic aspects of systemic lupus
erythematosus. Arthritis Rheum 1982, 25(7): 833-837.

7.

Hochberg MC. Updating the American College of Rheumatology revised criteria
for the classification of systemic lupus erythematosus. Arthritis Rheum 1997,
40(9): 1725.

8.

Kuhn A, Wenzel J, Weyd H. Photosensitivity, apoptosis, and cytokines in the
pathogenesis of lupus erythematosus: a critical review. Clinical reviews in allergy
& immunology 2014, 47(2): 148-162.

9.

Hamilton ME, Winfield JB. Tgamma cells in systemic lupus erythematosus.
Variation with disease activity. Arthritis Rheum 1979, 22(1): 1-6.

10.

Koike T, Kobayashi S, Yoshiki T, Itoh T, Shirai T. Differential sensitivity of
functional subsets of T cells to the cytotoxicity of natural T-lymphocytotoxic
autoantibody of systemic lupus erythematosus. Arthritis Rheum 1979, 22(2): 123129.

11.

Mittal KK, Rossen RD, Sharp JT, Lidsky MD, Butler WT. Lymphocyte cytotoxic
antibodies in systemic lupus erythematosus. Nature 1970, 225(5239): 1255-1256.

12.

Singer PA, Balderas RS, McEvilly RJ, Bobardt M, Theofilopoulos AN.
Tolerance-related V beta clonal deletions in normal CD4-8-, TCR-alpha/beta +
and abnormal lpr and gld cell populations. J Exp Med 1989, 170(6): 1869-1877.

182

13.

Kastner P, Franke H, Kleinert P, Gunther C, Malberg K, Lobnitz M. [Fc-receptor
mediated immune complex clearance function of the mononuclear phagocyte
system in systemic lupus erythematosus]. Allergie und Immunologie 1990, 36(2):
103-110.

14.

Chauhan AK, Moore TL. T cell activation by terminal complex of complement
and immune complexes. J Biol Chem 2011, 286(44): 38627-38637.

15.

Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell
development: 17 beta-estradiol impairs negative selection of high-affinity DNAreactive B cells at more than one developmental checkpoint. J Immunol 2006,
176(5): 2703-2710.

16.

Wenderfer SE, Ke B, Hollmann TJ, Wetsel RA, Lan HY, Braun MC. C5a
receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. J
Am Soc Nephrol 2005, 16(12): 3572-3582.

17.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al.
Belimumab reduces autoantibodies, normalizes low complement levels, and
reduces select B cell populations in patients with systemic lupus erythematosus.
Arthritis Rheum 2012, 64(7): 2328-2337.

18.

Iwata S, Saito K, Tokunaga M, Tanaka Y. Persistent memory B cell downregulation after 6-year remission induced by rituximab therapy in patients with
systemic lupus erythematosus. Lupus 2013, 22(5): 538-540.

19.

Group AT. Treatment of lupus nephritis with abatacept: the Abatacept and
Cyclophosphamide Combination Efficacy and Safety Study. Arthritis &
rheumatology 2014, 66(11): 3096-3104.

20.

Karassa FB, Isenberg DA. Efficacy of mycophenolate mofetil in patients with
diffuse proliferative lupus nephritis. The New England journal of medicine 2001,
344(5): 382-383.

21.

Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc
gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid
dendritic cells) and is required for the IFN-alpha production induced by apoptotic
cells combined with lupus IgG. J Immunol 2003, 171(6): 3296-3302.

22.

Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferonalpha production in plasmacytoid dendritic cells by immune complexes
containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG.
Arthritis Rheum 2004, 50(6): 1861-1872.

183

23.

Steinberg AD, Baron S, Talal N. The pathogenesis of autoimmunity in New
Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinicpolycytidylic acid. Proc Natl Acad Sci U S A 1969, 63(4): 1102-1107.

24.

Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic
lupus erythematosus. Arthritis Rheum 1982, 25(4): 401-406.

25.

Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL.
Immune interferon in the circulation of patients with autoimmune disease. The
New England journal of medicine 1979, 301(1): 5-8.

26.

Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al.
The nature of the principal type 1 interferon-producing cells in human blood.
Science 1999, 284(5421): 1835-1837.

27.

Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid
dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in
cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159(1): 237-243.

28.

Fiore N, Castellano G, Blasi A, Capobianco C, Loverre A, Montinaro V, et al.
Immature myeloid and plasmacytoid dendritic cells infiltrate renal
tubulointerstitium in patients with lupus nephritis. Molecular immunology 2008,
45(1): 259-265.

29.

Lindau D, Mussard J, Rabsteyn A, Ribon M, Kotter I, Igney A, et al. TLR9
independent interferon alpha production by neutrophils on NETosis in response to
circulating chromatin, a key lupus autoantigen. Ann Rheum Dis 2014, 73(12):
2199-2207.

30.

Liu Z, Bethunaickan R, Huang W, Lodhi U, Solano I, Madaio MP, et al.
Interferon-alpha accelerates murine systemic lupus erythematosus in a T celldependent manner. Arthritis Rheum 2011, 63(1): 219-229.

31.

Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F.
Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis:
role of interleukin-18. Arthritis Rheum 2008, 58(1): 251-262.

32.

Li J, Fu Q, Cui H, Qu B, Pan W, Shen N, et al. Interferon-alpha priming promotes
lipid uptake and macrophage-derived foam cell formation: a novel link between
interferon-alpha and atherosclerosis in lupus. Arthritis Rheum 2011, 63(2): 492502.

33.

Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus
psychosis. Arthritis Rheum 1992, 35(4): 417-422.
184

34.

Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL. Studies of
twins with systemic lupus erythematosus. A review of the literature and
presentation of 12 additional sets. Am J Med 1975, 59(4): 533-552.

35.

Abeler-Dorner L, Rieger CC, Berger B, Weyd H, Graf D, Pfrang S, et al.
Interferon-alpha abrogates the suppressive effect of apoptotic cells on dendritic
cells in an in vitro model of systemic lupus erythematosus pathogenesis. J
Rheumatol 2013, 40(10): 1683-1696.

36.

Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, et al.
Population-based incidence and prevalence of systemic lupus erythematosus: the
Michigan Lupus Epidemiology and Surveillance program. Arthritis &
rheumatology 2014, 66(2): 369-378.

37.

Wu G, Jia X, Gao D, Zhao Z. Survival rates and risk factors for mortality in
systemic lupus erythematosus patients in a Chinese center. Clin Rheumatol 2014,
33(7): 947-953.

38.

Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo
MA. The bimodal mortality pattern of systemic lupus erythematosus. The
American Journal of Medicine 1976, 60(2): 221-225.

39.

Skamra C, Ramsey-Goldman R. Management of cardiovascular complications in
systemic lupus erythematosus. International journal of clinical rheumatology
2010, 5(1): 75-100.

40.

Bengtsson C, Ohman ML, Nived O, Rantapaa Dahlqvist S. Cardiovascular event
in systemic lupus erythematosus in northern Sweden: incidence and predictors in
a 7-year follow-up study. Lupus 2012, 21(4): 452-459.

41.

Yang J, Xu D, Shen ZJ, Wang CH, Zhang SY, Fan ZJ, et al. [Clinical and
coronary features of systemic lupus erythematosus patients with coronary artery
disease]. Zhonghua xin xue guan bing za zhi 2012, 40(5): 382-385.

42.

Hua X, Su J, Svenungsson E, Hurt-Camejo E, Jensen-Urstad K, Angelin B, et al.
Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and
SLE-related cardiovascular disease. Scand J Rheumatol 2009, 38(3): 184-189.

43.

Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de
Faire U, et al. Risk factors for cardiovascular disease in systemic lupus
erythematosus. Circulation 2001, 104(16): 1887-1893.

44.

Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus
is associated with traditional cardiovascular risk factors, but not with disease
activity. J Rheumatol 2008, 35(7): 1300-1306.
185

45.

Santos MJ, Vinagre F, Silva JJ, Gil V, Fonseca JE. Cardiovascular risk profile in
systemic lupus erythematosus and rheumatoid arthritis: a comparative study of
female patients. Acta reumatologica portuguesa 2010, 35(3): 325-332.

46.

Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, et al.
Mortality and cardiovascular burden of systemic lupus erythematosus in a US
population-based cohort. J Rheumatol 2014, 41(4): 680-687.

47.

Drakoulogkona O, Barbulescu AL, Rica I, Musetescu AE, Ciurea PL. The
outcome of patients with lupus nephritis and the impact of cardiovascular risk
factors. Current health sciences journal 2011, 37(2): 70-74.

48.

Font J, Ramos-Casals M, Brito-Zeron P, Nardi N, Ibanez A, Suarez B, et al.
Association of mannose-binding lectin gene polymorphisms with
antiphospholipid syndrome, cardiovascular disease and chronic damage in
patients with systemic lupus erythematosus. Rheumatology (Oxford) 2007, 46(1):
76-80.

49.

Ward MM. Cardiovascular and cerebrovascular morbidity and mortality among
women with end-stage renal disease attributable to lupus nephritis. Am J Kidney
Dis 2000, 36(3): 516-525.

50.

Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et
al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus
erythematosus. The New England journal of medicine 2003, 349(25): 2399-2406.

51.

Bijl M. Endothelial activation, endothelial dysfunction and premature
atherosclerosis in systemic autoimmune diseases. Neth J Med 2003.

52.

Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA.
The bimodal mortality pattern of systemic lupus erythematosus. The American
Journal of Medicine 1976, 60(2): 221-225.

53.

Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, et al.
Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway
for abnormal vascular function and thrombosis propensity. Blood 2004, 103(10):
3677-3683.

54.

Bobadilla NA, Tapia E, Jiménez F, Sánchez-Lozada LG, Santamaría J, Monjardín
A, et al. Dexamethasone increases eNOS gene expression and prevents renal
vasoconstriction induced by cyclosporin. American journal of … 1999.

186

55.

Martens F, Rabelink TJ, Roodt JOat. TNF-α induces endothelial dysfunction in
diabetic adults, an effect reversible by the PPAR-γ agonist pioglitazone. European
heart … 2006.

56.

Yoshizumi M, Perrella MA, Burnett JC, Jr., Lee ME. Tumor necrosis factor
downregulates an endothelial nitric oxide synthase mRNA by shortening its halflife. Circ Res 1993, 73(1): 205-209.

57.

Katagiri H, Ito Y, Ito S, Murata T, Yukihiko S, Narumiya S, et al. TNF-alpha
induces thromboxane receptor signaling-dependent microcirculatory dysfunction
in mouse liver. Shock 2008, 30(4): 463-467.

58.

Sury MD, Frese-Schaper M, Muhlemann MK, Schulthess FT, Blasig IE, Tauber
MG, et al. Evidence that N-acetylcysteine inhibits TNF-alpha-induced
cerebrovascular endothelin-1 upregulation via inhibition of mitogen- and stressactivated protein kinase. Free Radic Biol Med 2006, 41(9): 1372-1383.

59.

Gertzberg N, Neumann P, Rizzo V, Johnson A. NAD(P)H oxidase mediates the
endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell
Mol Physiol 2004, 286(1): L37-48.

60.

Svenungsson E, Cederholm A, Jensen-Urstad K, Fei GZ, de Faire U, Frostegard J.
Endothelial function and markers of endothelial activation in relation to
cardiovascular disease in systemic lupus erythematosus. Scand J Rheumatol 2008,
37(5): 352-359.

61.

Andreozzi F, Laratta E, Procopio C, Hribal ML, Sciacqua A, Perticone M, et al.
Interleukin-6 impairs the insulin signaling pathway, promoting production of
nitric oxide in human umbilical vein endothelial cells. Molecular and cellular
biology 2007, 27(6): 2372-2383.

62.

Hung MJ, Cherng WJ, Hung MY, Wu HT, Pang JH. Interleukin-6 inhibits
endothelial nitric oxide synthase activation and increases endothelial nitric oxide
synthase binding to stabilized caveolin-1 in human vascular endothelial cells. J
Hypertens 2010, 28(5): 940-951.

63.

Erzen B, Sabovic M, Sebestjen M, Keber I, Poredos P. Interleukin-6 correlates
with endothelial dysfunction in young post-myocardial infarction patients.
Cardiology 2007, 107(2): 111-116.

64.

Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I.
Cytokine production, serum levels and disease activity in systemic lupus
erythematosus. Clin Exp Rheumatol 2000, 18(5): 565-570.

187

65.

Llorente L, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot MC, DurandGasselin I, et al. Spontaneous production of interleukin-10 by B lymphocytes and
monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993, 4(6): 421427.

66.

Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10
levels correlated with disease activity in systemic lupus erythematosus. Clin Exp
Rheumatol 1998, 16(3): 283-288.

67.

Gunnett CA, Heistad DD, Berg DJ, Faraci FM. IL-10 deficiency increases
superoxide and endothelial dysfunction during inflammation. Am J Physiol Heart
Circ Physiol 2000, 279(4): H1555-1562.

68.

Tinsley JH, South S, Chiasson VL, Mitchell BM. Interleukin-10 reduces
inflammation, endothelial dysfunction, and blood pressure in hypertensive
pregnant rats. American journal of physiology Regulatory, integrative and
comparative physiology 2010, 298(3): R713-719.

69.

Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE, et al. Role of interleukin
17 in inflammation, atherosclerosis, and vascular function in apolipoprotein edeficient mice. Arterioscler Thromb Vasc Biol 2011, 31(7): 1565-1572.

70.

Annie-Jeyachristy S, Geetha A, Surendran R. Changes in the level of cytosolic
calcium, nitric oxide and nitric oxide synthase activity during platelet
aggregation: an in vitro study in platelets from normal subjects and those with
cirrhosis. Journal of biosciences 2008, 33(1): 45-53.

71.

Popkova TV, Panafidina TA, Aleksandrova EN, Novikova DS, Novikov AA,
Alekberova ZS, et al. [Soluble CD40 ligand in systemic lupus erythematosus: link
with atherosclerotic vascular affection]. Ter Arkh 2008, 80(5): 37-41.

72.

Chen C, Chai H, Wang X, Jiang J, Jamaluddin MS, Liao D, et al. Soluble CD40
ligand induces endothelial dysfunction in human and porcine coronary artery
endothelial cells. Blood 2008, 112(8): 3205-3216.

73.

Schwartz R, Osborne-Lawrence S, Hahner L, Gibson LL, Gormley AK,
Vongpatanasin W, et al. C-reactive protein downregulates endothelial NO
synthase and attenuates reendothelialization in vivo in mice. Circ Res 2007,
100(10): 1452-1459.

74.

Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human Creactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo.
Atherosclerosis 2009, 206(1): 61-68.

188

75.

Eudy AM, Vines AI, Dooley MA, Cooper GS, Parks CG. Elevated C-reactive
protein and self-reported disease activity in systemic lupus erythematosus. Lupus
2014, 23(14): 1460-1467.

76.

Enocsson H, Sjowall C, Kastbom A, Skogh T, Eloranta ML, Ronnblom L, et al.
Association of serum C-reactive protein levels with lupus disease activity in the
absence of measurable interferon-alpha and a C-reactive protein gene variant.
Arthritis & rheumatology 2014, 66(6): 1568-1573.

77.

Enocsson H, Sjowall C, Skogh T, Eloranta ML, Ronnblom L, Wettero J.
Interferon-alpha mediates suppression of C-reactive protein: explanation for
muted C-reactive protein response in lupus flares? Arthritis Rheum 2009, 60(12):
3755-3760.

78.

Figueredo MA, Rodriguez A, Ruiz-Yague M, Romero M, Fernandez-Cruz A,
Gomez-de la Concha E, et al. Autoantibodies against C-reactive protein: clinical
associations in systemic lupus erythematosus and primary antiphospholipid
syndrome. J Rheumatol 2006, 33(10): 1980-1986.

79.

Amezcua-Guerra LM, Springall R, Arrieta-Alvarado AA, Rodriguez V, RiveraMartinez E, Castillo-Martinez D, et al. C-reactive protein and complement
components but not other acute-phase reactants discriminate between clinical
subsets and organ damage in systemic lupus erythematosus. Clin Lab 2011, 57(78): 607-613.

80.

Firooz N, Albert DA, Wallace DJ, Ishimori M, Berel D, Weisman MH. Highsensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus
erythematosus. Lupus 2011, 20(6): 588-597.

81.

Sjowall C, Bengtsson AA, Sturfelt G, Skogh T. Anti-CRP autoantibody levels
correlate with disease activity in systemic lupus erythematosus. Semin Arthritis
Rheum 2005, 35(1): 65; author reply 66.

82.

Szalai AJ, Weaver CT, McCrory MA, van Ginkel FW, Reiman RM, Kearney JF,
et al. Delayed lupus onset in (NZB x NZW)F1 mice expressing a human Creactive protein transgene. Arthritis Rheum 2003, 48(6): 1602-1611.

83.

Enocsson H, SjÃ wall C, Skogh T, Eloranta M-L, RÃ nnblom L, WetterÃ J.
Interferon-Î± mediates suppression of C-reactive protein: Explanation for muted
C-reactive protein response in lupus flares? Arthritis &amp; Rheumatism 2009,
60(12): 3755-3760.

84.

Alves JD, Ames PR. Atherosclerosis, oxidative stress and auto-antibodies in
systemic lupus erythematosus and primary antiphospholipid syndrome.
Immunobiology 2003, 207(1): 23-28.
189

85.

Stalc M, Tomsic M, Jezovnik MK, Poredos P. Endothelium-dependent and
independent dilation capability of peripheral arteries in patients with systemic
lupus erythematosus and antiphospholipid syndrome. Clin Exp Rheumatol 2011,
29(4): 616-623.

86.

Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK,
et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations
of systemic lupus erythematosus. Arthritis Rheum 2006, 54(12): 3918-3925.

87.

Montehermoso A, Cervera R, Font J, Ramos-Casals M, Garcia-carrasco M,
Formiga F, et al. Association of antiphospholipid antibodies with retinal vascular
disease in systemic lupus erythematosus. Semin Arthritis Rheum 1999, 28(5):
326-332.

88.

Hayem G, Nicaise-Roland P, Palazzo E, de Bandt M, Tubach F, Weber M, et al.
Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus
erythematosus with and without antiphospholipid syndrome. Lupus 2001, 10(5):
346-351.

89.

Lopez LR, Hurley BL, Simpson DF, Matsuura E. Oxidized low-density
lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with
type 2 diabetes mellitus. Ann N Y Acad Sci 2005, 1051: 97-103.

90.

Lopez LR, Salazar-Paramo M, Palafox-Sanchez C, Hurley BL, Matsuura E,
Garcia-De La Torre I. Oxidized low-density lipoprotein and beta2-glycoprotein I
in patients with systemic lupus erythematosus and increased carotid intima-media
thickness: implications in autoimmune-mediated atherosclerosis. Lupus 2006,
15(2): 80-86.

91.

Fang JC, Kinlay S, Behrendt D, Hikita H, Witztum JL, Selwyn AP, et al.
Circulating autoantibodies to oxidized LDL correlate with impaired coronary
endothelial function after cardiac transplantation. Arterioscler Thromb Vasc Biol
2002, 22(12): 2044-2048.

92.

Cines DB, Lyss AP, Reeber M, Bina M, DeHoratius RJ. Presence of complementfixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin
Invest 1984, 73(3): 611-625.

93.

Zhou SF, Wang XM, Zhong HP, Li A, Wang MX, Wang SL, et al. Pathogenetic
role of anti-vascular endothelial cell antibodies in systemic lupus erythematosus.
Chinese medical journal 1989, 102(7): 505-509.

94.

van der Zee JM, Siegert CE, de Vreede TA, Daha MR, Breedveld FC.
Characterization of anti-endothelial cell antibodies in systemic lupus
190

erythematosus (SLE). Clinical and experimental immunology 1991, 84(2): 238244.
95.

Constans J, Dupuy R, Blann AD, Resplandy F, Seigneur M, Renard M, et al.
Anti-endothelial cell autoantibodies and soluble markers of endothelial cell
dysfunction in systemic lupus erythematosus. J Rheumatol 2003, 30(9): 19631966.

96.

Satoskar AA, Brodsky SV, Nadasdy G, Bott C, Rovin B, Hebert L, et al.
Discrepancies in glomerular and tubulointerstitial/vascular immune complex IgG
subclasses in lupus nephritis. Lupus 2011, 20(13): 1396-1403.

97.

Meyer O, Hauptmann G, Tappeiner G, Ochs HD, Mascart-Lemone F. Genetic
deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro (SSA) antibodies. Clinical and experimental immunology 1985, 62(3): 678-684.

98.

Walport MJ, Davies KA, Morley BJ, Botto M. Complement deficiency and
autoimmunity. Ann N Y Acad Sci 1997, 815: 267-281.

99.

Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated
skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to
increase nitric oxide release. J Clin Invest 1994, 94(3): 1172-1179.

100.

Laine P, Pentikainen MO, Wurzner R, Penttila A, Paavonen T, Meri S, et al.
Evidence for complement activation in ruptured coronary plaques in acute
myocardial infarction. The American journal of cardiology 2002, 90(4): 404-408.

101.

Lewis MJ, Malik TH, Fossati-Jimack L, Carassiti D, Cook HT, Haskard DO, et al.
Distinct roles for complement in glomerulonephritis and atherosclerosis revealed
in mice with a combination of lupus and hyperlipidemia. Arthritis Rheum 2012,
64(8): 2707-2718.

102.

Parra S, Vives G, Ferre R, Gonzalez M, Guardiola M, Ribalta J, et al.
Complement system and small HDL particles are associated with subclinical
atherosclerosis in SLE patients. Atherosclerosis 2012, 225(1): 224-230.

103.

Lennon PF, Collard CD, Morrissey MA, Stahl GL. Complement-induced
endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences.
Am J Physiol 1996, 270(6 Pt 2): H1924-1932.

104.

Hertle E, van Greevenbroek MM, Arts IC, van der Kallen CJ, Feskens EJ,
Schalkwijk CG, et al. Complement activation products C5a and sC5b-9 are
associated with low-grade inflammation and endothelial dysfunction, but not with
atherosclerosis in a cross-sectional analysis: the CODAM study. Int J Cardiol
2014, 174(2): 400-403.
191

105.

Wang Y, He Q, Qin H, Xu J, Tong J, Gao L, et al. The complement C5b-9
complexes induced injury of glomerular mesangial cells in rats with Thy-1
nephritis by increasing nitric oxide synthesis. Life Sci 2006, 79(2): 182-192.

106.

Montalto MC, Hart ML, Jordan JE, Wada K, Stahl GL. Role for complement in
mediating intestinal nitric oxide synthase-2 and superoxide dismutase expression.
Am J Physiol Gastrointest Liver Physiol 2003, 285(1): G197-206.

107.

Von Feldt JM, Scalzi LV, Cucchiara AJ, Morthala S, Kealey C, Flagg SD, et al.
Homocysteine levels and disease duration independently correlate with coronary
artery calcification in patients with systemic lupus erythematosus. Arthritis
Rheum 2006, 54(7): 2220-2227.

108.

Ribeiro GG, Bonfa E, Sasdeli Neto R, Abe J, Caparbo VF, Borba EF, et al.
Premature coronary artery calcification is associated with disease duration and
bone mineral density in young female systemic lupus erythematosus patients.
Lupus 2010, 19(1): 27-33.

109.

Pearson JD. Endothelial cell biology. Radiology 1991, 179(1): 9-14.

110.

Nagy Z, Peters H, Huttner I. Fracture faces of cell junctions in cerebral
endothelium during normal and hyperosmotic conditions. Lab Invest 1984, 50(3):
313-322.

111.

Vink H, Duling BR. Identification of distinct luminal domains for
macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ
Res 1996, 79(3): 581-589.

112.

Fraser R, Dobbs BR, Rogers GW. Lipoproteins and the liver sieve: the role of the
fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and
cirrhosis. Hepatology 1995, 21(3): 863-874.

113.

Springer TA. Traffic signals for lymphocyte recirculation and leukocyte
emigration: the multistep paradigm. Cell 1994, 76(2): 301-314.

114.

van der Poll T, van Deventer SJ, Pasterkamp G, van Mourik JA, Buller HR, ten
Cate JW. Tumor necrosis factor induces von Willebrand factor release in healthy
humans. Thromb Haemost 1992, 67(6): 623-626.

115.

Paleolog EM, Carew MA, Pearson JD. Effects of tumour necrosis factor and
interleukin-1 on von Willebrand factor secretion from human vascular endothelial
cells. International journal of radiation biology 1991, 60(1-2): 279-285.

192

116.

Hahne M, Jager U, Isenmann S, Hallmann R, Vestweber D. Five tumor necrosis
factor-inducible cell adhesion mechanisms on the surface of mouse endothelioma
cells mediate the binding of leukocytes. J Cell Biol 1993, 121(3): 655-664.

117.

Rankin JA, Sylvester I, Smith S, Yoshimura T, Leonard EJ. Macrophages
cultured in vitro release leukotriene B4 and neutrophil attractant/activation protein
(interleukin 8) sequentially in response to stimulation with lipopolysaccharide and
zymosan. J Clin Invest 1990, 86(5): 1556-1564.

118.

Lee TH, Avraham H, Lee SH, Avraham S. Vascular endothelial growth factor
modulates neutrophil transendothelial migration via up-regulation of interleukin-8
in human brain microvascular endothelial cells. J Biol Chem 2002, 277(12):
10445-10451.

119.

Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and
inflammation. Nature reviews Immunology 2013, 13(3): 159-175.

120.

Pou S, Gunther MR, Pou WS, Cao GL, Bator JM, Cohen MS, et al. Effect of NPC
15669, an inhibitor of neutrophil recruitment and neutrophil-mediated
inflammation, on neutrophil function in vitro. Biochem Pharmacol 1993, 45(10):
2123-2127.

121.

Liu Z, Jiang Y, Li Y, Wang J, Fan L, Scott MJ, et al. TLR4 Signaling augments
monocyte chemotaxis by regulating G protein-coupled receptor kinase 2
translocation. J Immunol 2013, 191(2): 857-864.

122.

Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and
cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacological
reviews 2010, 62(3): 525-563.

123.

Lee SK, Kim JH, Yang WS, Kim SB, Park SK, Park JS. Exogenous nitric oxide
inhibits VCAM-1 expression in human peritoneal mesothelial cells. Role of cyclic
GMP and NF-kappaB. Nephron 2002, 90(4): 447-454.

124.

Berendji-Grun D, Kolb-Bachofen V, Kroncke KD. Nitric oxide inhibits
endothelial IL-1[beta]-induced ICAM-1 gene expression at the transcriptional
level decreasing Sp1 and AP-1 activity. Molecular medicine 2001, 7(11): 748-754.

125.

Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of
leukocyte adhesion. Proc Natl Acad Sci U S A 1991, 88(11): 4651-4655.

126.

Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and
targets for drug development. Front Biosci (Landmark Ed) 2009, 14: 1-18.

193

127.

Rivero-Vilches FJ, de Frutos S, Saura M, Rodriguez-Puyol D, Rodriguez-Puyol
M. Differential relaxing responses to particulate or soluble guanylyl cyclase
activation on endothelial cells: a mechanism dependent on PKG-I alpha activation
by NO/cGMP. Am J Physiol Cell Physiol 2003, 285(4): C891-898.

128.

Mahavadi S, Nalli A, Al-Shboul O, Murthy KS. Inhibition of MLC20
phosphorylation downstream of Ca2+ and RhoA: A novel mechanism involving
phosphorylation of myosin phosphatase interacting protein (M-RIP) by PKG and
stimulation of MLC phosphatase activity. Cell biochemistry and biophysics 2014,
68(1): 1-8.

129.

Amano M, Takahashi M, Kosaka T, Kinoshita M. Differential inhibition of
platelet aggregation and calcium mobilization by nitroglycerin and stabilized
nitric oxide. Journal of cardiovascular pharmacology 1994, 24(6): 860-866.

130.

Gries A, Bode C, Peter K, Herr A, Bohrer H, Motsch J, et al. Inhaled nitric oxide
inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding
in vitro and in vivo. Circulation 1998, 97(15): 1481-1487.

131.

Roberts W, Michno A, Aburima A, Naseem KM. Nitric oxide inhibits von
Willebrand factor-mediated platelet adhesion and spreading through regulation of
integrin alpha(IIb)beta(3) and myosin light chain. J Thromb Haemost 2009, 7(12):
2106-2115.

132.

Padmaja S, Huie RE. The reaction of nitric oxide with organic peroxyl radicals.
Biochemical and biophysical research communications 1993, 195(2): 539-544.

133.

Takeuchi K, Watanabe H, Tran QK, Ozeki M, Sumi D, Hayashi T, et al. Nitric
oxide: inhibitory effects on endothelial cell calcium signaling, prostaglandin I2
production and nitric oxide synthase expression. Cardiovasc Res 2004, 62(1):
194-201.

134.

Xu W, Charles IG, Moncada S, Gorman P, Sheer D, Liu L, et al. Mapping of the
genes encoding human inducible and endothelial nitric oxide synthase (NOS2 and
NOS3) to the pericentric region of chromosome 17 and to chromosome 7,
respectively. Genomics 1994, 21(2): 419-422.

135.

Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure,
function and inhibition. The Biochemical journal 2001, 357(Pt 3): 593-615.

136.

Crane BR, Arvai AS, Ghosh DK, Wu C, Getzoff ED, Stuehr DJ, et al. Structure
of nitric oxide synthase oxygenase dimer with pterin and substrate. Science 1998,
279(5359): 2121-2126.

194

137.

Walder CE, Thiemermann C, Vane JR. NG-hydroxy-L-arginine prevents the
haemodynamic effects of nitric oxide synthesis inhibition in the anaesthetized rat.
Br J Pharmacol 1992, 107(2): 476-480.

138.

Stuehr DJ, Kwon NS, Nathan CF, Griffith OW, Feldman PL, Wiseman J. N
omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide
from L-arginine. J Biol Chem 1991, 266(10): 6259-6263.

139.

Stuehr DJ. Mammalian nitric oxide synthases. Biochim Biophys Acta 1999,
1411(2-3): 217-230.

140.

Hemmens B, Mayer B. Enzymology of nitric oxide synthases. Methods in
molecular biology 1998, 100: 1-32.

141.

Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF. Purification and
characterization of the cytokine-induced macrophage nitric oxide synthase: an
FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A 1991, 88(17):
7773-7777.

142.

Baek KJ, Thiel BA, Lucas S, Stuehr DJ. Macrophage nitric oxide synthase
subunits. Purification, characterization, and role of prosthetic groups and substrate
in regulating their association into a dimeric enzyme. J Biol Chem 1993, 268(28):
21120-21129.

143.

Hibbs JB, Jr., Westenfelder C, Taintor R, Vavrin Z, Kablitz C, Baranowski RL, et
al. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in
patients receiving interleukin-2 therapy. J Clin Invest 1992, 89(3): 867-877.

144.

Quillon A, Fromy B, Debret R. Endothelium microenvironment sensing leading
to nitric oxide mediated vasodilation: A review of nervous and biomechanical
signals. Nitric Oxide 2015, 45: 20-26.

145.

Henry Y, Lepoivre M, Drapier JC, Ducrocq C, Boucher JL, Guissani A. EPR
characterization of molecular targets for NO in mammalian cells and organelles.
FASEB J 1993, 7(12): 1124-1134.

146.

Stauss HM, Godecke A, Mrowka R, Schrader J, Persson PB. Enhanced blood
pressure variability in eNOS knockout mice. Hypertension 1999, 33(6): 13591363.

147.

Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, et al. Development of heart
failure and congenital septal defects in mice lacking endothelial nitric oxide
synthase. Circulation 2002, 106(7): 873-879.

195

148.

Lee TC, Zhao YD, Courtman DW, Stewart DJ. Abnormal aortic valve
development in mice lacking endothelial nitric oxide synthase. Circulation 2000,
101(20): 2345-2348.

149.

Lee PC, Salyapongse AN, Bragdon GA, Shears LL, 2nd, Watkins SC, Edington
HD, et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. The
American journal of physiology 1999, 277(4 Pt 2): H1600-1608.

150.

Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, et al. Insulin
resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric
oxide synthase. Circulation 2001, 104(3): 342-345.

151.

Tsutsui M, Tanimoto A, Tamura M, Mukae H, Yanagihara N, Shimokawa H, et al.
Significance of nitric oxide synthases: Lessons from triple nitric oxide synthases
null mice. Journal of pharmacological sciences 2015, 127(1): 42-52.

152.

Yoshikawa T, Shimano H, Chen Z, Ishibashi S, Yamada N. Effects of probucol
on atherosclerosis of apoE-deficient or LDL receptor-deficient mice. Hormone
and metabolic research = Hormon- und Stoffwechselforschung = Hormones et
metabolisme 2001, 33(8): 472-479.

153.

Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, et al. Effects of D-4F
on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptornull and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.
Circ Res 2005, 97(11): 1190-1197.

154.

Liu Y, Lin T, Lei B. [Comparative study of retinopathy in C57BL/6 and eNOSknockout mouse models of type 1 diabetes mellitus]. Nan fang yi ke da xue xue
bao = Journal of Southern Medical University 2012, 32(12): 1683-1688.

155.

Mohan S, Reddick RL, Musi N, Horn DA, Yan B, Prihoda TJ, et al. Diabetic
eNOS knockout mice develop distinct macro- and microvascular complications.
Lab Invest 2008, 88(5): 515-528.

156.

Gilkeson GS, Mashmoushi AK, Ruiz P, Caza TN, Perl A. Endothelial Nitric
Oxide Synthase Reduces Crescentic and Necrotic Glomerular Lesions, Reactive
Oxygen Production, and MCP1 Production in Murine Lupus …. PloS one 2013.

157.

Al Gadban MM, German J, Truman JP, Soodavar F, Riemer EC, Twal WO, et al.
Lack of nitric oxide synthases increases lipoprotein immune complex deposition
in the aorta and elevates plasma sphingolipid levels in lupus. Cellular
Immunology 2012, 276(1-2): 42-51.

196

158.

Pointer MA, Daumerie G, Bridges L, Yancey S, Howard K, Davis W, et al.
Physiological stress increases renal injury in eNOS-knockout mice. Hypertens Res
2012, 35(3): 318-324.

159.

Li Q, Verma A, Han PY, Nakagawa T, Johnson RJ, Grant MB, et al. Diabetic
eNOS-knockout mice develop accelerated retinopathy. Invest Ophthalmol Vis Sci
2010, 51(10): 5240-5246.

160.

Mohan S, Reddick RL, Musi N, Horn DA, Yan B. Diabetic eNOS knockout mice
develop distinct macro-and microvascular complications. Laboratory … 2008.

161.

Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N.
Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are
ameliorated by enalapril treatment. The Journal of clinical investigation 2000,
105(4): 451-458.

162.

Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric
oxide and atherosclerosis: an update. Nitric Oxide 2006, 15(4): 265-279.

163.

Paradossi U, Ciofini E, Clerico A, Botto N, Biagini A, Colombo MG. Endothelial
function and carotid intima-media thickness in young healthy subjects among
endothelial nitric oxide synthase Glu298-->Asp and T-786-->C polymorphisms.
Stroke; a journal of cerebral circulation 2004, 35(6): 1305-1309.

164.

Tamemoto H, Ishikawa SE, Kawakami M. Association of the Glu298Asp
polymorphism of the eNOS Gene with ischemic heart disease in Japanese diabetic
subjects. Diabetes research and clinical practice 2008, 80(2): 275-279.

165.

Zhang C, Lopez-Ridaura R, Hunter DJ, Rifai N, Hu FB. Common variants of the
endothelial nitric oxide synthase gene and the risk of coronary heart disease
among U.S. diabetic men. Diabetes 2006, 55(7): 2140-2147.

166.

Vazgiourakis V, Sidiropoulos P, Bertsias G, Koutsounaki E, Fragouli E,
Raptopoulou A, et al. Association of the nitric oxide synthase (eNOS) gene
polymorphism with increased risk for both lupus glomerulonephritis and
rheumatoid arthritis in a single genetically homogeneous population. Lupus 2007,
16(11): 867-874.

167.

Lee YH, Lee HS, Choi SJ, Ji JD, Song GG. Associations between eNOS
polymorphisms and susceptibility to systemic lupus erythematosus: a metaanalysis. Inflamm Res 2012, 61(2): 135-141.

168.

Li X, An J, Guo R, Jin Z, Li Y, Zhao Y, et al. Association of the genetic
polymorphisms of the ACE gene and the eNOS gene with lupus nephropathy in
northern Chinese population. BMC medical genetics 2010, 11: 94.
197

169.

Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric
oxide synthase promoter. Sp1 and GATA factors are necessary for basal
transcription in endothelial cells. J Biol Chem 1995, 270(25): 15320-15326.

170.

Li H, Oehrlein SA, Wallerath T, Ihrig-Biedert I, Wohlfart P, Ulshofer T, et al.
Activation of protein kinase C alpha and/or epsilon enhances transcription of the
human endothelial nitric oxide synthase gene. Molecular pharmacology 1998,
53(4): 630-637.

171.

Grumbach IM, Chen W, Mertens SA, Harrison DG. A negative feedback
mechanism involving nitric oxide and nuclear factor kappa-B modulates
endothelial nitric oxide synthase transcription. J Mol Cell Cardiol 2005, 39(4):
595-603.

172.

Davis ME, Grumbach IM, Fukai T, Cutchins A, Harrison DG. Shear stress
regulates endothelial nitric-oxide synthase promoter activity through nuclear
factor kappaB binding. J Biol Chem 2004, 279(1): 163-168.

173.

Rodriguez-Porcel M, Lerman LO, Holmes DR, Jr., Richardson D, Napoli C,
Lerman A. Chronic antioxidant supplementation attenuates nuclear factor-kappa
B activation and preserves endothelial function in hypercholesterolemic pigs.
Cardiovasc Res 2002, 53(4): 1010-1018.

174.

Mata-Greenwood E, Liao WX, Wang W, Zheng J, Chen DB. Activation of AP-1
transcription factors differentiates FGF2 and vascular endothelial growth factor
regulation of endothelial nitric-oxide synthase expression in placental artery
endothelial cells. J Biol Chem 2010, 285(23): 17348-17358.

175.

Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor upregulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res
1999, 41(3): 773-780.

176.

Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase.
Am J Physiol Renal Physiol 2001, 280(2): F193-206.

177.

Neumann P, Gertzberg N, Johnson A. TNF-alpha induces a decrease in eNOS
promoter activity. Am J Physiol Lung Cell Mol Physiol 2004, 286(2): L452-459.

178.

Srinivasan S, Bolick DT, Hatley ME, Natarajan R, Reilly KB, Yeh M, et al.
Glucose regulates interleukin-8 production in aortic endothelial cells through
activation of the p38 mitogen-activated protein kinase pathway in diabetes. J Biol
Chem 2004, 279(30): 31930-31936.

198

179.

Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that Creactive protein decreases eNOS expression and bioactivity in human aortic
endothelial cells. Circulation 2002, 106(12): 1439-1441.

180.

Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG. Transcriptional
and posttranscriptional regulation of endothelial nitric oxide synthase expression
by hydrogen peroxide. Circ Res 2000, 86(3): 347-354.

181.

Kline ER, Kleinhenz DJ, Liang B, Dikalov S, Guidot DM, Hart CM, et al.
Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are
reversed by glutathione restoration. Am J Physiol Heart Circ Physiol 2008,
294(6): H2792-2804.

182.

Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide
bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide
synthase. Proc Natl Acad Sci U S A 2005, 102(25): 9056-9061.

183.

Sun HX, Zeng DY, Li RT, Pang RP, Yang H, Hu YL, et al. Essential role of
microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting
endothelial nitric oxide synthase. Hypertension 2012, 60(6): 1407-1414.

184.

Wu XY, Fan WD, Fang R, Wu GF. Regulation of microRNA-155 in endothelial
inflammation by targeting nuclear factor (NF)-kappaB P65. J Cell Biochem 2014,
115(11): 1928-1936.

185.

Searles CD. Transcriptional and posttranscriptional regulation of endothelial nitric
oxide synthase expression. Am J Physiol Cell Physiol 2006, 291(5): C803-816.

186.

Resh MD. Myristylation and palmitylation of Src family members: the fats of the
matter. Cell 1994, 76(3): 411-413.

187.

Casey PJ. Protein lipidation in cell signaling. Science 1995, 268(5208): 221-225.

188.

Prabhakar P, Cheng V, Michel T. A chimeric transmembrane domain directs
endothelial nitric-oxide synthase palmitoylation and targeting to plasmalemmal
caveolae. J Biol Chem 2000, 275(25): 19416-19421.

189.

Hooper NM. Detergent-insoluble glycosphingolipid/cholesterol-rich membrane
domains, lipid rafts and caveolae (review). Molecular membrane biology 1999,
16(2): 145-156.

190.

Woodman SE, Schlegel A, Cohen AW, Lisanti MP. Mutational analysis identifies
a short atypical membrane attachment sequence (KYWFYR) within caveolin-1.
Biochemistry 2002, 41(11): 3790-3795.
199

191.

Michel JB, Feron O, Sacks D, Michel T. Reciprocal regulation of endothelial
nitric-oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem 1997,
272(25): 15583-15586.

192.

Michel JB, Feron O, Sase K, Prabhakar P, Michel T. Caveolin versus calmodulin.
Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol
Chem 1997, 272(41): 25907-25912.

193.

Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial
nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin
dissociation and calmodulin association. J Biol Chem 1998, 273(52): 3472434729.

194.

Yeh DC, Duncan JA, Yamashita S, Michel T. Depalmitoylation of endothelial
nitric-oxide synthase by acyl-protein thioesterase 1 is potentiated by Ca(2+)calmodulin. J Biol Chem 1999, 274(46): 33148-33154.

195.

Fulton D, Babbitt R, Zoellner S, Fontana J, Acevedo L, McCabe TJ, et al.
Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi
complex or plasma membrane regulates Akt- versus calcium-dependent
mechanisms for nitric oxide release. J Biol Chem 2004, 279(29): 30349-30357.

196.

Schleicher M, Brundin F, Gross S, Muller-Esterl W, Oess S. Cell cycle-regulated
inactivation of endothelial NO synthase through NOSIP-dependent targeting to
the cytoskeleton. Molecular and cellular biology 2005, 25(18): 8251-8258.

197.

Zimmermann K, Opitz N, Dedio J, Renne C, Muller-Esterl W, Oess S.
NOSTRIN: a protein modulating nitric oxide release and subcellular distribution
of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2002, 99(26):
17167-17172.

198.

Mookerjee RP, Wiesenthal A, Icking A, Hodges SJ, Davies NA, Schilling K, et al.
Increased gene and protein expression of the novel eNOS regulatory protein
NOSTRIN and a variant in alcoholic hepatitis. Gastroenterology 2007, 132(7):
2533-2541.

199.

Chen W, Xiao H, Rizzo AN, Zhang W, Mai Y, Ye M. Endothelial nitric oxide
synthase dimerization is regulated by heat shock protein 90 rather than by
phosphorylation. PLoS One 2014, 9(8): e105479.

200.

Barrera-Chimal J, Perez-Villalva R, Ortega JA, Uribe N, Gamba G, CortesGonzalez C, et al. Intra-renal transfection of heat shock protein 90 alpha or beta
(Hsp90alpha or Hsp90beta) protects against ischemia/reperfusion injury. Nephrol
Dial Transplant 2014, 29(2): 301-312.
200

201.

Bauer M, Suppmann S, Meyer M, Hesslinger C, Gasser T, Widmer HR, et al.
Glial cell line-derived neurotrophic factor up-regulates GTP-cyclohydrolase I
activity and tetrahydrobiopterin levels in primary dopaminergic neurones. Journal
of neurochemistry 2002, 82(5): 1300-1310.

202.

Crabtree MJ, Tatham AL, Hale AB, Alp NJ, Channon KM. Critical role for
tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of
endothelial nitric-oxide synthase coupling: relative importance of the de novo
biopterin synthesis versus salvage pathways. J Biol Chem 2009, 284(41): 2812828136.

203.

Hammermann R, Bliesener N, Mossner J, Klasen S, Wiesinger H, Wessler I, et al.
Inability of rat alveolar macrophages to recycle L-citrulline to L-arginine despite
induction of argininosuccinate synthetase mRNA and protein, and inhibition of
nitric oxide synthesis by exogenous L-citrulline. Naunyn-Schmiedeberg's archives
of pharmacology 1998, 358(6): 601-607.

204.

Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression
of arginase II in human diabetic corpus cavernosum: in diabetic-associated
erectile dysfunction. Biochem Biophys Res Commun 2001, 283(4): 923-927.

205.

Toque HA, Tostes RC, Yao L, Xu Z, Webb RC, Caldwell RB, et al. Arginase II
deletion increases corpora cavernosa relaxation in diabetic mice. J Sex Med 2011,
8(3): 722-733.

206.

Casanello P, Krause B, Torres E, Gallardo V, Gonzalez M, Prieto C, et al.
Reduced l-arginine transport and nitric oxide synthesis in human umbilical vein
endothelial cells from intrauterine growth restriction pregnancies is not further
altered by hypoxia. Placenta 2009, 30(7): 625-633.

207.

Shin WS, Berkowitz DE, Ryoo SW. Increased arginase II activity contributes to
endothelial dysfunction through endothelial nitric oxide synthase uncoupling in
aged mice. Exp Mol Med 2012, 44(10): 594-602.

208.

Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, Soucy KG, et al. Arginase
inhibition restores NOS coupling and reverses endothelial dysfunction and
vascular stiffness in old rats. Journal of Applied Physiology 2009, 107(4): 12491257.

209.

Fayh AP, Krause M, Rodrigues-Krause J, Ribeiro JL, Ribeiro JP, Friedman R, et
al. Effects of L-arginine supplementation on blood flow, oxidative stress status
and exercise responses in young adults with uncomplicated type I diabetes.
European journal of nutrition 2013, 52(3): 975-983.

201

210.

Lucotti P, Monti L, Setola E, La Canna G, Castiglioni A, Rossodivita A, et al.
Oral L-arginine supplementation improves endothelial function and ameliorates
insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an
aortocoronary bypass. Metabolism: clinical and experimental 2009, 58(9): 12701276.

211.

Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM.
Activation of nitric oxide synthase in endothelial cells by Akt-dependent
phosphorylation. Nature 1999, 399(6736): 601-605.

212.

Gelinas DS, Bernatchez PN, Rollin S, Bazan NG, Sirois MG. Immediate and
delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC
and PLC pathways. Br J Pharmacol 2002, 137(7): 1021-1030.

213.

Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of
Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase
activity. Circ Res 2001, 88(11): E68-75.

214.

Michell BJ, Griffiths JE, Mitchelhill KI, Rodriguez-Crespo I, Tiganis T,
Bozinovski S, et al. The Akt kinase signals directly to endothelial nitric oxide
synthase. Current biology : CB 1999, 9(15): 845-848.

215.

Braam B, Verhaar MC. Understanding eNOS for pharmacological modulation of
endothelial function: a translational view. Current pharmaceutical design 2007,
13(17): 1727-1740.

216.

Ruan L, Torres CM, Buffett RJ, Kennard S, Fulton D, Venema RC. Calcineurinmediated dephosphorylation of eNOS at serine 116 affects eNOS enzymatic
activity indirectly by facilitating c-Src binding and tyrosine 83 phosphorylation.
Vascul Pharmacol 2013, 59(1-2): 27-35.

217.

Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of
insulin signaling through IRS-1 phosphorylation. Biochimie 2005, 87(1): 99-109.

218.

Briand SI, Bernier SG, Guillemette G. Calcium-calmodulin plays a major role in
bradykinin-induced arachidonic acid release by bovine aortic endothelial cells. J
Cell Biochem 1996, 63(3): 292-301.

219.

Ramirez-Sanchez I, Maya L, Ceballos G, Villarreal F. (-)-Epicatechin induces
calcium and translocation independent eNOS activation in arterial endothelial
cells. Am J Physiol Cell Physiol 2011, 300(4): C880-887.

220.

Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO
synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007, 42(2):
271-279.
202

221.

Jiang X, Yang F, Tan H, Liao D, Bryan RM, Jr., Randhawa JK, et al.
Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC
activation. Arterioscler Thromb Vasc Biol 2005, 25(12): 2515-2521.

222.

Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, et al. Reciprocal
phosphorylation and regulation of endothelial nitric-oxide synthase in response to
bradykinin stimulation. J Biol Chem 2001, 276(19): 16587-16591.

223.

Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of
eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J
Biol Chem 2001, 276(32): 30392-30398.

224.

Kimura A, Mora S, Shigematsu S, Pessin JE, Saltiel AR. The insulin receptor
catalyzes the tyrosine phosphorylation of caveolin-1. J Biol Chem 2002, 277(33):
30153-30158.

225.

Wang H, Wang AX, Liu Z, Chai W, Barrett EJ. The trafficking/interaction of
eNOS and caveolin-1 induced by insulin modulates endothelial nitric oxide
production. Molecular endocrinology 2009, 23(10): 1613-1623.

226.

Marshall HE, Stamler JS. Inhibition of NF-kappa B by S-nitrosylation.
Biochemistry 2001, 40(6): 1688-1693.

227.

Yao X, Huang Y. From nitric oxide to endothelial cytosolic Ca2+: a negative
feedback control. Trends in pharmacological sciences 2003, 24(6): 263-266.

228.

Zhou J, Kim DD, Peluffo RD. Nitric oxide can acutely modulate its biosynthesis
through a negative feedback mechanism on L-arginine transport in cardiac
myocytes. Am J Physiol Cell Physiol 2010, 299(2): C230-239.

229.

Levy Z, Rachmani R, Trestman S, Dvir A, Shaish A, Ravid M, et al. Low-dose
interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse
model. Eur J Intern Med 2003, 14(8): 479-483.

230.

Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-Giri A, et al.
Type I interferons modulate vascular function, repair, thrombosis, and plaque
progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012,
64(9): 2975-2985.

231.

Yao H, Cao CM, Jin HF, Shan QX, Wang LL, Xia Q. [Treatment of interferonalpha in reducing the endothelium-dependent relaxation of rat thoracic aorta].
Zhejiang Da Xue Xue Bao Yi Xue Ban 2003, 32(3): 202-206.

203

232.

Werner N, Wassmann S, Ahlers P, Schiegl T, Kosiol S, Link A, et al. Endothelial
progenitor cells correlate with endothelial function in patients with coronary
artery disease. Basic research in cardiology 2007, 102(6): 565-571.

233.

Aicher A, Heeschen C, Mildner-Rihm C, Urbich C. Essential role of endothelial
nitric oxide synthase for mobilization of stem and progenitor cells. Nature
Medicine 2003.

234.

Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, et al.
Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of
bone marrow-derived endothelial progenitor cells contributes to
reendothelialization after arterial injury. Circulation 2003, 108(25): 3115-3121.

235.

Laufs U, Urhausen A, Werner N, Scharhag J, Heitz A, Kissner G, et al. Running
exercise of different duration and intensity: effect on endothelial progenitor cells
in healthy subjects. Eur J Cardiovasc Prev Rehabil 2005, 12(4): 407-414.

236.

George AL, Bangalore-Prakash P, Rajoria S, Suriano R, Shanmugam A,
Mittelman A, et al. Endothelial progenitor cell biology in disease and tissue
regeneration. J Hematol Oncol 2011, 4: 24.

237.

Denny MF, Thacker S, Mehta H. Interferon-α promotes abnormal vasculogenesis
in lupus: a potential pathway for premature atherosclerosis. … 2007.

238.

Lee HJ, Oh YK, Rhee M, Lim JY, Hwang JY, Park YS, et al. The role of
STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial
transmembrane potential during hepatic cell death induced by LPS/d-GalN.
Journal of molecular biology 2007, 369(4): 967-984.

239.

Teragawa H, Hondo T, Amano H, Watanabe H, Ohe H, Hattori N, et al.
Cardiogenic shock following recombinant alpha-2b interferon therapy for chronic
hepatitis C. A case report. Japanese heart journal 1996, 37(1): 137-142.

240.

Lenci I, Piccolo P, Francioso S, Di Paolo D, Galante A, Angelico M. Recurrent
myocardial ischaemia during combination antiviral therapy in a patient with
chronic hepatitis C and normal aminotransferase levels. Dig Liver Dis 2008,
40(9): 785-790.

241.

Cauli C, Serra G, Chessa L, Balestrieri C, Scioscia R, Lai ME, et al. Severe
autoimmune hemolytic anemia in a patient with chronic hepatitis C during
treatment with peginterferon alfa-2a and ribavirin. Haematologica 2006, 91(6
Suppl): ECR26.

242.

Sasaki M, Sata M, Suzuki H, Tanikawa K. A case of chronic hepatitis C with
sinus bradycardia during IFN therapy. Kurume Med J 1998, 45(1): 161-163.
204

243.

Kouno H, Aimitsu S, Ikemoto Y, Nakanishi T, Kajiyama G. [Cardiovascular
complications of interferon therapy in chronic hepatitis C]. Nihon rinsho
Japanese journal of clinical medicine 1994, 52(7): 1914-1918.

244.

Takase B, Uehata A, Fujioka T, Kondo T, Nishioka T, Isojima K, et al.
Endothelial dysfunction and decreased exercise tolerance in interferon-alpha
therapy in chronic hepatitis C: relation between exercise hyperemia and
endothelial function. Clin Cardiol 2001, 24(4): 286-290.

245.

Panasiuk A, Prokopowicz D, Panasiuk B. Monocyte chemotactic protein-1 and
soluble adhesion molecules as possible prognostic markers of the efficacy of
antiviral treatment in chronic hepatitis C. World journal of gastroenterology :
WJG 2004, 10(24): 3639-3642.

246.

Erol MK, Erol S, Koruk M, Ertek M, Bozkurt E. Effects of interferon-alpha
therapy on cardiac function in patients with chronic hepatitis B infection. Heart
Vessels 2004, 19(6): 263-266.

247.

Zhu Y, Tibensky I, Schmidt J, Hackert T, Ryschich E, Jager D, et al. Interferonalpha in combination with chemotherapy has potent antiangiogenic properties in
an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother 2008,
31(1): 28-33.

248.

Radaeva S, Jaruga B, Hong F, Kim WH, Fan S, Cai H, et al. Interferon-alpha
activates multiple STAT signals and down-regulates c-Met in primary human
hepatocytes. Gastroenterology 2002, 122(4): 1020-1034.

249.

Kumar S, Sun X, Wedgwood S, Black SM. Hydrogen peroxide decreases
endothelial nitric oxide synthase promoter activity through the inhibition of AP-1
activity. Am J Physiol Lung Cell Mol Physiol 2008, 295(2): L370-377.

250.

Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, et al.
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the proangiogenic effect of vascular endothelial growth factor in superficial bladder
cancer. The Journal of urology 2007, 177(5): 1900-1906.

251.

Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers
Arch 2010, 459(6): 793-806.

252.

Yang X, Nath A, Opperman MJ, Chan C. The double-stranded RNA-dependent
protein kinase differentially regulates insulin receptor substrates 1 and 2 in
HepG2 cells. Molecular Biology of the Cell 2010, 21(19): 3449-3458.

205

253.

Chu WM, Ostertag D, Li ZW, Chang L, Chen Y, Hu Y, et al. JNK2 and IKKbeta
are required for activating the innate response to viral infection. Immunity 1999,
11(6): 721-731.

254.

Goh KC, deVeer MJ, Williams BR. The protein kinase PKR is required for p38
MAPK activation and the innate immune response to bacterial endotoxin. The
EMBO journal 2000, 19(16): 4292-4297.

255.

Salven P, Anttonen K, Repo H, Joensuu H, Orpana A. Endotoxins induce and
interferon alpha suppresses vascular endothelial growth factor (VEGF) production
in human peripheral blood mononuclear cells. FASEB journal : official
publication of the Federation of American Societies for Experimental Biology
2001, 15(7): 1318-1320.

256.

Wada H, Nagano H, Yamamoto H, Noda T, Murakami M, Kobayashi S, et al.
Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell
growth directly and by regulation of angiogenic factors released by tumor cells.
BMC Cancer 2009, 9: 361.

257.

Tsutsui M, Milstien S, Katusic ZS. Effect of tetrahydrobiopterin on endothelial
function in canine middle cerebral arteries. Circulation research 1996, 79(2):
336-342.

258.

Katusic ZS, d'Uscio LV. Tetrahydrobiopterin: mediator of endothelial protection.
Arteriosclerosis, Thrombosis, and Vascular Biology 2004, 24(3): 397-398.

259.

Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction.
The Journal of clinical investigation 1997, 100(9): 2153-2157.

260.

Kitagami T, Yamada K, Miura H, Hashimoto R, Nabeshima T, Ohta T.
Mechanism of systemically injected interferon-alpha impeding monoamine
biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier.
Brain research 2003, 978(1-2): 104-114.

261.

Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, et al.
Tyrosine metabolism during interferon-alpha administration: Association with
fatigue and CSF dopamine concentrations. Brain Behav Immun 2013, 31: 153-160.

262.

Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P,
et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in
prehypertensive rats. The Journal of clinical investigation 1998, 101(7): 15301537.

263.

Schildknecht S, van der Loo B, Weber K, Tiefenthaler K, Daiber A, Bachschmid
MM. Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2
206

formation and aggregation in human platelets. Free Radic Biol Med 2008, 45(4):
512-520.
264.

Fekkes D, Bannink M, Kruit WH, Van Gool AR, Mulder PG, Sleijfer S, et al.
Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and
arginine in melanoma patients. Amino Acids 2007, 32(1): 121-126.

265.

Lu DY, Leung YM, Su KP. Interferon-alpha induces nitric oxide synthase
expression and haem oxygenase-1 down-regulation in microglia: implications of
cellular mechanism of IFN-alpha-induced depression. Int J
Neuropsychopharmacol 2013, 16(2): 433-444.

266.

Arnal JF, Tack I, Besombes JP, Pipy B, Negre-Salvayre A. Nitric oxide and
superoxide anion production during endothelial cell proliferation. The American
journal of physiology 1996, 271(5 Pt 1): C1521-1526.

267.

Sukumar P, Viswambharan H, Imrie H, Cubbon RM, Yuldasheva N, Gage M, et
al. Nox2 NADPH oxidase has a critical role in insulin resistance-related
endothelial cell dysfunction. Diabetes 2013, 62(6): 2130-2134.

268.

Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, et al. Systemic
regulation of vascular NAD(P)H oxidase activity and nox isoform expression in
human arteries and veins. Arteriosclerosis, Thrombosis, and Vascular Biology
2004, 24(9): 1614-1620.

269.

Kou B, Ni J, Vatish M, Singer DR. Xanthine oxidase interaction with vascular
endothelial growth factor in human endothelial cell angiogenesis.
Microcirculation 2008, 15(3): 251-267.

270.

Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased
endothelial tetrahydrobiopterin synthesis by targeted transgenic GTPcyclohydrolase I overexpression reduces endothelial dysfunction and
atherosclerosis in ApoE-knockout mice. Arteriosclerosis, Thrombosis, and
Vascular Biology 2004, 24(3): 445-450.

271.

Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases
endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 2007,
43(6): 780-791.

272.

Munzel T, Daiber A, Ullrich V, Mulsch A. Vascular consequences of endothelial
nitric oxide synthase uncoupling for the activity and expression of the soluble
guanylyl cyclase and the cGMP-dependent protein kinase. Arteriosclerosis,
Thrombosis, and Vascular Biology 2005, 25(8): 1551-1557.

207

273.

Nistala R, Whaley-Connell A, Sowers JR. Redox control of renal function and
hypertension. Antioxid Redox Signal 2008, 10(12): 2047-2089.

274.

Nishiwaki H, Ogura Y, Miyamoto K, Hiroshiba N, Hamada M, Honda Y.
Prednisolone, platelet-activating factor receptor antagonist, or superoxide
dismutase reduced leukocyte entrapment induced by interferon alpha in retinal
microcirculation. Invest Ophthalmol Vis Sci 1997, 38(5): 811-816.

275.

Kamen DL, Barron M, Parker TM, Shaftman SR, Bruner GR, Aberle T, et al.
Autoantibody prevalence and lupus characteristics in a unique African American
population. Arthritis Rheum 2008, 58(5): 1237-1247.

276.

Oh H, Siano B, Diamond S. Neutrophil isolation protocol. J Vis Exp 2008(17).

277.

Haimov-Kochman R, Fisher SJ, Winn VD. Modification of the standard Trizolbased technique improves the integrity of RNA isolated from RNase-rich
placental tissue. Clin Chem 2006, 52(1): 159-160.

278.

Vaziri ND, Ni Z, Oveisi F. Upregulation of renal and vascular nitric oxide
synthase in young spontaneously hypertensive rats. Hypertension 1998, 31(6):
1248-1254.

279.

Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, et al.
Mechanisms of increased vascular superoxide production in human diabetes
mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase.
Circulation 2002, 105(14): 1656-1662.

280.

Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms
underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001, 88(2):
E14-22.

281.

Karbach S, Wenzel P, Waisman A, Munzel T, Daiber A. eNOS uncoupling in
cardiovascular diseases--the role of oxidative stress and inflammation. Current
pharmaceutical design 2014, 20(22): 3579-3594.

282.

Szelenyi Z, Fazakas A, Szenasi G, Kiss M, Tegze N, Fekete BC, et al.
Inflammation and oxidative stress caused by nitric oxide synthase uncoupling
might lead to left ventricular diastolic and systolic dysfunction in patients with
hypertension. Journal of geriatric cardiology : JGC 2015, 12(1): 1-10.

283.

Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human
nitric oxide synthase gene delivery. Hypertension 1997, 30(3 Pt 1): 307-313.

284.

Miller WH, Brosnan MJ, Graham D, Nicol CG, Morecroft I, Channon KM, et al.
Targeting endothelial cells with adenovirus expressing nitric oxide synthase
208

prevents elevation of blood pressure in stroke-prone spontaneously hypertensive
rats. Molecular therapy : the journal of the American Society of Gene Therapy
2005, 12(2): 321-327.
285.

Palatka K, Serfozo Z, Vereb Z, Batori R, Lontay B, Hargitay Z, et al. Effect of
IBD sera on expression of inducible and endothelial nitric oxide synthase in
human umbilical vein endothelial cells. World J Gastroenterol 2006, 12(11):
1730-1738.

286.

Tiefenbacher CP, Lee CH, Kapitza J, Dietz V, Niroomand F. Sepiapterin reduces
postischemic injury in the rat heart. Pflugers Arch 2003, 447(1): 1-7.

287.

Gilkeson GS, Mashmoushi AK, Ruiz P, Caza TN, Perl A, Oates JC. Endothelial
nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive
oxygen production, and MCP1 production in murine lupus nephritis. PLoS One
2013, 8(5): e64650.

288.

Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, et al.
Tetrahydrobiopterin: a novel antihypertensive therapy. Journal of human
hypertension 2008, 22(6): 401-407.

289.

Maier A, Lorenz P, Voncken F, Clayton C. An essential dimeric membrane
protein of trypanosome glycosomes. Molecular microbiology 2001, 39(6): 14431451.

290.

Cosentino U, Pitea D, Moro G, Saracino GA, Caria P, Vari RM, et al. The antifibrillogenic activity of tetracyclines on PrP 106-126: a 3D-QSAR study. Journal
of molecular modeling 2008, 14(10): 987-994.

291.

Manzi S, Meilahn EN, Rairie JE. Age-specific incidence rates of myocardial
infarction and angina in women with systemic lupus erythematosus: comparison
with the Framingham Study. American journal of … 1997.

292.

Abu-Shakra M, Urowitz MB, Gladman DD. Mortality studies in systemic lupus
erythematosus. Results from a single center. II. Predictor variables for mortality.
The Journal of … 1995.

293.

Fischer K. [Risk factors of thickened intima-media and atherosclerotic plaque
development in carotid arteries in patients with systemic lupus erythematosus].
Annales Academiae Medicae Stetinensis 2008, 54(2): 22-32.

294.

Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, et al. Type I
interferon as a novel risk factor for endothelial progenitor cell depletion and
endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007,
56(11): 3759-3769.
209

295.

Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, et al.
Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway
for premature atherosclerosis. Blood 2007, 110(8): 2907-2915.

296.

Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in
systemic lupus erythematosus plasma and association with anti-RNA binding
protein autoantibodies. Arthritis Rheum 2006, 54(6): 1906-1916.

297.

Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, et al. Association of elevated
transcript levels of interferon-inducible chemokines with disease activity and
organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 2008,
10(5): R112.

298.

Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al.
Association of increased interferon-inducible gene expression with disease
activity and lupus nephritis in patients with systemic lupus erythematosus.
Arthritis Rheum 2006, 54(9): 2951-2962.

299.

Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME. Mechanism of
platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane
receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A 1998,
95(9): 4888-4893.

300.

Yoshimoto H, Suehiro A, Kakishita E. Exogenous nitric oxide inhibits platelet
activation in whole blood. Journal of cardiovascular pharmacology 1999, 33(1):
109-115.

301.

Qian J, Fulton DJ. Exogenous, but not Endogenous Nitric Oxide Inhibits
Adhesion Molecule Expression in Human Endothelial Cells. Frontiers in
physiology 2012, 3: 3.

302.

Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia
decreases nitric oxide production by promoting the interaction of caveolin and
endothelial nitric oxide synthase. J Clin Invest 1999, 103(6): 897-905.

303.

Boger RH, Tsikas D, Bode-Boger SM, Phivthong-Ngam L, Schwedhelm E,
Frolich JC. Hypercholesterolemia impairs basal nitric oxide synthase turnover
rate: a study investigating the conversion of L-[guanidino-(15)N(2)]-arginine to
(15)N-labeled nitrate by gas chromatography--mass spectrometry. Nitric Oxide
2004, 11(1): 1-8.

304.

Toda N, Toda H. Nitric oxide-mediated blood flow regulation as affected by
smoking and nicotine. Eur J Pharmacol 2010, 649(1-3): 1-13.
210

305.

Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that Creactive protein decreases eNOS expression and bioactivity in human aortic
endothelial cells. Circulation 2002.

306.

Mineo C, Gormley AK, Yuhanna IS, Osborne-Lawrence S, Gibson LL, Hahner L,
et al. FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO
synthase. Circ Res 2005, 97(11): 1124-1131.

307.

Musicki B, Liu T, Lagoda GA, Strong TD, Sezen SF, Johnson JM, et al.
Hypercholesterolemia-induced erectile dysfunction: endothelial nitric oxide
synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase. J Sex Med
2010, 7(9): 3023-3032.

308.

Wagner L, Laczy B, Tamasko M, Mazak I, Marko L, Molnar GA, et al. Cigarette
smoke-induced alterations in endothelial nitric oxide synthase phosphorylation:
role of protein kinase C. Endothelium : journal of endothelial cell research 2007,
14(4-5): 245-255.

309.

Manganaro A, Ciraci L, Andre L, Trio O, Manganaro R, Saporito F, et al.
Endothelial Dysfunction in Patients With Coronary Artery Disease: Insights From
a Flow-Mediated Dilation Study. Clinical and applied thrombosis/hemostasis :
official journal of the International Academy of Clinical and Applied
Thrombosis/Hemostasis 2014, 20(6): 583-588.

310.

Yokoyama H, Sone H, Saito K, Yamada D, Honjo J, Haneda M. Flow-mediated
dilation is associated with microalbuminuria independent of cardiovascular risk
factors in type 2 diabetes - interrelations with arterial thickness and stiffness.
Journal of atherosclerosis and thrombosis 2011, 18(9): 744-752.

311.

Kirou KA, Mavragani CP, Crow MK. Activation of type I interferon in systemic
lupus erythematosus. Expert Rev Clin Immunol 2007, 3(4): 579-588.

312.

Tavares-Murta BM, Machado JS, Ferreira SH, Cunha FQ. Nitric oxide mediates
the inhibition of neutrophil migration induced by systemic administration of LPS.
Inflammation 2001, 25(4): 247-253.

313.

Balamayooran G, Batra S, Theivanthiran B, Cai S, Pacher P, Jeyaseelan S.
Intrapulmonary G-CSF rescues neutrophil recruitment to the lung and neutrophil
release to blood in Gram-negative bacterial infection in MCP-1-/- mice. J
Immunol 2012, 189(12): 5849-5859.

314.

Gil J, Alcami J, Esteban M. Activation of NF-kappa B by the dsRNA-dependent
protein kinase, PKR involves the I kappa B kinase complex. Oncogene 2000,
19(11): 1369-1378.
211

315.

DelaTorre A, Schroeder RA, Kuo PC. Alteration of NF-kappa B p50 DNA
binding kinetics by S-nitrosylation. Biochem Biophys Res Commun 1997, 238(3):
703-706.

316.

Kelleher ZT, Matsumoto A, Stamler JS, Marshall HE. NOS2 regulation of NFkappaB by S-nitrosylation of p65. J Biol Chem 2007, 282(42): 30667-30672.

317.

Lee KS, Kim J, Kwak SN, Lee KS, Lee DK, Ha KS, et al. Functional role of NFkappaB in expression of human endothelial nitric oxide synthase. Biochem
Biophys Res Commun 2014, 448(1): 101-107.

318.

Sugimoto M, Nakayama M, Goto TM, Amano M, Komori K, Kaibuchi K. Rhokinase phosphorylates eNOS at threonine 495 in endothelial cells. Biochem
Biophys Res Commun 2007, 361(2): 462-467.

319.

Crow MK. Interferon-alpha: a therapeutic target in systemic lupus erythematosus.
Rheum Dis Clin North Am 2010, 36(1): 173-186, x.

320.

Cates AM, Holden VI, Myers EM, Smith CK, Kaplan MJ, Kahlenberg JM.
Interleukin 10 hampers endothelial cell differentiation and enhances the effects of
interferon alpha on lupus endothelial cell progenitors. Rheumatology (Oxford)
2014.

321.

Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies
and immunostimulatory plasmid DNA in combination mimic the endogenous
IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999, 163(11):
6306-6313.

322.

Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, et al. Type I
interferons are associated with subclinical markers of cardiovascular disease in a
cohort of systemic lupus erythematosus patients. PLoS One 2012, 7(5): e37000.

323.

Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers
Arch 2010, 459(6): 793-806.

324.

Reynolds JA, Ray DW, Zeef LA, O'Neill T, Bruce IN, Alexander MY. The effect
of type 1 IFN on human aortic endothelial cell function in vitro: relevance to
systemic lupus erythematosus. Journal of interferon & cytokine research : the
official journal of the International Society for Interferon and Cytokine Research
2014, 34(5): 404-412.

325.

Nicolescu AC, Reynolds JN, Barclay LR, Thatcher GR. Organic nitrites and NO:
inhibition of lipid peroxidation and radical reactions. Chemical research in
toxicology 2004, 17(2): 185-196.
212

326.

Yang X, Nath A, Opperman MJ, Chan C. The double-stranded RNA-dependent
protein kinase differentially regulates insulin receptor substrates 1 and 2 in
HepG2 cells. Mol Biol Cell 2010, 21(19): 3449-3458.

327.

Zhou H, Huang X, Cui H, Luo X, Tang Y, Chen S, et al. miR-155 and its starform partner miR-155* cooperatively regulate type I interferon production by
human plasmacytoid dendritic cells. Blood 2010, 116(26): 5885-5894.

328.

Furchgott RF, Cherry PD, Zawadzki JV, Jothianandan D. Endothelial cells as
mediators of vasodilation of arteries. Journal of cardiovascular pharmacology
1984, 6 Suppl 2: S336-343.

329.

Cherry PD, Furchgott RF, Zawadzki JV, Jothianandan D. Role of endothelial cells
in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci U S A 1982,
79(6): 2106-2110.

330.

Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the
relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288(5789):
373-376.

331.

Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K,
et al. Essential role of endothelial nitric oxide synthase for mobilization of stem
and progenitor cells. Nat Med 2003, 9(11): 1370-1376.

332.

Hamed S, Brenner B, Roguin A. Nitric oxide: a key factor behind the
dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2.
Cardiovasc Res 2011, 91(1): 9-15.

333.

Yang YM, Huang A, Kaley G, Sun D. eNOS uncoupling and endothelial
dysfunction in aged vessels. Am J Physiol Heart Circ Physiol 2009, 297(5):
H1829-1836.

334.

Youn JY, Gao L, Cai H. The p47phox- and NADPH oxidase organiser 1
(NOXO1)-dependent activation of NADPH oxidase 1 (NOX1) mediates
endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction
in a streptozotocin-induced murine model of diabetes. Diabetologia 2012, 55(7):
2069-2079.

335.

Al Gadban MM, German J, Truman JP, Soodavar F, Riemer EC, Twal WO, et al.
Lack of nitric oxide synthases increases lipoprotein immune complex deposition
in the aorta and elevates plasma sphingolipid levels in lupus. Cell Immunol 2012,
276(1-2): 42-51.

213

336.

Cosentino F, Hurlimann D, Delli Gatti C, Chenevard R, Blau N, Alp NJ, et al.
Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and
oxidative stress in hypercholesterolaemia. Heart 2008, 94(4): 487-492.

337.

Vasquez-Vivar J, Martasek P, Whitsett J, Joseph J, Kalyanaraman B. The ratio
between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls
superoxide release from endothelial nitric oxide synthase: an EPR spin trapping
study. The Biochemical journal 2002, 362(Pt 3): 733-739.

338.

Cheng M, Li Y, Wu J, Nie Y, Li L, Liu X, et al. IL-8 induces imbalances between
nitric oxide and endothelin-1, and also between plasminogen activator inhibitor-1
and tissue-type plasminogen activator in cultured endothelial cells. Cytokine 2008,
41(1): 9-15.

339.

Marshall HE, Hess DT, Stamler JS. S-nitrosylation: physiological regulation of
NF-kappaB. Proc Natl Acad Sci U S A 2004, 101(24): 8841-8842.

340.

delaTorre A, Schroeder RA, Punzalan C, Kuo PC. Endotoxin-mediated Snitrosylation of p50 alters NF-kappa B-dependent gene transcription in ANA-1
murine macrophages. J Immunol 1999, 162(7): 4101-4108.

341.

Dunand-Sauthier I, Santiago-Raber ML, Capponi L, Vejnar CE, Schaad O, Irla M,
et al. Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell
maturation and function. Blood 2011, 117(17): 4490-4500.

342.

Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M, et al. MicroRNA-155
deficiency results in decreased macrophage inflammation and attenuated
atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol
2014, 34(4): 759-767.

214

Biography
Joy Buie was born in Rock Hill, SC and graduated from Northwestern High School in
2003.

She attended Clemson University where she majored in Biological

Sciences/Microbiology and graduated with honors in 2007. While at Clemson, she met
her husband Stevyn Buie and they married in 2008. Following college, she worked at
BASF, The Chemical Company, for 1.5 years prior to starting graduate school at MUSC
in 2009 as an IMSD scholar. While at MUSC, Joy was elected to serve on the First Year
Curriculum Committee, as President of the Multicultural Graduate Student Association,
and served as a member of the Graduate Council. Joy was also selected to speak at the
Ernest E. Just Symposium in 2010. As a student in the Division of Rheumatology, Joy
had the opportunity to serve as a member of the Arthritis Foundation D’Vine Affair and
Lupus Patient Education planning committees. Joy was also selected twice as one of two
SC representatives for the American College of Rheumatology “Advocates for Arthritis”
event, held annually in Washington, DC.

While in graduate school, Joy became

passionate about helping others get healthy and became a certified Zumba instructor. She
also joined Black Girls Run, a group that she’s completed several races with, including a
half-marathon. To further aid in her quest to assist others in living a healthier life, she’s
decided to complete the Master’s in Clinical Research Program while finishing her PhD
in hopes that she can help identify alternative therapies to prevent disease and promote
healing in autoimmune disease populations.

215

